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ABSTRACT  
Background: Abundant evidence supporting the ergogenic effect of caffeine during 
endurance exercise exists. Single sporting events, laboratory based studies and 
inappropriate research design questions the applicability of these studies to triathlon 
performance.  
Objectives: The main aims of this study were to i) investigate the ergogenic effect of 
caffeine supplementation during a triathlon; ii) evaluate parameters that could in part explain 
why caffeine supplementation is ergogenic, iii) investigate possible factors influencing the 
ergogenicity of caffeine supplementation and iv) investigate possible confounding factors 
influencing triathlon performance.  
Methods: A double-blind, randomized, crossover, controlled, clinical field trial was 
conducted. Performance data (time to complete (TTC), rating of perceived exertion (RPE) 
and mood state), parameters explaining the mechanism of action (endocrine-stress 
response, oxidative stress and plasma lactate), factors influencing ergogenicity (lifestyle, 
gender and genetics) and triathlon performance (general health, energy- and nutrient intake, 
body composition, training regime, side-effects of caffeine withdrawal- and supplementation 
and hydration status) was collected during two Olympic-distance triathlons (T1 and T2).  
Results: Twenty six Caucasian triathletes (Nm=14, Nf=12) participated (age: 37.8±10.6 
years, habitual caffeine intake: 412.7±504.8 mg/day, percentage body fat: 14.5±7.2 %, 
training/week: 12.8±4.5 hours). There was a 3.7% reduction in swim time (33.5±7.0 vs. 
34.8±8.1 minutes) (p=0.05*) and a 1.3% reduction in the overall time to complete the 
triathlon (149.6±19.8 vs. 151.5±18.6 minutes) (p=0.02*) in the caffeine group. Caffeine did 
not statistically influence mood state (p=0.72) or RPE (p=0.87), however, a trend was 
observed for decreased RPE values in the caffeine group. Caffeine supplementation made 
no difference to markers of endocrine-stress, except for cortisol, which increased beyond the 
effect observed from exercise (p=0.00*). Oxidative stress was more pronounced in the 
caffeine group, as seen with elevated leukocyte (p=0.05*), lymphocyte (p=0.05*) and 
monocyte (p = 0.05*) counts. Caffeine facilitated greater blood lactate accumulation 
(p=0.04*). Lifestyle, menstrual cycle, menopause, oral contraceptive use and CYP1A2 gene 
polymorphisms did not statistically influence the effect of caffeine supplementation on 
triathlon performance. The mean energy- and nutrient intake two days before T1 and T2 was 
low for energy (36.5±17.6 and 38.9±18.2 kcal/kg BW), estimated energy availability (estEA) 
(27.9±28.0 and 28.8±25.6 kcal/kg fat free mass) and carbohydrate (CHO) intake (4.1±1.6 
and 4.6±2.5 g/kg body weight (BW)) compared to recommendations. The pre-event meal 
was low in CHO (0.7±0.4 and 0.7±0.5 g/kg BW) and only 62% (N=16) ingested a 
carbohydrate-electrolyte solution during T1 (CHO: 1.6±2.3 g/kg BW) and T2 (CHO: 0.7±0.4 
g/kg BW). Eighty-five percent (N=22) used supplements. Seventy-two percent of pre-
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menopausal (Nf pre-men=5) and 40% of post-menopausal (Nf post-men=2) females were 
osteopenic. Of the males, 18% (Nm<50 = 2) had low anterior-posterior spine BMD and 33% 
(Nm>50 = 1) were osteopenic. Caffeine withdrawal presented as headaches (46%, N=12) and 
flu-like symptoms (38%, N=10). Side effects of caffeine experienced included shakiness 
(42%, N=11), heart palpitations (38%, N=10) and gastrointestinal disturbances (38%, N=10). 
Plasma volume and hydration was not influenced (p=0.70).  
Conclusion: Caffeine enhanced triathlon performance, but the effect was not as 
pronounced as seen in previous laboratory trials and did not affect RPE or mood state. 
Caffeine supplementation augments the endocrine-stress response by further increasing 
cortisol levels beyond that resulting from endurance exercise and it induces leukocytosis, 
neutrophillia and lymphocytosis, suggesting the primary ergogenic effect of caffeine may 
result due to stimulation of both the central and autonomic nervous systems. Lifestyle, 
gender and genetics did not significantly influence caffeine’s effect on triathlon performance 
in this cohort. The subjects had low energy, estEA and carbohydrate intake and a high 
prevalence of osteopenia. 
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OPSOMMING  
Agtergrond: Voldoende bewyse rakende die ergogeniese effek van kaffeïen gedurende 
uithouvermoë oefening bestaan. Enkel sportsoorte, laboratorium studies en ongeskikte 
navorsingsontwerpe bevraagteken die toepaslikheid van hierdie studies op driekamp 
prestasie. 
Doelwitte: Die hoofdoelwitte van die studie was om i) die verbetering van prestasie of 
ergogeniese effek van kaffeïen supplementasie tydens ‘n driekamp kompetisie waar te 
neem; ii) om verskeie parameters wat die ergogeniese effek van kaffeïen supplementasie 
deels te verduidelik te ondersoek, iii) om moontlike faktore wat die ergogeniese effek van 
kaffeïen supplementasie kan beïnvloed te ondersoek en iv) om moontlike faktore wat 
Olimpiese-afstand driekamp prestasie kan beïnvloed te ondersoek.  
Metodes: ‘n Dubbel-blinde, lukrake, oorkruis, gekontroleerde, kliniese veldproef is uitgevoer.  
Prestasie data (tyd om die driekampe te voltooi, waargenome inspanning en 
gemoedstoestand), parameters wat moontlik die aksie van kaffeïen kan verduidelik 
(endokrien-stress respons, oksidatiewe stress en plasma laktaat), faktore wat die 
ergogeniese effek van kaffeïen kan beïnvloed (lewensstyl, geslag en genetika) en faktore 
wat moontlik driekamp prestasie kan beïnvloed (algemene gesondheid, energie- en 
nutriëntinname twee dae voor en op die dag van die driekampe, liggaamsamestelling en 
beendigtheid, oefening twee dae voord die driekampe, newe-effekte van kaffeïen 
ontrekking- en supplementasie en hidrasie status) is ingesamel tydens twee Olimpiese 
afstand driekampe (T1 en T2). 
Resultate: Ses-en-twintig Kaukasiese driekamp atlete (Nm=14, Nf=12) is ingesluit 
(ouderdom: 37.8±10.6, daaglikse kaffeïen inname: 412.7±504.8 mg/dag, % liggaamsvet: 
14.5±7.2%, oefening/week: 12.8±4.5 uur). Daar was 'n 3.7% afname in swem tyd (33.5±7.0 
teenoor 34.8±8.1) (p=0.05*) en 'n 1.3% afname in totale tyd om die driekampe te voltooi 
(149.6±19.8 teenoor 151.5±18.6) (p=0.02*) in die kaffeïen groep. Kaffeïen het nie ‘n 
statisties beduidende effek op die gemoedstoestand (p=0.72) of die waargenome inspanning 
(p=0.87) gehad nie, maar 'n tendens is waargeneem vir laer waargenome inspannings-
waardes in die kaffeïen groep. Kaffeïen het geen verskil gemaak aan parameters van die 
stres respons nie, behalwe vir kortisol, wat verhoog het bo- en behalwe die effek van 
oefening (p=0.00*). Oksitdatiewe stres was meer uitgesproke in die kaffeïen groep, soos 
waargeneem deur verhoogde witbloedsel (p=0.05*), limfosiet (p=0.05*) en neutrofiel (p = 
0.05*) tellings. Kaffeïen fasiliteer die verhoging in bloedlaktaat vlakke (p=0.04*). Lewensstyl, 
menstruele siklus, menopause, orale voorbehoedmiddel gebruik en CYP1A2 geen 
polimorfismes het geen beduidende effek op die vermoë van kaffeïen om driekamp prestasie 
te beïnvloed gehad nie. Die gemiddelde energie- en nutriëntinname twee dae voor T1 en T2 
was laer as die aanbevelings vir energie (36.5±17.6 en 38.9±18.2 kcal/kg LG), geskatte 
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energie beskikbaarheid (29.9±28.0 en 28.8±25.6 kcal/kg vetvrye massa) en koolhidraat 
(CHO) inname (4.1±1.6 en 4.6±2.5 g/kg LG). Die voor-driekamp ete was laag in CHO 
(0.7±0,4 en 0.7±0.5 g / kg LG) en slegs 62% (N=16) het ‘n koolhidraat-elektroliet oplossing 
tydens T1 (CHO: 1.6±2.3 g/kg LG) en T2 (CHO: 0.7±0.4 g/kg LG) ingeneem. Vyf-en-tagtig 
persent (N=22) gebruik dieetaanvullings. Twee-en-sewentig persent van die pre-
menopausale (Nf pre-men=5) en 40% van die post-menopausale (Nf post-men=2) vroue het 
osteopenie volgens die totale liggaams been mineraal digtheid. Van die mans, het 18% 
(Nm<50 = 2) met lae beendigtheid van die anterior-posterior spina en 33% (Nm>50 = 1) met 
osteopenie gepresenteer. Waargenome ontrekkingsimptome van kaffeïen was hoofpyn 
(46%, N=12) en griepagtige simptome (38%, N=10) en newe-effekte was bewerigheid (42%, 
N=11), hartkloppings (38%, N=10) en spysverteringskanaal versteurings (38%, N=10). 
Plasma volume en hidrasie was nie beïnvloed nie (p=0.70).  
Gevolgtrekking: Kaffeïen verbeter driekamp prestasie, maar die effek is nie so uitgesproke 
soos waargeneem tydens laboratorium studies nie en het nie ‘n beduidende effek op 
waargenome inspanning of gemoedstoestand getoon nie. Kaffeïen verhoog die stres 
respons deur die verdere verhoging van kortisol vlakke, bo- en behalwe vlakke waargeneem 
tydens uithouvermoë oefening en verhoog witbloedsel, limfosiet en neutrofiel tellings. Dit dui 
daarop dat die primêre ergogeniese effek van kaffeïen supplementasie moontlik as gevolg 
van stimulasie van beide die sentrale en autonome senuweestelsel voorkom. Lewensstyl, 
geslag en genetika het nie ‘n beduidende effek op die ergogeniese vermoë van kaffeïen 
getoon in hierdie studiepopulasie nie. Die deelnemers het ‘n lae energie, geskatte energie 
beskikbaarheid en koolhidraatinname gehad. Die studiegroep het ‘n hoë prevalensie van 
osteopenie.  
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GLOSSARY  
 
Allele  each of two or more alternative forms of a gene that 
arise by mutation and are found at the same place on a 
chromosome (1)  
Amenorrhea  abnormal absence of menstruation (cycle length >90 
days) (1) 
Drafting (slipstreaming) technique where two vehicles or other moving objects 
(bicycles) are caused to align in a close group reducing 
the overall effect of drag due to exploiting the lead 
object’s slipstream. In triathlon, drafting referts to 
completing the physical activity behind another athlete 
completing the same activity in a “sheltered” position 
(2) 
Drug any chemical substance that has an effect on the body 
(3) 
Estimated energy availability  dietary energy intake minus energy expended in 
exercise (EA = EI-EEE) and is expressed in kcal/kg fat 
free mass (FFM) (4) 
Ergogenic  intended to enhance physical performance, stamina, or 
recovery (1) 
Eumenorrhea   normal menstruation, a normal menstrual cycle is 
typically between 21 and 35 days between menstrual 
periods (1) 
Follicular phase  also known as the proliferative phase, it is the phase of 
the menstrual cycle during which follicles in the ovary 
mature and end with ovulation (1) 
Genotype  the genetic constitution of an individual organism (1) 
Glycogen multi-branched polysaccharide that serves as a form of 
energy storage (storage form of glycogen) (5) 
Gynaecological age  current age minus the age of menarche (number of 
years since menarche (6) 
Habituation the gradual acclimatisation or familiarisation with a 
substance or phenomenon to the point at which it goes 
unnoticed (7) 
Half-life of a drug time taken for concentration of a drug in the blood to 
fall by half its original value (3) 
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Heterozygotes  an individual having two different alleles of a particular 
gene or genes (1) 
Homozygous  an individual having two identical alleles of a particular 
gene or genes (1) 
Luteal phase  also known as the secretory phase, it is the latter phase 
of the menstrual cycle and begins with the formation of 
the corpus luteum and ends in either pregnancy or 
luteolysis (structural and functional degradation of the 
corpus luteum) (1) 
Menarche     the first occurrence of menstruation (1) 
Menopause permanent cessation of the primary functions of the 
human ovaries; the ripening and release of ova and the 
release of hormones that cause both the creation of the 
uterine lining and the subsequent shedding of the 
uterine lining. Typically occurs in women in midlife, 
during their late 40s or early 50s, and signals the end of 
the fertile phase of a woman's life (1) 
Metabolic equivalent of task oxygen cost of energy expenditure measured at supine 
rest (1 MET = 3.5 ml O2 per kg body weight per 
minute); multiples of METs are used to estimate the 
oxygen cost of activity (7) 
Oligomenorrhea  abnormal menstrual cycle, cycle length between 35-90 
days or < 10 cycles/12 months (1) 
Olympic-distance triathlon  an athletic contest consisting of three different events, 
typically swimming, cycling, and long-distance running, 
an Olympic or standard distance triathlon comprises of 
a sequential swim (1.5 km), swim-to-cycle transition, 
cycle (40 km), cycle-to-run transition and run (10 km) 
(2, 8) 
Osteopenia  a medical condition in which the protein and mineral 
content of bone tissue is reduced, but less severely 
than in osteoporosis (1)  
Osteoporosis  a medical condition in which the bones become brittle 
and fragile from loss of tissue, typically as a result of 
hormonal changes, or deficiency of calcium or vitamin 
D (1) 
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Pharmacodynamics  the branch of pharmacology concerned with the effects 
of drugs and the mechanism of their action (1, 3) 
Pharmacokinetics  the branch of pharmacology concerned with the 
movement of drugs within the body (absorption, 
distribution, metabolism and elimination) (1, 3) 
Phenotype  the set of observable characteristics of an individual 
resulting from the interaction of its genotype with the 
environment (1) 
Phlebotomy obtaining blood from a vein (7) 
Rating of perceived exertion exertion is the expenditure of energy by skeletal 
muscles, the intensity of this action can be measured 
by the rate of which oxygen is expended, heat is 
produced and heart rate, a frequently used term is 
rating of perceived exertion or RPE-scale, also known 
as the Borg scale, which is use of a scale to indicate a 
quantitative feeling of fatigue (9)  
Single nucleotide polymorphism variation in a single base pair in a DNA sequence (1) 
Stress response the physiological response of the whole animal, in 
contrast to cellular stress responses, the induction and 
regulation of which are distinct from responses of the 
intact animal. Stimuli that induce stress responses are 
stressors, and common stressors include 
psychological, physical, and drug or chemical stimuli. 
Activation of this physiological response almost always 
is associated with activation of the hypothalamic-
pituitary-adrenal (HPA) axis and the sympathetic 
nervous system, leading to changes in the 
concentrations of stress-related mediators (10) 
Sub-maximal exercise an exercise test halted at a predetermined point that is 
less than the maximal exercise capability of the subject, 
usually at a particular percentage of the maximal heart 
rate or after a set time interval (7) 
Time trial  a test of a competitor’s individual speed over a set 
distance, especially a cycling race in which competitors 
are separately timed, an exercise designed to test the 
time needed for a task or activity (1) 
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Transition  the process or a period of changing from one state or 
condition to another (1), in the context of triathlon, the 
changeover from the swim to the cycle and from the 
cycle to the run sections of the triathlon (2, 8) 
Triathlon 1 first time trial of the current research study, comprising 
of an Olympic-distance triathlon (swim (1.5 km), swim-
to-cycle transition, cycle (40 km), cycle-to-run transition 
and run (10 km) held at Gordon’s Bay beach, Western 
Cape, South Africa on 22 May 2011 
Triathlon 2 second time trial of the current research study, 
comprising of an Olympic-distance triathlon (swim (1.5 
km), swim-to-cycle transition, cycle (40 km), cycle-to-
run transition and run (10 km) held at Gordon’s Bay 
beach, Western Cape, South Africa on 5 June 2011 
T-score relevant measure when screening for osteoporosis, the 
bone mineral density (BMD) at the site when compared 
to the young normal reference mean, it is a comparison 
of a patient's BMD to that of a healthy thirty-year-old of 
the same sex and ethnicity, value is used in post-
menopausal women and men over aged 50 because it 
better predicts risk of future fracture (11) 
the criteria of the World Health Organization are; 
normal is a T-score of -1.0 or higher, osteopenia is 
defined as between -1.0 and -2.5 and osteoporosis is 
defined as -2.5 or lower, meaning a bone density that is 
two and a half standard deviations below the mean of a 
thirty year old man/woman (12) 
Vacutainer blood collection tube that is a sterile glass or plastic 
tube with a closure that is evacuated to create a 
vacuum inside the tube facilitating the draw of a 
predetermined volume of liquid (7)  
Venipuncture puncture of a vein through the skin in order to withdraw 
blood for analysis (7) 
VO2 max  the maximum or optimum rate at which the heart, 
lungs, and muscles can effectively use oxygen during 
exercise, used as a way of measuring a person’s 
individual aerobic capacity (1) 
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Z-score the comparison to the age-matched normal and is 
usually used in cases of severe osteoporosis, this is the 
number of standard deviations a patient's BMD differs 
from the average BMD of their age, sex, and ethnicity, 
this value is used in premenopausal women, men 
under the age of 50, and in children, it is most useful 
when the score is less than 2 standard deviations 
below this normal (11) 
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CHAPTER 1: INTRODUCTION 
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1.1 Background, research contextualisation and problem statement 
There is abundant evidence regarding the ergogenic effect of caffeine during endurance 
exercise and general consensus amongst published reports about the ergogenic properties 
of caffeine. Most of these studies have investigated the effect of caffeine on performance in 
cycling, running, swimming, rowing and skiing, but none of these studies has considered the 
effect of caffeine supplementation on a combination of these events, specifically triathlon 
performance.  
 
The present research study focused on four distinct aspects in terms of caffeine 
supplementation and triathlon performance. This study investigated the possible ergogenic 
effect of caffeine supplementation on real life Olympic-distance triathlon performance, 
including an evaluation of several parameters that could in part explain why caffeine 
supplementation is ergogenic. In addition, it provides an in depth investigation of possible 
factors influencing the ergogenicity of caffeine supplementation on Olympic-distance 
triathlon as well as possible confounding factors influencing triathlon performance. The 
rationale for investigating these aspects will be discussed briefly in this Chapter. 
 
1.2 The possible ergogenic effect of caffeine supplementation on 
real life Olympic-distance triathlon performance 
Published studies have investigated the ergogenic properties of caffeine supplementation 
during or before various time trial performance tests in swimming, cycling, running and 
rowing (13-18); cycling and running time to exhaustion protocols (19-30); ratings of 
perceived exertion (15, 27, 29, 31, 32); prolonged cycling at 60-70% VO2 max (27, 29, 30) 
and high intensity intermittent team sport (33, 34). It was concluded from these studies that 
caffeine supplementation decreases the time to complete time trial events, increases 
endurance when exercising to exhaustion (i.e. increases the time to fatigue), decreases 
ratings of perceived exertion and increases prolonged sub-maximal cycling performance.  
 
Studies that found no beneficial effect of caffeine supplementation on sports performance 
involved non-endurance exercise tests or events.  These studies looked at athletic agility 
(35), weight training (36), exercise in extreme conditions (37), repeated sprints in team-sport 
athletes (38), maximal ability to generate power, reduction in fatigue during high-intensity 
dynamic exercise (39) or repeated bouts of short term intense exercise measured by 
Wingate tests (40). Other studies showing similar results were not standardised in terms of 
nutrition or environmental factors. Therefore, although these studies all addressed specific 
problems and provide valuable information about performance under particular conditions, 
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these reported results are not directly applicable to a competitive endurance event like a 
triathlon. 
 
There are also several limitations in the research design and methodology employed in 
many of these published studies on the effects of caffeine supplementation on performance. 
In most of these studies, for example, performance was measured by means of “time to 
exhaustion” protocols. Although this provides valuable laboratory information on the effect of 
caffeine supplementation, it is not an accurate reflection of exercising in the field. There is a 
greater coefficient of variation when a subject performs a time to exhaustion protocol in 
comparison to a time trial performance (41-43). Time to exhaustion does not measure the 
true exercise performance benefit of caffeine as no sport requires an athlete to endure more 
or complete a longer distance than his/her competitors (41, 42).  
 
Another limitation is that several studies (28-30) also use protocols in which athletes 
exercise for longer periods of time (a total of 120-240 minutes) at constant sub-maximal 
intensity, which is not applicable to a race situation. The few field studies published on the 
ergogenic effect on caffeine are not applicable to long-duration endurance exercise, (such as 
a triathlon), under normal environmental conditions (13, 41, 44-46).   
 
A triathlon specifically requires an athlete to complete the set amount of work or distance in 
the shortest amount of time; it is thus a time trial performance. Triathletes experience a 
variety of environmental factors, functional demands and other factors such as drafting 
position, power output and the selection of cycling cadence, to a greater extent than 
encountered in single sporting events of equal duration (47, 48).  
 
There is a difference between the elements affecting exercise performance during a race 
and those acknowledged during laboratory experiments. One of the biggest variances is 
related to the stability of power output in experimental studies when compared to pacing 
strategies used during competition, particularly when the competitive stakes are high (49). 
Field studies allow for more strength of performance measures because field studies include 
real airflow and ground resistance, real life pacing tactics, fluctuations in the environment 
and course over the event and the effect of rivalry and other extrinsic factors (42). 
Laboratory-based studies with very close control over the environment and the athlete have 
shown that caffeine has an effect on metabolism and exercise performance (42). This 
cannot, however, always be extrapolated to real-life events.  
 
Stellenbosch University http://scholar.sun.ac.za
32 
 
Most published studies on the ergogenic effect of caffeine supplementation use healthy or 
well-trained individuals in more widely practised disciplines such as running or cycling, and 
usually do not focus specifically on triathletes. Therefore, the present study aimed to 
investigate the possible ergogenic effect of caffeine supplementation on Olympic-distance 
triathlon in near real life conditions, specifically focussing on the effect of caffeine 
supplementation on triathlon performance, rating of perceived exertion and changes in mood 
state.  
 
1.3 Parameters that could in part explain why caffeine 
supplementation is ergogenic 
Available research on the mechanism(s) by which caffeine supplementation results in an 
ergogenic effect is controversial and more research in this field is needed to fully understand 
and comprehend the mechanism(s) by which caffeine enhances performance as well as the 
extent of improvement in endurance performance. This is of particular importance when 
research is conducted in the field compared to the laboratory setting, as the biochemical 
effect of caffeine supplementation may be altered when an athlete is removed from the 
controlled laboratory environment and is highly motivated and aroused to compete in a real-
life competition (50, 51). Due to the fact that exercise and caffeine supplementation can both 
be seen as independent stressors, the real-life setting as simulated in the present study 
provides valuable information regarding the endocrine-stress response (cortisol, prolactin, 
dehydroepiandrosterone sulphate and testosterone), oxidative stress response (total and 
differential white blood cell count) and the adrenergic response (lactate) that have all been 
associated with the ergogenic effect of caffeine supplementation. These parameters result 
either from the direct effect of caffeine on the central nervous system or indirectly from the 
effect of caffeine on the hypothalamic-pituitary-adrenal axis (HPA-axis), autonomic nervous 
system and immune response (52, 53). Further biophysiological rationals for including these 
parameters is presented in Chapter 2.  
 
1.4 Possible factors influencing the ergogenicity of caffeine 
supplementation on Olympic-distance triathlon performance 
Various factors such as lifestyle, gender and genetics can affect the pharmacokinetics of 
caffeine and thus influence the ergogenic effect of caffeine. 
 
First, lifestyle factors important to consider include caffeine habituation, where increased 
doses of caffeine are needed to elicit the same effect of caffeine supplementation. The pre-
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event dietary intake, smoking and excessive alcohol intake may also affect the ergogenicity 
of caffeine supplementation (54-63).  
 
Second, the influence of gender should be accounted for. There are a limited number of 
studies differentiating between subjects and/or results on a gender basis. A large amount of 
the existing research on caffeine consumption in sport or exercise has only included male 
athletes. In a 2009 systematic review, only 10 of the 29 trials included women in the study 
population, of which two studies tested only female subjects and statistical analysis in the 
other eight trials did not distinguish between males and females (41). This is of importance, 
as gender, and more specifically the phase of the menstrual cycle, menopause and oral 
contraceptive use has the potential to influence caffeine metabolism and thereby its effect on 
exercise performance. Caffeine excretion is slower during the late luteal phase of the 
menstrual cycle and the use of oral contraceptive medication increases plasma caffeine 
concentrations. Menopause has also been shown to influence caffeine metabolism. 
 
Third, the risk and/or benefit of caffeine supplementation depend largely on the metabolism 
thereof, which is genetically determined. The enzyme that is responsible for the breakdown 
of caffeine in the liver (CYP1A2) is genetically determined and therefore some people may 
be more sensitive to the use of caffeine than others. This may account for the contradictions 
found in the current literature with regards to the increased or decreased risk of adverse 
health effects and the effect thereof on sport performance. The prevalence and influence of 
CYP1A2 gene polymorphism can therefore also potentially affect the ergogenicity of caffeine 
supplementation.  
 
It is evident that various factors, such as lifestyle, gender and genetics can affect the 
pharmacokinetics of caffeine. It is thus imperitive when studying the performance enhancing 
effect of caffeine supplementation to take these factors into consideration. 
 
Additionally, in order to attribute the ergogenic effect seen during endurance exercise to 
caffeine supplementation, one has to also consider other possible confounding factors that 
can influence Olympic-distance triathlon performance, apart from the abovementioned 
factors influencing the ergogenicity of caffeine supplementation. 
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1.5 Possible confounding factors influencing Olympic-distance 
triathlon performance 
Well-controlled field research studies should ideally control for not only the factors 
influencing the ergogenicity of caffeine supplementation, but also for factors that can 
influence endurance performance above and beyond the intervention. General health, 
dietary intake, body composition and training in the days leading up to the event, symptoms 
of caffeine withdrawal and side-effects of caffeine supplementation, as well as hydration are 
important aspects to consider in this regard. 
  
There are at least two approaches toward conducting research in the field setting. One can 
either conduct the research at real life conditions, whilst measuring and accounting for all 
possible confounding factors or one can control for these confounding factors. After long 
deliberation, the researcher decided to make the brave decision to conduct a clinical trial in 
real life circumstances, whilst noting all factors that could possibly influence performance. It 
is the opinion of the author that this type of approach leads to wider applicability and 
increased practical application of the results. It is important to test the effect of ergogenic 
aids in the situation in which it will ultimately be used. Although this approach would dilute 
the actual effect of the ergogenic aid, this is the actual effect that will be observed when 
used in real life situations, such as in the present study. In the South African context this is of 
particular importance as athletes have either limited resources or knowledge regarding 
optimal pre-race strategies. Although this situation is not ideal, it is reality in South Africa. 
 
Therefore, this research protocol allowed for subjects to follow their own preparational, 
including nutritional strategies and the use of their own equipment in order to imitate real-life 
practices. Because of the major impact of dietary intake and body composition on exercise 
and more specifically endurance performance, this study also focussed on the 
comprehensive assessment of the dietary intake and body composition and its effect on 
triathlon performance. 
 
1.6 Aim and objectives 
1.6.1 Aim 
Given the limitations explored above and the fact that most research on caffeine 
supplementation has been conducted in a laboratory setting, the need arose to conduct a 
double-blind, randomized, crossover, controlled, clinical field trial, utilizing optimal 
performance assessment tools, to establish the true effect of caffeine supplementation on 
provincial-level male and female Olympic-distance triathletes and triathlon performance in 
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the Western Cape, South Africa. The use of a double-blind research design and appropriate 
statistical methods is imperative, because the margin between the athletes winning and 
losing can be measured in seconds.  
 
Therefore, the main aims of this study were to i) investigate the performance-enhancing or 
ergogenic effect of caffeine supplementation during a real-life triathlon competition; ii) 
evaluate several parameters that could in part explain why caffeine supplementation is 
ergogenic, iii) investigate possible factors influencing the ergogenicity of caffeine 
supplementation and iv) investigate possible confounding factors influencing Olympic-
distance triathlon performance.  
 
1.6.2 Research objectives 
Data was collected during two triathlons held 14 days apart (22 May and 5 June 2011), at 
the same venue in Gordon’s Bay, Western Cape Province, South Africa. Both triathlons 
consisted of a sequential 1.5 km swim, 40 km cycle and 10 km run (T1 and T2).  
 
To investigate the performance-enhancing or ergogenic effect of caffeine supplementation 
during a real-life triathlon competition with regard to: 
i) Effect on triathlon performance by measuring the time to complete the swim, cycle, 
run and overall time to complete the Olympic-distance triathlon; 
ii) Rating of perceived exertion during and after an Olympic-distance triathlon; and 
iii) Mood state before and after an Olympic-distance triathlon 
 
Evaluation of parameters that could in part explain why caffeine supplementation is 
ergogenic, with specific focus on the following: 
i) Endocrine-stress response (serum cortisol, prolactin, testosterone and 
dehydroepiandrosterone-sulphate (DHEAs)); 
ii) Infection, inflammation and oxidative stress (total and differential white cell count); 
iii) Plasma lactate 
 
To investigate possible factors influencing the ergogenicity of caffeine supplementation, such 
as: 
i) Lifestyle habits including caffeine habituation and the pre-event meal; 
ii) The influence of gender and more specifically the effect of the phase of the menstrual 
cycle, oral contraceptive use and menopause on the ergogenic effect of caffeine 
supplementation; 
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iii) The prevalence and influence of CYP1A2 gene polymorphism on the ergogenic 
effect of caffeine supplementation; 
 
To investigate possible confounding factors influencing exercise or specifically Olympic-
distance triathlon performance, such as: 
i) General health  
ii) Energy- and nutrient intake two days before as well as dietary strategies followed on 
the race day 
iii) Body composition and bone mineral density 
iv) Training two days before race day; 
v) Side effects of caffeine withdrawal  
vi) Side effects of caffeine supplementation 
vii) Hydration status and changes in plasma volume (plasma albumin, heamatocrit and 
hemoglobin)  
 
1.6.3 Hypothesis 
Four hypotheses were subsequently investigated, in a sample of provincial-level, Olympic-
distance triathlon athletes in the Western Cape, South Africa. These hypotheses are outlined 
below. 
 
i) Double-blind, randomized, crossover, controlled, clinical field trials and not only 
laboratory experiments are necessary to establish the real effect of caffeine 
supplementation on the performance time, rating of perceived exertion and mood state 
before, during and after an Olympic-distance triathlon. 
ii) The endocrine-stress response, oxidative stress and plasma lactate levels could 
potentially explain the ergogenic effect of caffeine supplementation; 
iii) Lifestyle, gender and genetics influence the ergogenicity of caffeine supplementation. 
iv) General health, energy- and nutrient intake, body composition, training status, caffeine 
withdrawal symptoms and side effects of caffeine supplementation influence Olympic-
distance triathlon performance.  
 
The conceptual framework shown in Figure 1.1 below was established according to these 
research arguments.  
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Figure 1.1 Conceptual framework illustrating the research arguments in this study 
TTC: time to complete; RPE: rating of perceived exertion; DHEAs: dehydroepiandrosterone sulphate. 
 
 
1.7 Brief chapter overview 
This dissertation is structured according to the four main aims of the study. First, the 
possible ergogenic effect of caffeine supplementation with a biophysiological rational for 
evaluating several parameters that could potentially explain why caffeine exerts an 
ergogenic effect, factors influencing the ergogenicity of caffeine supplementation as well as 
factors that can influence exercise performance. In line with this, Chapter 2 focusses on a 
comprehensive overview of the literature, followed by a detailed description of the research 
design and methodology employed is provided in Chapter 3. Chapter 4 presents the results 
of the study and the statistical analysis of these, while Chapter 5 discusses and interprets 
the results in the context of current literature on the topic. The dissertation concludes with 
Chapter 6, which consists of the summary of the main findings and practical application 
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thereof, the limitations of the study, recommendations for future research, and the 
concluding remarks.   
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CHAPTER 2: LITERATURE OVERVIEW  
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2.1 Introduction 
Caffeine (1,3,7-trimethylxanthine, molecular weight 194.2) (54, 64), taken in moderate 
dosages of 200-300 mg/day is not harmful to general health (65, 66). It is widely found in 
non-prescription medication (30-200 mg/tablet), coffee (40 – 180 mg/150ml), Ceylon tea (24 
– 50 mg/150ml), soft drinks (15 – 40 mg/180ml), chocolate bars (1 – 36 mg/ 28g), cocoa (2 – 
10 mg/150ml) (57, 67, 68), energy gels and energy drinks (30-85mg/250ml) (42, 54, 57, 64).  
 
Although caffeine is not a nutrient, such as carbohydrate (CHO), protein, fat, vitamins or 
minerals, it is a commonly-used dietary constituent. Of all the non-alcoholic drinks, coffee is 
second to water with regards to consumption worldwide (66). Every year, the global 
population consumes approximately 500 billion cups of coffee (66). Coffee is also the 
second biggest trade commodity across the globe after petroleum (66). Habitual caffeine 
consumption from coffee, tea and cocoa has been reported in almost 80% of the total 
population, with South Africa (40 mg/person/day) at the lower end of consumption in 
comparison to countries such as the Netherlands (414 mg/person/day), Sweden (407 
mg/person/day), Norway (400 mg/person/day), Denmark (390 mg/person/day), Finland (329 
mg/person/day) and Germany (313 mg/person/day) (57). Caffeine consumption from all 
sources can be estimated to around 70-76 mg/person/day worldwide	  (57).	  
 
Caffeine is a substance with no nutritional value and has attracted the consideration of many 
elite and amateur athletes as an ergogenic aid (69). Self-reported mean daily caffeine intake 
amongst athletes varies widely, with the mean daily intake of six Canadian male recreational 
athletes (running or cycling five times a week for more than three months) found to be as 
high as 761.3±11.8 mg (26). However, a study by Chester et al. (2008) of British athletes 
stated that although most of the cyclists used caffeine, levels remained below 200 mg/day 
(70). In South Africa, 42% of triathletes living in the Western Province consume herbal 
supplements with or without caffeine on a daily basis and only 4% consume caffeine on a 
habitual basis as reported by the researcher in a previous study on this group of athletes 
(71). 
 
A recent review of the risks and benefits of coffee/caffeine consumption concluded that 
caffeine can have a significant effect on the body, despite controversy and conflicting 
research (66). Moderate amounts of caffeine can increase energy substrate availability and 
daily energy expenditure; reduce fatigue and the sense of effort associated with physical 
activity; increase physical, motor and cognitive performance; increase alertness, 
wakefulness and feelings of energy; decrease mental fatigue; quicken and increase the 
accuracy of reactions; enhance concentration and short-term memory; improve the ability to 
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focus; solve problems requiring reasoning and make correct decisions; and increase 
cognitive function capabilities and neuromuscular coordination (65).  
 
2.2 Ergogenic effect of caffeine supplementation 
2.2.1 Caffeine and sport legislation 
Caffeine used to be on the International Olympic Committee’s (IOC’s) list of prohibited 
substances, but with the provision that the urinary caffeine levels exceeded 12 mg/l. 
However, on 1 January 2004 the World Anti-Doping Association (WADA) removed the 
substance from the prohibited list and instead placed it in the organisation’s monitoring 
program (64, 72-74). It is impractical for caffeine to be listed as a banned substance, as the 
dose needed to elicit a performance-enhancing effect is relatively small (3-6 mg/kg body 
weight) and an athlete can easily ingest this amount in common foodstuffs (64, 72-74).  
 
The American National Collegiate Athletic Association (NCAA) currently uses a urinary 
caffeine cut-off value of 15 mg/l (72, 73) and the South African Institute for Drug Free Sports 
uses the WADA guidelines in South African anti-doping rules and policies. Furthermore, only 
5% of an administered dose of caffeine is eliminated in urine. Acute dosages of up to 9-13 
mg/kg body weight can thus be administered without reaching a urinary caffeine level of 12 
mg/l (64, 72, 73). 
 
2.2.2 Evidence in support of the ergogenic effect of caffeine  
Performance in several types of exercise, including endurance exercise, high-intensity team 
sport, strength-power performance and special force operations, has been shown to be 
significantly increased by the ingestion of caffeine (72). 
 
Table 2.1 summarizes various studies on the ergogenic properties of caffeine 
supplementation during or before various endurance exercises, such as time trial swimming, 
cycling, running and rowing, cycling and running time to exhaustion protocols, ratings of 
perceived exertion, prolonged cycling at 60-70% VO2 max, and high intensity intermittent 
team sport.  
 
 
  
Stellenbosch University http://scholar.sun.ac.za
42 
 
Table 2.1 Studies examining the effect of caffeine supplementation on 
endurance sport performance (cycling, running, swimming or rowing)  
 
Reference Participants Supplementation / Intervention Outcome measured Conclusion 
Desbrow et al. (2012)  
16 male cyclists 
Habitual caffeine 
consumers 
Abstained 24 hours 
prior 
3 & 6 mg/kg  
90 minutes prior  
Set amount of work @ 75%  
peak sustainable power output 
for 60 minutes 
Similar ↑ performance in both 
groups 
No effect on RPE 
 
Roelands et al. 
(2011) 8 male cyclists 
6 mg/kg 
60 minutes prior 
Cycled for 60 minutes @ 55% 
Wmax, followed by TT (30ºC) 
No change in performance 
 
Ganio et al. (2011)  
11 male cyclists 
Low daily users 
Abstained 3 days prior 
3 mg/kg 
60 minutes prior & 
again 45 minutes 
into exercise 
90 minutes @ 65% VO2 max, 
followed by 15 minute TT 
RPE not affected by caffeine 
↑ exercise capacity 
↓ leg muscle pain in heat 
 
Ganio et al. (2011) 
11 male cyclists 
Habitual and non-
users 
Abstained 3 days prior 
3 mg/kg  
60 minutes prior & 
after 45 minutes of 
exercise 
90 minutes @ 65% VO2 max + 
15 minute TT (12ºC and 33ºC) 
↑ performance independent 
of temperature 
 
Ely et al. (2011)  10 males Non-users 9 mg/kg 
Cycle ergometer exercise for 
30 minutes @ 50% VO2 max 
(40ºC, 25% humidity) 
No significant change in heat 
balance 
 
Carr et al. (2011)  
6 male & 2 female 
rowers 
Abstained 48 hours 
prior 
6 mg/kg  
30 minutes prior 2000 m rowing ergometer tests ↑ power 
	  
Backhouse et al. 
(2011)  
12 male cyclists 
Low to moderate 
consumers 
Abstained for 60 hours 
prior 
6 mg/kg  
60 minutes prior 90 minutes @ 70% VO2 max ↓RPE 
	  
Simmonds et al. 
(2010) 
6 male cyclists 
Habitual caffeine 
users 
Abstained 24 hours 
prior 
5 mg/kg  Supra-maximal cycle bouts (120% VO2 max) to exhaustion  
Beneficial to supra-maximal 
cycling performance 
 
Ping et al. (2010) 
9 heat-adapted male 
runners 
Non-users of caffeine 
Abstained at least 10 
hours 
5 mg/kg  
60 minutes prior  
Running @ 70% VO2 max  
(31ºC, 70% humidity) 
 
↑ running performance 
No change in RPE 
	  
Hadjicharalambous et 
al. (2010) 
10 male cyclists 
Abstained 48 hours 
prior 
High fat meal vs. 
high fat meal + 7.5 
mg/kg caffeine 
Cycle TTE 
(10ºC & 70% humidity) 
@ ± 73% VO2 max  
Artificial elevation in plasma 
FFA no additional ↑ in 
endurance performance from 
caffeine 
 
Walter et al. (2009) 20 males 200 mg  30 minutes prior TTE @ 80% VO2 max No difference in TTE 
	  
Ivy et al. (2009) 
6 male & 6 female 
cyclists 
Abstained overnight 
160 mg  
40 minutes prior 
Time to complete standard 
amount of work equal to 60 
minutes cycling @ 70% Wmax 
 ↑ performance 
No change in RPE 
	  
Desbrow et al. (2009) 
9 male cyclists 
Habitual and non-
users 
Abstained 24 hours 
prior 
1.5or 3 mg/kg 
60 minutes prior 
120 minutes steady state 
cycling @ 70% VO2 max + TT 
No significant ↑ TT 
performance 
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Reference Participants Supplementation / Intervention Outcome measured Conclusion 
Candow et al. (2009) 
9 male, 8 female 
Abstained 48hours 
prior 
2 mg/kg  Run TTE @ 80% VO2 max 
No difference in TTE, RPE or 
blood lactate 
	  
McNaughton et al. 
(2008) 
6 male cyclists 
Habitual caffeine 
consumers 
Abstained 24 hours 
6 mg/kg  
120 minutes prior 60 minutes cycling TT 
↑ distance cycled during TT 
↑ performance 
 
Hogervorst et al. 
(2008) 
24 cyclists 
Moderate habitual 
caffeine Abstained 
overnight 
Performance bar 
with 100 mg 
caffeine 
2.5 hour cycling @ 60% VO2 
max  &  
TTE @ 75% VO2 max 
↑ performance & complex 
cognitive ability during & after 
exercise 
 
Del Coso et al. (2008) 
7 endurance trained 
males 
Light caffeine users 
6 mg/kg BW 
45 minutes prior 
 
Prolonged exercise in heat,  
pedaled for 120 minutes @ 
63% VO2 max in hot-dry 
environment 
↑ maximal cycling power  
When combined with water & 
CES: ↑ increases maximal 
leg force  
↓ reducing central fatigue 
	  
Beck et al. (2008) 31 male 201 mg 45 minutes prior  Running TTE @ 85% VO2 max No effect on running TTE 
 
Demura et al. (2007) 10 males Abstained overnight 
6 mg/kg BW  
60 minutes prior 
Submaximal endurance cycling 
60 minutes @ 60% VO2 max  
↓ RPE  
No difference in oxygen 
uptake RER, HR / plasma 
lactate 
 
Cureton et al. (2007) 
16 cyclists 
Habitual caffeine 
consumers 
Abstained the day 
prior 
5.3 mg/kg 
Cycled for 135 minutes (60%-
75% VO2 max) &  
15 minute performance ride 
Work completed during 
performance ride ↑,  ↓RPE  
↓ maximal voluntary 
contraction  
 
Hadjicharalambous et 
al. (2006) 
8 male endurance 
athletes 
Abstained 48 hours 
prior 
High fat meal vs. 
high fat meal + 7.0 
mg/kg  
60 minutes prior 
3 constant-load cycling tests @ 
± 73% VO2 max for 30 minutes 
et al.  (20ºC), followed by 
incremental exercise to fatigue 
↓RPE  
10 male cyclists 
Abstained 48 hours 
prior 
 
High fat meal vs. 
high fat meal + 7.5 
mg/kg 
60 minutes prior 
3 constant-load cycling tests to 
limit of tolerance at 10ºC 
↓ RPE did not ↑ 
performance  
 
Bridge et al. (2006) 
8 male distance 
runners 
Habitual caffeine 
consumers 
Abstained 48 hours 
prior 
3 mg/kg 8 km running TT  ↓ 8 km running time  
 
Beedie et al. (2006) 6 male cyclists No abstinence 
4.5 mg/kg & 
9 mg/kg (placebo 
masked as 
caffeine) 
Evaluated placebo effect  Placebo effect present 
 
O’Connor et al. 
(2004) 
12  males 
Low habitual caffeine 
consumers 
Abstained 1 week 
prior 
5 / 10 mg/kg  
60 minutes prior 
30 minutes cycling @ 60% VO2 
max 
 
↓ leg muscle pain  
 
McLellan et al. (2004) 
9 male + 4 female 
untrained subjects 
Habitual users 
3, 5, 7 mg/kg 
90 minutes prior Cycling at 80% VO2 TTE ↑TTE, regardless of dose 
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Reference Participants Supplementation / Intervention Outcome measured Conclusion 
Haller et al. (2004) 
7 men & 3 females 
Non-users of caffeine 
Abstained 24 hours 
prior 
303.8 mg caffeine RPE ↓ RPE 
 
Doherty et al. (2004) 
11 male cyclists 
Abstained 24 hours 
prior 
5 mg/kg High intensity cycling performance 
↓ RPE 
↑ mean power output 
 
Birnbaum et al. 
(2004) 
5 male & 5 female 
cross country runners 
Habitual and non-
users 
Abstained 4 days prior 
7 mg/kg 
60 minutes prior 30 minute run @ 70% VO2 max 
↑ respiratory efficiency 
↓RPE 
 
 Conway et al. (2003) 
9 male cyclists & 
triathletes 
Abstained 48 hours 
prior 
6 mg/kg 
 60 minutes prior 
OR 
3 mg/kg, 60 
minutes prior & 
again 3 mg/kg 45 
minutes into 
exercise 
Cycled 90 minutes @ 68% VO2 
max  
Self-paced TT @ 80% VO2 max 
over 30 minutes 
No change in TT 
performance 
“tended” to be faster 
 
Bell et al. (2003) 
9 recreational male 
cyclists 
Habitual caffeine 
consumers Abstained 
12 hours prior 
5 mg/kg AM + 2.5 
mg/kg PM (5 hours 
later) 
OR 5 mg/kg AM 
OR 5 mg/kg PM 
60 minutes prior 
(AM & PM) 
TTE @ 80% VO2 max  
Re-dosing not necessary to 
maintain ergogenic effect 
during subsequent exercise 6 
hours later 
↓ RPE 
 
Cox et al. (2002) 
12 male 
cyclists/triathletes 
Habitual caffeine 
users 
6 mg/kg  
60 minutes prior  
and 
6 X 1 mg/kg every 
20 minutes 
120 minutes steady state 
cycling @ 70% VO2 max  
+ 7 kJ/kg TT  
↑	  TT performance 
independent of timing of 
intake 
8 highly trained male 
cyclists or triathletes 
Occasional – habitual 
intake (150mg /day 
3 X 5 ml 
decaffeinated cola 
drink (6% CHO) 
OR caffeinated 
cola drink 
(13mg/100ml) (6% 
CHO) OR 
decaffeinated cola 
drink (11% CHO) 
OR caffeinated 
(13mg/100ml) cola 
drink (11% CHO) 
Replacing sports drink with 
coca-cola during latter stages 
↑ endurance performance 
↓ RPE  
 
Bell et al. (2002) 
10 male & 2 female 
runners Habitual and 
non-users 6 Abstained 
24 hours prior 
4 mg/kg  
90 minutes prior 
10 km running on treadmill 
(wearing helmet & backpack 
(11 kg, 12-13◦C) 
Ergogenic effect due to 
ephedrine, NOT caffeine 
 
Bell et al. (2002) 
15 male & 6 female 
Habitual & non-users 
Abstained 12 hours 
prior 
5 mg/kg BW  
1, 3 or 6 hours 
prior 
TTE 
↑TTE 
Effect ↑ in nonusers vs. 
users 
↓ RPE 
 
Greer et al. (2000) 
8 males 
Abstained 48 hours 
prior 
6 mg/kg 
90 minutes prior Cycle TTE ↑TTE 
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Reference Participants Supplementation / Intervention Outcome measured Conclusion 
Bruce et al. (2000) 
8 male rowers 
Abstained 72 hours 
prior 
0, 6, 9 mg/kg  
60 minutes prior  
2000 m rowing performance on 
an air-braked ergometer 
↓ performance time 
↑ mean power 
↓ RPE 
 
Anderson et al. 
(2000) 
8 oarswomen 
Abstained 72 hours 
prior 
6 or 9 mg/kg  
60 minutes prior 2 000 m rowing trials 
↓ performance time (both 
dosages) 
RPE not ↓ 
 
Van Soeren et al.  
(1998) 
6 male cyclist/runners 
Habitual caffeine 
consumers 
No abstinence, 2 day 
abstinence and 4 day 
abstinence 
 6 mg/kg  
60 minutes prior 
60 minute cycle TTE @ 80-
85% VO2 max 
↑ endurance NOT related to 
prior caffeine habituation  
 
Kovacs et al. (1998) 
15 male cyclists & 
triathletes 
Habitual and non -
users 
Abstained 48 hour 
prior 
150, 225 & 320 mg 
(+ CES) 
60 minute TT @ 90rpm & 70% 
Wmax 
↑ performance  
 
Graham et al. (1998) 
8 male, 1 female 
runner 
Habitual and non-
users Abstained 48 
hours prior 
4.45 mg/kg  
60 minutes prior  
Running @ 85% VO2 max until 
voluntary exhaustion  
(~32 minutes) 
↑ endurance with caffeine  
 
Denadai et al. (1998) 8 males Non-users 
5 mg/kg  
60 minutes prior 
Cycle TTE (10% above and 
below AT) 
10% below AT: ↓ RPE, ↑TTE 
10% above AT: no effect on 
RPE / TTE 
 
Bell et al. (1998) 
8 males 
Habitual caffeine 
users 
5 mg/kg  
60 minutes prior 
TTE during high intensity 
cycling  
RPE 
↑ TTE (caffeine + ephedrine) 
C / E alone no effect on TTE 
↓ RPE 
 
Cole et al. (1996) 
10  male runners & 
triathletes 
Habitual and non-
users 
Abstained 48 hours 
prior 
6 mg/kg  
60 minutes prior 
30 minutes of isokinetic 
variable-resistance cycling 
exercise 
Ergogenic role identified 
 
Cohen et al. (1996) 5 male, 2 female runners 
5 & 9 mg/kg 
 21 km during heat & humidity  
No significant effect on 
performance 
 
Trice et al. (1995) 8 male cyclists 5 mg/kg  60 minutes prior  
Intermittent cycling at high 
intensity & cycling TTE 
↑ TTE 
 
Pasman et al. (1995) 
9 cyclists 
Habitual and non-
users 
Abstained 3 days prior 
5, 9 & 13 mg/kg 
 Cycling TTE @ 80% Wmax 
↑ performance when 
compared to placebo 
No difference at different 
dosages 
 
MacIntosh et al. 
(1995) 
7 male & 4 female 
swimmers 
Habitual and non-
users 
Abstained 48 hours 
prior 
6 mg/kg  
2½ hours prior  
1500 m swim 
 (~ 20-25 minutes) 
↓ RPE for 100 m warm-up 
swims 
↓ time to swim 1500m 
 
Graham et al. (1995) 
8 male runners 
Habitual and non-
users  
Abstained 48h prior 
3, 6 or 9 mg/kg  
60 minutes prior 
Running at 85% VO2 max  to 
voluntary exhaustion 
↑ endurance with 3 & 6 
mg/kg 
No significant effect with 9 
mg/kg 
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Reference Participants Supplementation / Intervention Outcome measured Conclusion 
Graham et al. (1991) 
1 female & 6 male 
runners 
Habitual and non-
users Abstained 48 
hours prior 
9 mg/kg  
60 minutes prior  
Running & cycling TTE @ 85% 
VO2 max 
↑ TTE during running & 
cycling 
 
French et al. (1991) 6 male runners Non-users 
10 mg/kg 
Immediately prior 
Treadmill run @ 75% VO2 max 
for 45 minutes, speed 
increased and TTE measured 
↑ distance covered 
↑ lactate (final 
measurement) 
TG ↑ 
 
Dodd et al. (1991) 
17 moderately trained 
males 
Habitual & nonusers 
0.3 & 5 mg/kg Cycling TTE No ↑TTE 
 
Rodrigues et al. 
(1990) 6 male runners 5 mg/kg Incremental cycling TTE 
No effect on TTE 
↓RPE 
 
Gastin et al. (1990) 8 runners Non-users 
5 mg/kg  
3.5 hours prior Incremental treadmill running  
Running TTE, VO2 max & 
lactate threshold unaltered 
↓ RPE 
 
Flinn et al. (1990) 9 male cyclists Non-users 
10 mg/kg 
3 hours prior TTE ↑TTE 
	  
Tarnopolsky et al.  
(1989) 
6 runners 
Habitual caffeine 
consumers 
6 mg/kg 
60 minutes prior 
90 minutes treadmill running @ 
70% VO2 max 
↑ FFA, but no metabolic / 
neuromuscular effect that 
would prove ergogenic 
↓ RPE 
	  
Falk et al. (1989) 23 males 
5 mg/kg & again 2 
doses of 2.5 mg/kg 
during exercise 
Following a 40 km march, 
subjects completed cycle TTE 
protocol  
No difference in TTE / RPE 
↑ lactate  
 
Fisher et al. (1986) 
6 females 
Habitual caffeine 
users 
Abstained 4 days prior 
5 mg/kg  60 minutes @ 75% VO2 max treadmill 
Caffeine after withdrawal ↑ 
effects 
 
Powers et al. (1983) 
7 male cyclists 
Abstaining 2 weeks 
prior 
5 mg/kg  
60 minutes prior 
Graded cycle ergometer 
exercise, TTE 
No significant difference in 
the TTE  
 
Ivy et al. (1979) 
7 male & 2 female 
cyclists 
Abstained 12 hours 
prior 
250 mg  
60 minutes prior 
Repeated doses of 
250 mg every 15 
minutes for the first 
90 minutes 
120 minutes of isokinetic 
cycling exercise @ 80 rpm 
↑ work production 
RPE unchanged 
 
Costill et al. (1978) 
7 male & 2 female 
cyclists 
Abstained 6-12 hour 
prior 
330 mg caffeine in 
coffee 60 minutes 
prior  
Cycle TTE @ 80% VO2 max 
↑ TTE  
↓ RPE 
 
Perkins et al. (1975) 14 female students 0, 4, 7 &10 mg/kg  Incremental cycling TTE No effect on performance or RPE 
 
Sources: (13-15, 19-22, 25-27, 29, 30, 32, 37, 45, 53, 75-118) 
RPE: Rating of perceived exertion; TTE: Time to exhaustion; TT: Time Trial; mg/kg: milligrams per kilogram body weight; CES: 
Carbohydrate-electrolyte solution; HR: Heart rate; RER: Respiratory exchange ratio; FFA: Free fatty acids; kJ/kg: kilojoules per 
kilogram body weight; AT: Anaerobic threshold 
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By analysing the abovementioned studies in Table 2.1, it appears that caffeine 
supplementation decreases the time to complete time trial events, increases endurance 
when exercising to exhaustion (i.e. increases time to fatigue), decreases ratings of perceived 
exertion and increases prolonged sub-maximal cycling performance. This is also evident 
when reading earlier reviews on the beneficial effect of caffeine supplementation on 
decreasing time to exhaustion during endurance testing (28) and reducing the rating of 
perceived exertion (31).  
 
There appears to be four performance indicators often used when studying the ergogenic 
effect of caffeine supplementation (Table 2.1). These indicators include endurance time to 
exhaustion, steady-state exercise, ratings of perceived exertion and time trial performance. 
From Table 2.1 one can see that most studies were completed using time to exhaustion or 
steady state exercise trials 
 
Only a few studies have found a beneficial effect of caffeine supplementation on increased 
exercise performance following time trial protocols. These include studies examining the 
effect of caffeine supplementation on i) 8 km running (13), ii) 90 minutes cycling at 65% 
VO2max followed by a 15 minute time trial (78), iii) 60 minute cycling (16, 25), iv) 2000 m 
rowing (14, 102) and v) 1500 m swim (15).  
 
Previous studies on caffeine supplementation involved subjects abstaining from caffeine for 
periods of between 2-4 days. The general consensus is that the dosage of caffeine 
supplementation needed to result in an ergogenic effect is 3-13 mg/kg body weight (69) 
(Table 2.1). Lower dosages (3 mg/kg body weight) also appear to be ergogenic (69). It is 
also suggested that the timing of caffeine ingestion (before and then repeatedly during 
exercise) is not of paramount importance, provided that the initial dose of caffeine is 
sufficient to maintain optimal plasma levels for the duration of the exercise (27, 98, 100). 
These abovementioned studies evaluating caffeine supplementation on time trial 
performance are standardized in terms of utilizing a time trial protocol as well as dose of 
caffeine supplementation (3-6 mg/kg BW), timing of caffeine supplementation (60-120 
minutes prior to exercise) and abstinence from caffeine (24-72 hours). 
 
There is also a large amount of studies demonstrating decreased RPE following caffeine 
supplementation (27, 29, 81, 91, 92, 96, 97, 99, 104, 109, 110, 112, 117, 118). This 
decrease in RPE does not necessarily always translate to an increased exercise 
performance (91, 92, 99, 109, 110), however various studies have found an increase in 
exercise performance without observing decreased RPE (75, 77, 83, 85, 102). 
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The majority of the studies regarding exercise and caffeine supplementation employ TTE 
exercise protocols. Although these studies show an increased TTE with caffeine 
supplementation and therefore promise of its ergogenicity, it is limited in terms of practical 
applicability of the results obtained compared to the field setting. There is a greater 
coefficient of variation when a subject performs a TTE protocol in comparison to time trial 
performance (41-43). Time to exhaustion does not measure the true exercise performance 
benefit of caffeine as no sport requires an athlete to endure more or complete a longer 
distance than his / her competitors (41, 42). Another limitation is that several studies (28-30) 
also use protocols in which athletes exercise for longer periods of time (a total of 120-240 
minutes) at constant sub-maximal intensity (steady state), which is not applicable to a race 
situation. 
 
Studies that found that caffeine supplementation did not have a beneficial effect on sports 
performance were performed using non-endurance exercise tests or events.  These studies 
investigated the following aspects: i) athletic agility (35), ii) weight training (36), iii) 10 km 
running performance while wearing a helmet and backpack weighing 11 kg in a climate suite 
during environmental conditions of 12 – 13°C (37), iv) repeated sprints in team-sport athletes 
(38), v) maximal ability to generate power or reduction in fatigue during high-intensity 
dynamic exercise (39), or vi) repeated bouts of short term intense exercise measured by 
Wingate tests (40).  
 
Other studies (45, 106, 110, 119) that also showed little or no beneficial effect of caffeine 
supplementation were not standardised in terms of nutrition, environmental factors, or the 
type of exercise performed. For example, the time to exhaustion during high-intensity cycling 
was measured in non-athletic males consuming caffeine on a habitual basis, but caffeine 
intake prior to the test was not standardised (45), endurance racing during hot and humid 
conditions (106), activities requiring strength and short-term endurance (119), and 
incremental treadmill running (110).  
 
The addition of other dietary components, such as CHO, which is common practice during 
endurance exercise, negates some of the ergogenic effects of caffeine, as shown in a review 
on the effect of the ingestion of CHO and caffeine compared to the effect of caffeine intake 
alone. Caffeine intake increased performance, irrespective of CHO intake; however, the 
magnitude of difference was smaller when combining caffeine with CHO (120). 
 
It thus seems that caffeine has a clear benefit in enhancing exercise performance in steady-
state endurance exercise. During a triathlon, however, exercise can be stochastic at times, 
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making it difficult to extrapolate research findings from the abovementioned studies to a 
triathlon.  
 
Although studies employ triathletes as part of the study population, it is evident from the 
literature explored that the discipline of triathlons is not commonly researched, especially in 
terms of caffeine supplementation. This is possibly due to the complexity of the sport as a 
model. Triathlon encompasses three sporting disciplines namely swimming, cycling and 
running. An Olympic or standard distance triathlon comprises of a sequential swim (1.5 km), 
swim-to-cycle transition, cycle (40 km), cycle-to-run transition and run (10 km) (2, 8). The 
time spent completing an Olympic-distance triathlon can range from 1 hour 50 minutes for 
professional male athletes, to slightly over 2 hours for professional female athletes and 2 
hours 20 minutes for amateur-level male and female triathletes (121).  
 
Studies completed on endurance athletes, using protocols including swimming, cycling and 
running, can be indicative of triathlon performance to a certain degree. However, this is not 
always ideal, as the physiological requirements of a triathlete differs significantly from that of 
an athlete competing in only one discipline, due to long-term training conditioning. Triathletes 
exhibit different physical and physiological characteristics, which may enable them to 
perform better in different environmental conditions and landscapes (2). For example, a host 
of environmental circumstances, the use of a wetsuit, drafting during swimming and cycling, 
power output and cycling cadence selection, all potentially increase the functional demand of 
a triathlon (47, 48). The variety of event distances available for triathletes to compete in also 
leads to differences in training programs; and technical, physiological and nutritional 
differences, depending on the distance of the triathlon and should be taken into 
consideration (122). 
 
There is therefore a need for sport-specific studies to be conducted that investigate the use 
of potential performance-enhancing supplements, such as caffeine, particularly in semi-elite 
or provincial level athletes. 
 
2.3 Mechanism(s) of action of caffeine 
The mechanism of action of caffeine in order to produce an ergogenic effect can be 
explained by the pharmacodynamic properties of caffeine. The pharmacodynamics of a drug 
considers the concentration-effect relationship and thereby explaining the effect that the drug 
has on the body (3). 
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In vitro studies have helped to elucidate a multitude of cellular actions of caffeine. Although 
these effects are not always significant in vivo, it does appear that these various possible 
cellular actions of caffeine contribute to its observed effects (64). The paucity of research on 
the mechanism of action of caffeine and the controversy surrounding this has also been 
documented and many authors ascribe the ergogenic properties of caffeine to more than 
one mechanism (51, 54, 57, 101, 123-126).  
 
Caffeine has numerous effects on the body, including effects on the central nervous system 
(CNS); and on metabolic, hormonal, cardiovascular, pulmonary and renal functioning during 
rest and exercise (69) (Figure 2.1). These effects can lower the respiratory exchange ratio, 
peripheral fatigue, rating of perceived exertion (RPE), and the threshold for exercise-induced 
cortisol and beta-endorphin release; caffeine can increase oxygen uptake, cardiac output, 
ventilation, circulating levels of epinephrine, metabolic rate and fat oxidation during 
endurance exercise in trained and untrained subjects (69). 
 
 
Figure 2.1 The effects of caffeine on body systems and sports performance 
Source: (69) 
 
Numerous methods of action of caffeine have been reported. A systematic review of the 
effect of caffeine on sport-specific endurance performance proposed three mechanisms for 
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the ergogenic effect of caffeine, namely (41): i) Enhanced mobilization of intracellular 
calcium; ii) an increase in free fatty acid oxidation; and iii) antagonism of adenosine 
receptors in the CNS. An additional mechanism of action of the ergogenic effect of caffeine 
that has been proposed is the inhibition of cyclic nucleotide phosphodiesterases (57). This 
involves inhibition of cyclic nucleotide breakdown via the inhibition of phoshodiesterase and 
high quantities of caffeine is needed to elicit this effect (20 times higher concentrations) (57).  
 
Dated and more recent reviews by Goldstein et al. (2010), Tarnopolsky (2010), Davis et al. 
(2009), Ganio et al. (2009), Sokmen et al. (2008), Jones (2008), Keisler et al. (2006), Kalmar 
et al. (2004), Graham et al. (2001), Sinclair et al. (2000), Spriet (1995) and Clarkson (1993) 
have been published with detailed information on the mechanisms of action of caffeine in 
relation to exercise performance (41, 50, 51, 54, 69, 72, 74, 123, 127-130). Figure 2.2 
illustrates the most important of these in vivo mechanisms with regard to sport performance. 
The section thereafter highlights these mechanisms with regard to the biophysiological 
rational for investigating these mechanisms in terms of sport performance.  
 
 
Figure 2.2 In vivo mechanisms of action of caffeine with regard to sport performance 
Sources: (52, 53, 131-134)  
 
2.3.1 The direct effect of caffeine on the central nervous system 
It is evident from the literature that the most profound effect of caffeine supplementation on 
performance is as a result of direct stimulation of the CNS (72) where caffeine acts as an 
antagonist of adenosine receptors (41, 50, 51, 54, 69, 73, 74, 123, 128-130), particularly 
adenosine receptors A1 and A2. This receptor antagonism results in delayed fatigue, 
increased arousal, motivation, wakefulness, alertness and vigilance (123, 130). There are 
multiple actions resulting from the direct effect of caffeine on the CNS and the antagonism of 
adenosine receptors. These include a decreased brain serotonin:dopamine ratio (and 
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consequently a decrease in prolactin levels), increased testorone and blood lactate levels, 
as well as leukocytosis. The implication of which will now be briefly discussed. 
 
The antagonism of the adenosine receptors leads to a decreased serotonin:dopamine ratio 
in the brain (53). Increased levels of serotonin are found during prolonged exercise and 
leads to increased fatigue (central fatigue hypothesis). The release of the hormone, prolactin 
is under control of the central serotonergic system and is responsible for increasing 
serotonin synthesis and decreasing levels of dopamine. Caffeine decreases serotonin and 
increases dopamine, leading to a favourable serotonin:dopamine ratio. Thus, if caffeine acts 
by means of improving the brain serotonin:dopamine ratio and thereby reducing fatigue, 
increasing arousal, motivation and decreasing perceived pain and exertion, prolactin levels 
could be reduced in exercise trials examining the effect of caffeine supplementation (53).  
 
The abovementioned effect of caffeine on the adenosine receptors of the CNS thus leads to 
a decrease in perceived pain and decreased ratings of perceived exertion (41, 54, 74, 127, 
130) by binding to receptors (A1 and A2A) and decreasing neurotransmitters (69, 123). This 
action leads to reduced tiredness, improved mental alertness, mood and energy (69). 
 
In addition to the effect of caffeine on prolactin, caffeine may increase testosterone levels. 
Although the exact mechanism by which caffeine supplementation can increase testosterone 
levels is unclear (134), it can be hypothesized that because caffeine antagonizes the 
adenosine receptors in the CNS, it facilitates an increase in muscular work output. An 
increase in testosterone is linked to the intensity of exercise and increases with an increased 
exercise intensity. Therefore, if caffeine can further increase work output, testosterone levels 
would be further elevated (134). However, the elevated testosterone might be counteracted 
by an increased release of cortisol as discussed in section 2.3.2. 
 
Caffeine also increases blood lactate levels during endurance exercise, primarily due to 
increased levels of epinephrine as discussed in section 2.3.3 or due to stimulation of the 
CNS (51, 130). Caffeine has been shown to increase blood lactate levels (51), particularly 
during endurance exercise (130). This has been observed more frequently than increases in 
the levels of FFA, or decreases in respiratory exchange ratio’s (51). Increased lactic acid 
levels have also been observed at rest following caffeine ingestion (130).  
 
Davis, in a review published in 2009 found enhanced exercise performance with caffeine 
supplementation, irrespective of whether lactate levels had increased or not. The author 
speculated that the reason for the increased lactate levels may be that caffeine stimulates 
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either the release of epinephrine or the CNS and thereby reducing pain. The reduced pain 
sensation can also increase lactate accumulation and therefore the two factors can also be 
present as a coincidence (130).  
 
A further result of the antagonism of the adenosine receptors by which caffeine has its affect 
on the body can be seen on circulating neutrophils. This action is most likely also due to the 
antagonism of the adenosine receptors, which leads to an increase in the neutrophil 
oxidative burst response. An effect on neutrophils may also be present due to the adrenergic 
effect of caffeine (Section 2.3.3), although this would result in a detrimental effect on the 
neutrophil response (132, 133). Plasma adenosine is increased during exercise due to the 
dephosphyrylation of AMP. Neutrophils express A1 and A2 adenosine receptors on their 
surfaces. Adenosine acting via A1 receptors promotes neutrophil chemotaxis and 
phagocytosis and adenosine acting via A2 receptors inhibit neutrophil phagocytosis and 
superoxide generation. Caffeine is a non-selective adenosine receptor antagonist and can 
therefore affect positive and negative aspects of neutrophil function (132, 133). Neutrophils 
form 50-60% of circulating white blood cells and are important for the release of reactive 
oxygen species and antimicrobial enzymes. It provides the first line of defence against 
infectious agents and is typically reduced during or after prolonged, intensive exercise. The 
neutrophil oxidative burst response is the capacity of neutrophils to generate reactive 
oxygen species and caffeine has been shown to attenuate the reduction in this response 
(132, 133). 
 
2.3.2 The indirect of caffiene on the HPA-axis and autonomic 
nervous system 
There is enhanced secretion of β-endorphins following supplementation with caffeine, which 
reduces pain perception during exercise (72). The resulting reduction in perception of pain 
can decrease RPE and improve exercise performance. 
 
Stimulation of the HPA-axis also increases the release of cortisol. The resulting cortisol 
release can lead to metabolic, cardiovascular and CNS implications (54) and it increases 
cognitive behavior, performance and mood. 
 
Furthermore, physical exercise is recognized as being an impetus for the release of 
hormones from the endocrine system in both males and females (135, 136). The release of 
these hormones, though, is dependent on various factors related to physical activity, such as 
the intensity, time, and type of exercise, as well as the individual’s level of fitness (136).  
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The term “stress” was defined by Pruett (2003) as “the physiological response of the whole 
animal, in contrast to cellular stress responses, the induction and regulation of which are 
distinct from responses of the intact animal. Stimuli that induce stress responses are 
stressors, and common stressors include psychological, physical, and drug or chemical 
stimuli. Activation of this physiological response almost always is associated with activation 
of the hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic nervous system, 
leading to changes in the concentrations of stress-related mediators.” (10) The effects of 
such stressors on the endocrine system are illustrated in Figure 2.3. 
 
 
Figure 2.3 Effects of stressors on the endocrine response  
Source: (10, 137) 
HPA: Hypothalamic-anterior Pituitary-Adrenocortical axis; SAM: Sympatho-Adrenomedullary axis 
*extent dependent on intensity, duration & tissue specificity  
 
A stressor can be defined as a “non-specific stimuli that disturb homeostasis and elicit an 
invariable stress response” (138). The stress response stimulates the adrenal glands and 
lead to suppression of the immune system, mainly due to increased levels of glucocorticoids 
(133). The stress response includes the “fight-or-flight” reaction, which is due to acute stress, 
followed by the endocrine-stress response (138).  
 
Various hormones are affected by stressors; these include cortisol, prolactin, 
dehydroepiandrosterone sulphate (DHEAs) and testosterone.  
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Cortisol 
Cortisol is one of the main glucocorticoids secreted in response to stress after stimulation of 
the HPA axis (139). Caffeine, the mental stress of competing in a race environment and the 
exertion of exercising at the high intensity required during a triathlon, all increase cortisol 
secretion (140).  
 
Caffeine and exercise independently elevate cortisol levels (141). Increased cortisol levels 
have been found after marathon running (136, 142-146) and the authors concluded that this 
was primarily due to stimulation of the HPA axis. The degree to which cortisol levels are 
elevated during or after exercise, though, is dependent on the duration of exercise (136, 
145, 147). Exercise is seen as a stressor and the response of cortisol to stress varies widely 
between individuals (148) and between genders. Following exercise, the elevated levels of 
cortisol may illicit metabolic effects, such as increased blood glucose levels due to 
gluconeogenesis and lipolysis as shown in Figure 2.4 (141).  
 
 
Figure 2.4 The control pathway for cortisol 
Source: (5) 
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Lovallo et al. (2006) has described the main effects of caffeine and gender on the cortisol 
release response. Exercise and mental stress have different effects on cortisol secretion, 
with mental stress exerting a much more pronounced and rapid effect than exercise. Men 
and women also respond differently to psychological stress. Caffeine, in combination with 
stress, was found to result in a small, transient increase in cortisol levels in women, but lead 
to a substantial, prolonged increase in men. Without the introduction of caffeine, both males 
and females have similar cortisol responses after exercise. Caffeine thus enhances the 
stress response in both men and women and there are metabolic factors that can modify 
these relationships, especially during prolonged exercise where an increase in cortisol is 
present due to an increased metabolic fuel demand (140). 
 
Prolactin 
In addition to the role of neuro-modulation described in 2.3.1, prolactin also plays a role in 
both reproductive and other non-reproductive processes. Prolactin and growth hormone 
appear to be needed for T-lymphocyte differentiation in the thymus gland and prolactin 
levels increase, along with cortisol levels, in the presence of a variety of stressors (5, 10). 
Prolactin levels are known to increase in response to physical stress, such as during or after 
marathon running (136). Prolactin and cortisol increase together in response to stress, and 
the increase in prolactin levels vary depending on the intensity of the stressors. Prolactin and 
cortisol can both thus be useful markers of stress (149). In females, in particular, prolactin 
increases during prolonged exercise. This may occur to some degree as a result of 
increased body temperature or passive heating (135). Caffeine supplementation may have 
the opposite effect on prolactin compared to prolonged exercise as discussed in Section 
2.3.1. The resulting decrease in prolactin due to caffeine supplementation can be favourable 
in terms of decreasing fatigue, increasing arousal and motivation, decreasing perceived pain 
and exertion and thereby improving endurance performance.  
 
DHEAs 
DHEAs play a role in the immune and stress response, and levels of this hormone increase 
during endurance exercise (136, 150). DHEAs is a stress-related androgen, and is a 
precursor required for testosterone production (135).  
 
Androgens, such as DHEAs and testosterone, have various roles in the human body, for 
example in the reproductive system, in muscle growth, the prevention of bone loss, in 
maintaining bone density and in erythrocyte production (135). In female athletes, excessive 
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physical exercise can lead to a delayed onset of menarche, amenorrhea and osteoporosis, 
and these androgens thus become increasingly important (135). Numerous factors, including 
the phase of the menstrual cycle, age, nutrition, the use of oral contraceptive medication and 
exercise can influence androgen levels (135). DHEAs levels are increased following acute 
exercise in pre –and post-menopausal women, primarily due to increased release from the 
adrenal cortex in response to adrenocorticotropic hormone (ACTH) stimulation (135). It is 
also known that women who regularly participate in endurance exercise have decreased 
resting DHEAs levels as a result of decreased levels ACTH following an endurance training 
program (135). 
 
Testosterone  
Testosterone is an anabolic hormone, mainly in the male reproductive system. Testosterone 
levels decrease in response to stress (10). Testosterone and cortisol have a unique 
interaction, as both are competitive agonists of muscular cells. The testosterone/cortisol ratio 
is often used as an indicator of the anabolic/catabolic balance in the body. Acute exercise, 
as well as long periods of training or repetitive competition can decrease this ratio. This ratio 
between testosterone and cortisol can indicate the actual physiological strain induced by 
training or exercise (151). 
 
Studies have shown that testosterone levels increase after resistance or endurance training 
and decreases with prolonged endurance training, for example running a marathon. 
However, some studies have shown an increase in testosterone concentrations after 
prolonged endurance exercise (136, 150). The response of testosterone following exercise is 
largely dependent on exercise intensity, duration and training status (136, 146, 147). 
However, some studies have shown an increase in testosterone concentrations after 
prolonged endurance exercise (136, 150). 
  
In females, testosterone levels are increased after prolonged endurance exercise (135) and 
no changes in testosterone levels are observed due to menstrual cycle changes. This 
increase in testosterone is mostly due to increased metabolic clearance and decreased 
hepatic flow during endurance exercise. Haemoconcentration due to dehydration, sweating 
and hydrostatic pressure that can occur during or after exercise may also play a role. It is 
also known that women who engage in regular physical activity, have lower baseline 
testosterone levels compared to sedentary counterparts (135). During resistance training, 
caffeine has been found to increase testosterone levels, although this effect may be 
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diminished by an increased release of cortisol due to the physical activity and caffeine’s role 
as a metabolic stressor (152) as discussed in Section 2.3.1. 
 
2.3.3 Adrenergic effect 
The most controversial and widely-discussed mechanism of action of caffeine in the 
literature is its possible effect on substrate metabolism during exercise. It has been 
postulated that caffeine can decrease the body’s reliance on glycogen and increase its 
dependence on free fatty acids (FFA) (72) as a fuel source during exercise. This proposed 
effect is due to the increased lipolysis of adipose tissue and intramuscular triglycerides, 
which results in increased levels of FFA due to the caffeine-induced release of 
epinephrine/adrenaline, an adrenergic effect (41, 50, 51, 54, 69, 73, 74, 127-130). The 
above explanation, however, lacks empirical evidence (50) and cannot explain increased 
performance in shorter-duration muscle fatigue protocols (50, 51, 130). It has also been 
noted that this glycogen-sparing effect of caffeine is overridden by the adrenergic effect of 
exercise (74).  
 
Another potential mechanism that forms part of the glycogen-sparing model is that caffeine 
increases intracellular cyclic AMP (cAMP) levels. In vitro studies show that this is achieved 
through inhibition of phosphodiesterases (54, 128-130). Increased levels of cAMP lead to 
enhanced lipolysis and fatty acid oxidation, and can result in glycogen sparing (128-130). 
However, this mechanism is unlikely to explain the effect of caffeine on high intensity 
exercise (130) and is argued to not be likely in humans (74, 153). 
 
Raised blood glucose levels occur after caffeine supplementation, due to increased 
epinephrine (51, 130). The release of epinephrine can reduce pain, leading to increased 
lactate concentrations. This increased lactate can be converted to glucose during endurance 
exercise, maintaining blood glucose levels and thereby decreasing the demand on liver and 
muscle glycogen, reducing fatique and improving endurance performance. 
 
The increase in epinephrine is also linked to reduced neutrophil reactive oxygen species 
production and it stimulates β-2 adrenoreceptors expressed by neutrophils, which leads to 
the activation of adenyl cyclase and inducing cAMP synthesis, inhibiting the activation of 
neutrophils (132, 133). 
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2.3.4 Other possible mechanisms 
2.3.4.1 Increased intracellular calcium release from the sarcoplasmic reticulum  
Caffeine increases muscular force production as a result of increased intracellular calcium 
concentrations, resulting in alterations in neuromuscular function and / or skeletal muscle 
contraction (41, 51, 54, 69, 72-74, 127-130). This positively affects exercises such as short 
sprints, and power performance (69). However, this effect has been described in in vitro 
models only, using levels of caffeine that are toxic to the human body (pharmaceutical 
concentrations needed) (50, 51, 54, 129, 130).  
 
2.3.4.2 Altered excitation-contraction coupling 
The Na+/K+ ATP-ase pump is important for maintaining the electrochemical gradient by 
transporting sodium ions (Na+) out of cells and potassium ions (K+) into cells (54, 129). It has  
been proposed that caffeine-induced increases in muscular force production occur as a 
result of increased Na+/K+ ATP-ase pump activity (54, 69, 129, 130).  
 
Additional mechanisms of action of caffeine that have been proposed in the literature, but 
not fully supported include the fact that caffeine exerts a thermogenic effect by increasing 
energy expenditure (72) and an increase in energy status due to less phosphocreatine 
degradation and less accumulation of adenosine diphosphate (ADP) and monophosphate 
(AMP). The significance of which is questionable (51). 
 
2.4 Factors influencing the ergogenic effect of caffeine 
supplementation 
Various factors such as lifestyle, gender and genetics can influence the pharmacokinetics of 
caffeine and therefore the ergogenic effect of caffeine supplementation (Figure 2.5).  
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Figure 2.5 Factors influencing inter-individual differences in plasma caffeine 
concentrations 
Sources: (54-63) 
  
The pharmacokinetic profile of a drug considers the dose-concentration relationship and 
thereby describes the movement of the drug in the body. The pharmacokinetic properties of 
caffeine with special regard to the factors influencing the ergogenicity thereof (Figure 2.5) 
are discussed below. 
 
2.4.1 Pharmacokinetic profile of caffeine 
The pharmacokinetic profile of caffeine comprises the absorption, distribution, metabolism 
and elimination of the pharmacologically active compound (64).  
 
2.4.1.1 Absorption   
Drug absorption takes place from when the drug is administered, until it reaches the 
systemic circulation (3). Drug absorption can be influenced by a number of factors, such as 
the route of administration, type of formulation, particle size, lipid solubility, stability of the 
drug in an acidic environment and towards enzymatic degradation, presence of food in the 
stomach, drug interactions, motility of the gastro-intestinal tract and how much of the drug is 
subjected to first-pass metabolism (3). The timing and method of drug administration, as well 
as the extent to which the drug undergoes first pass metabolism. The absorption of a drug is 
measured by its bioavailability, which is the proportion of the dose of the drug that is 
administered that reaches the systemic circulation (3).  
Lifestyle	  habits	  
• Caﬀeine	  habitua?on	  increases	  amount	  of	  caﬀeine	  needed	  to	  elicit	  
eﬀect	  
• t½	  reduced	  by	  30-­‐50%	  in	  smokers	  versus	  non-­‐smokers	  
• Dietary	  intake:	  cruciferous	  vegetables	  &	  foods	  containing	  large	  
amounts	  of	  ﬂavonoids	  increase	  caﬀeine	  metabolism	  	  
• Pre-­‐event	  meal	  may	  reduce	  absorp?on	  of	  caﬀeine	  prior	  to	  
exercise	  
• Alcohol	  decreases	  caﬀeine	  metabolism	  
Gender	  
• Inﬂuence	  of	  menstrual	  cycle;	  caﬀeine	  excre?on	  is	  slower	  during	  
the	  late	  luteal	  phase	  of	  the	  menstrual	  cycle	  
• t½	  prolonged	  during	  the	  last	  trimester	  of	  pregnancy	  
• t½	  doubled	  in	  women	  taking	  oral	  contracep?ves	  leading	  to	  
increased	  plasma	  caﬀeine	  concentra?ons	  
Gene?cs	   • CYP1A2	  gene	  polymorphism	  has	  an	  eﬀect	  on	  the	  way	  in	  which	  caﬀeine	  is	  metabolized	  and	  diﬀers	  between	  individuals	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Caffeine habituation (>300 mg/day) can also lead to increased levels of caffeine needed to 
elicit the same effect. Repeated exposure to caffeine, or a high habitual intake, causes 
habituation or tolerance to develop to caffeine and can diminish the body’s responsiveness 
to caffeine supplementation (69). Repeated intake of moderate to high amounts of caffeine 
can increase adenosine receptor activity as well as β-adrenergic activity, which leads to the 
development of tolerance within 5-6 days of moderate caffeine use (69). It is important to 
take habitual caffeine use into consideration (72) when seeking to enhance exercise 
performance by means of caffeine supplementation, as increased dosages will be needed to 
elicit the same effect if a subject is a habitual user (73).  
 
The general consensus is that the dosage of caffeine supplementation needed to result in an 
ergogenic effect is 3-13 mg/kg body weight (69) (Table 2.1). Lower dosages (3 mg/kg body 
weight) also appear to be ergogenic (69). It is also suggested that the timing of caffeine 
ingestion (before and then repeatedly during exercise) is not of paramount importance, 
provided that the initial dose of caffeine is sufficient to maintain optimal plasma levels for the 
duration of the exercise (27, 98, 100).  
 
It has also been found that when the initial dose and volume of caffeine are the same, the 
type of formulation in which the caffeine was administered (for example gum, capsules, 
coffee, soft drinks or chocolate) does not appear to have an effect on plasma caffeine levels 
(64). It has been documented that caffeine in capsule form is easy to ingest and the dosage 
can be controlled effectively (72). When caffeine is ingested in the form of coffee, it is difficult 
to attribute the true effect to caffeine and it is also difficult to establish the exact amount of 
caffeine found in varieties of coffee (72). During the roasting of coffee, chlorogenic acids are 
produced. These derivatives may influence the effect caffeine has on the CNS and thereby 
reducing the capacity of caffeine to inhibit adenosine receptors (154). Although the type of 
formulation can influence the onset of effect, and should thus be considered when 
determining the times of administration, the magnitude of the effect of a caffeine dose is not 
dependent on the type of formulation used (64).  
 
Caffeine is absorbed quickly in the small intestine of the gastro-intestinal tract (GIT). 
Caffeine promotes gastric emptying by stimulating the internal myenteric and submucous 
nerves in the stomach. The drug is then absorbed directly from the stomach into the blood 
stream.  Ninety nine percent of the caffeine ingested in a dose is absorbed into the blood 
within 30-75 minutes (57, 69, 155-157).  
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2.4.1.2 Distribution  
Once a drug has reached the systemic circulation, it gets distributed into various 
compartments, such as the vascular, extracellular or intracellular fluid compartments, 
depending on the properties of the drug. Distribution is often described as the half-life of a 
drug (t½), meaning the time taken for the concentration of a drug in the blood to fall by half its 
original value. The measurement of t½ allows the calculation of the elimination rate of the 
drug (3). 
   
The peak concentration of caffeine (8-10 mg/l) for doses of 5-8 mg/kg body weight is 
typically reached in the blood after 15-120 minutes (57, 156). There is also a direct 
correlation between the dose of caffeine ingested and the peak concentration in plasma for 
dosages of 1-10 mg/kg body weight. For dosages lower than 10 mg/kg body weight, the half-
life (t½) can be up to 4-5 hours (57, 69) and can be longer (6-7 hours) for absolute dosages 
exceeding 300 mg (69). 
 
There are considerable inter-individual differences in plasma caffeine concentrations after 
caffeine ingestion (64). The extent of this variation is dependent on various factors, including 
gender, lifestyle habits, the type and intensity of training, genetics and the concurrent use of 
medication (54).  
 
As shown in Figure 2.1, two of these factors affecting the plasma concentrations of caffeine 
are the phase of the menstrual cycle (i.e. whether it is the luteal or follicular phase) and the 
use of oral contraceptive medication. Caffeine excretion is slower during the late luteal 
phase of the female menstrual cycle, which occurs prior to menstruation. This increases 
plasma caffeine concentrations. Although this effect of the menstrual cycle is not influenced 
by habitual caffeine intake, the metabolism of caffeine with dosages up to 6 mg/kg body 
weight may be affected by the phase of menstrual cycle. (62). The use of oral contraceptives 
and hormone replacement therapy has also been known to interfere with caffeine 
metabolism and chronic use of these drugs has been found to lead to increased plasma 
concentrations of caffeine (63).  
 
2.4.1.3 Metabolism  
Drug metabolism occurs mainly in the liver and the aim of drug metabolism is to make the 
drug more hydrophilic, in order for it to be excreted by the kidneys (3). There are two main 
stages of hepatic drug metabolism. A phase 1 reaction is when a drug is converted into more 
polar metabolites. The main enzyme system involved in this is cytochrome P450. Phase II 
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reactions are when drugs or metabolites are still not sufficiently hydrophilic and become 
conjugated with endogenous compounds in order to be metabolised (3).  
 
Caffeine is metabolized in the liver to more than 25 pharmacologically active metabolites. 
Caffeine metabolism takes place via cytochrome P450 (CYP450) mediated pathways in the 
liver (64). Although various CYP subfamilies are involved in the oxidation of caffeine to its 
metabolites, the oxidation of caffeine to its four main metabolites is catalysed predominantly 
by CYP1A2, the major CYP in the human liver (Figure 2.6) (158-160). The main metabolic 
pathway of caffeine (72-80% of ingested caffeine) is characterized by the quantitative 
importance of 3-methyl demethylation leading to the formation of paraxanthine (3-N-
demethylation) (57, 159). This metabolism of caffeine to paraxanthine is catalysed by 
CYP1A2 and can thus be used to phenotype individuals with regard to CYP1A2 (57).  
 
Due to genetic and environmental factors, there is a large inter-individual variation in 
CYP1A2 enzyme activity (161).  CYP1A2 gene polymorphism and epigenetic factors (DNA 
methylation), as well as ethnicity and gender have been reported to affect the way in which 
caffeine is metabolized (161, 162). Environmental factors such as smoking, use of oral 
contraceptive medication, habitual caffeine intake (>3 cups per day increases enzyme 
activity), the use of medication (proton-pump inhibitors, antimalarial drugs, drugs given for 
schizophrenia) and dietary factors (intake of cruciferous vegetables and char-broiled meat) 
can also influence CYP1A2 activity (162). Due to these inhibitory/inductor factors, a large 
variability in the metabolism of caffeine exists (160).  
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Figure 2.6 Main metabolic pathways of caffeine and the contribution of P450 isoforms 
Source: (159) 
 
The CYP1A gene cluster is mapped to chromosome 15 and there is a close link between 
CYP1A1 and CYP1A2, sharing a common 5’-flanking region. CYP1A2 is primarily regulated 
by the aromatic hydrocarbon receptor (AhR) (160). The CYP1A2 gene spans 7.8 kb, 
comprising of seven exons and six introns. More than 20 variant alleles and sub variants of 
the CYP1A2 gene have been found (http://www.cypalleles.ki.se/cyp1a2.htm) and five variant 
alleles have been shown in the literature to be associated with altered caffeine metabolism, 
i.e.  CYP1A2*1F (rs762551) and CYP1A2*1D (rs35694136) (160), variants between 
CYP1A1 and CYP1A2 (rs2472297-T (163),  and rs2470893-A, (164)), and the variant near 
the AHR gene (rs698865-T (163)).  
 
Of these, only the effect of CYP1A2*1F (rs762551) has been studied with regards to its 
effect on caffeine supplementation in terms of sport performance (165). Womack et al. 
(2012) investigated the effect of this specific polymorphism on the performance enhancing 
effect of 6 mg/kg body weight caffeine supplementation in 35 well trained male cyclists. The 
authors found that the 40 km cycle time was reduced by almost 4 minutes in the A/A 
homozygotes vs. only ~1 minute reduction in the C-allele carriers (165). This is in keeping 
with literature on this single nucleotide polymorphism (SNP), indicating that carriers of the C-
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allele has an increased risk for developing heart disease due to slower caffeine metabolism 
(158, 165). Carriers of the C-allele are “slower” metabolizers of caffeine and therefore have 
increased levels of plasma caffeine after the ingestion thereof compared to individuals who 
are homozygous for the CYP1A2*1F-allele, who are “rapid” metabolizers of caffeine (158). 
The increased plasma caffeine levels may increase the chances of experiencing side-effects 
associated with caffeine ingestion, such as nervousness, restlessness, shakiness, anxiety, 
heart palpitations, flushing, sleep alteration, headaches and gastro-intestinal disturbances 
and ultimately negatively affect general health and exercise performance. 
 
2.4.1.4 Elimination 
The elimination of a drug and / or its metabolites refers to getting the drug and/or metabolite 
out of the body. Elimination mainly takes place via the kidneys, through urine, but can also 
take place through bile into the small intestine, sweat, faeces and exhalation (3). 
 
Caffeine is reported to have a half-life (t½) ranging between 2.5-10 hours. The t½ is dose 
dependent, with higher caffeine dosages and repeated dosages increasing t½ (64). This, 
however, is only true for dosages up to 10 mg/kg as saturation of plasma caffeine levels 
occur when plasma caffeine concentrations approach 100 µM (64). Caffeine is mainly 
excreted by the kidneys via urine. Five percent of an administered dose of caffeine is 
eliminated in the urine (155 ml/kg/hour) (57). This is favourable in terms of sport, as previous 
guidelines included restricting caffeine use in sport to urinary caffeine levels below 12 ug/l.  
Dosages of up to 9 mg/kg body weight can be administered without reaching these urinary 
caffeine levels (64).  
 
Caffeine can be a mild diuretic; however, the effect of caffeine on rennin is usually only seen 
a few hours (approximately 4 hours) after ingestion. In the case of a sporting event lasting 
between two and two and a half hours, the diuretic effect of caffeine will be minimal. This is 
because the exercise occurs and overrides the potential for diuresis, due to an increased 
release of catecholamines and the renin-angiotensin-aldosterone cascade increasing solute 
reabsorption and improving water retention by the kidneys.  
 
Studies that investigated the loss of body mass, sweat rates, plasma volume and 
electrolytes, and core temperature found that caffeine ingestion did not influence these 
parameters for between 1-4 hours (51). A review by Graham et al. (2001) concluded that 
“there does not appear to be any basis for the common concern that caffeine ingestion will 
dehydrate athletes”. Even though a mild diuresis can be present, literature indicates that this 
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does not have any measurable effect on plasma volume, sweat rate or plasma or urine 
osmolality (51, 72, 74). Reviews by Armstrong (2002 and 2007) also concluded that caffeine 
ingestion before or during exercise will not lead to fluid –and electrolyte imbalances or impair 
exercise-heat tolerance (166, 167). 
 
2.5 Factors influencing triathlon performance 
In order to establish whether improved performance results from caffeine supplementation, it 
is important to also consider confounding factors influencing triathlon performance. 
 
These factors include general health, dietary intake two days before and dietary strategies 
followed on race day, body composition and bone mineral density, training or tapering before 
the event, withdrawal symptoms of caffeine abstinence, side-effects of caffeine 
supplementation and hydration status. A brief overview of the effect of dietary intake, body 
composition and bone mineral density on endurance performance is provided below. The 
remainder of the factors are described in Chapter 3 as part of the methodology.  
 
2.5.1 Dietary intake  
The importance of sound scientific guidelines on the amount and timing of food intake in 
relation to exercise cannot be disputed. Nutrition compliments exercise programs, assists 
athletes in training more effectively, and decreases the risk of becoming ill or injured. A 
variety of foods should be included in a typical diet; there should be ample amounts of CHO, 
protein, fat and micronutrients. For most athletes, a well-balanced diet is sufficient to meet 
their energy, macro- and micronutrient requirements. This was supported by results of a 
previous study examining the habitual dietary intake of a group of provincial-level triathletes 
in the Western Cape (71). The triathletes in this study reached most of their daily dietary 
requirements through food intake.  
 
2.5.1.1 Energy and energy availability 
In this specific study by the researcher (71), the body composition, dietary intake and 
supplement use of 26 triathletes residing in the Western Cape was studied. The average 
habitual dietary energy intake for men and women was 14535 kJ and 9004 kJ respectively. 
The CHO (CHO) intake was 5.3 g/kg body weight for males and 3.5 g/kg body weight for 
females. Protein intake was at the upper end of requirements for males at 2 g/kg body 
weight and 1.2 g/kg body weight for females. Fat intake ranged from 30-35% in males and 
females. We concluded from this study that overall habitual dietary intake was adequate. In 
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specific groups where the CHO intake was insufficient, this was attenuated by the majority of 
these athletes using CHO supplements (71).  
 
In athletes with a high body mass and those participating in extreme high volume, intense 
training, it might prove more difficult to meet dietary requirements (168-170), especially as 
high intensity training can easily decrease an athlete’s appetite (4, 170, 171). Endurance 
athletes in particular have been known to have a negative energy balance. This is primarily 
because body composition and factors such as gastrointestinal comfort play an important 
role in athletic performance (4, 170).  
 
In order for endurance athletes to reach dietary requirements, without additional 
supplementation, care should be taken to eat 4-6 meals per day, including energy-dense 
sources of macro –and micronutrients (170, 172). According to the latest International 
Olympic Committee (IOC) consensus conference on sport nutrition, an important part of 
managing an athlete’s diet includes the calculation of estimated energy availability (estEA). 
Estimated energy availability is defined as “dietary energy intake minus energy expended in 
exercise (estEA = EI-EEE) and is expressed in kcal/kg fat free mass (FFM)” (4). Endurance 
athletes are at an increased risk to develop an energy deficit and thus have a low estEA.  The 
estEA of 41 studies on endurance athletes were retrospectively calculated and ranges 
between 15-45 kcal/kg FFM was found amongst amenorrheic and euhmenorrheic female 
runners, while male runners had estEAs between 40-45 kcal/kg FFM (173). Possible reasons 
given by the authors for this low estEA, especially in female endurance athletes, include 
optimizing body composition, prevalence of eating disorders, having no “biological drive to 
match energy intake to activity-induced energy expenditure” and therefore establishing that 
appetite is not an accurate indicator of energy requirements, especially in endurance 
athletes (173). Furthermore, other factors not pertaining to the sport itself, such as pressure 
from media and the perception of being overweight, even when the athlete is clearly not 
overweight was also possible contributors (173). 
 
2.5.1.2 Carbohydrate 
The frequency and timing of CHO intake is important in physically active individuals. 
Optimizing pre, during- and post-workout nutrition is an essential complimentary factor to 
any training program. If this is not possible, it is imperative to ensure sufficient intake of CHO 
during the day (168). Muscle glycogen and blood glucose are the main sources of energy for 
contracting muscles. Optimal CHO intake assists endurance athletes specifically with 
refuelling glycogen stores post-exercise. This may be difficult in some instances, especially 
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when including high-fibre CHO (168, 170, 174). The body has restricted glycogen stores, 
and when these are full, they only last for between 90 – 180 minutes during moderate and 
high intensity exercise (174). Loading with CHO prior to an endurance event thus optimizes 
glycogen stores and is essential for exercise lasting longer than 90 minutes (168). This is 
important in order to sustain work output and increase performance.  
 
This regime of fuelling glycogen stores in the days leading up to a race or competition is 
complimented by eating a high CHO pre-event meal before the competition (168, 169). For 
endurance events lasting longer than 90 minutes, it is essential to include CHO intake during 
the event. Common complaints during endurance events include muscle fatigue and 
hypoglycaemia, often as a result of decreased muscle glycogen stores. The type, amount 
and timing of CHO intake during exercise are important factors to consider and should be 
tailored according to individual preferences. As mentioned above, CHO intake is primarily 
responsible for filling the body’s glycogen stores. Adequate amounts of CHO taken after 
exercise are also important, to increase muscle glycogen synthesis and therefore refuelling. 
This is especially pertinent when there is less than 8 hours’ recovery time between events or 
training sessions (168, 169). 
 
2.5.1.3 Protein 
Dietary protein requirements are increased with exercise, albeit strength, speed or 
endurance training. Other factors, such as total energy intake, exercise intensity and 
duration, ambient temperature, gender and age also influence protein requirements (175). 
Protein requirements are slightly elevated in endurance exercises in particular, compared to 
the requirements of sedentary individuals, due to the increased oxidation of leucine, a 
branched chain amino acid, during endurance exercise (175). The average protein 
requirement for a sedentary person, according to the Dietary Reference Intakes (DRIs) and 
more specifically the Recommended Dietary Allowance (RDA) is 0.8 g/kg body weight/day 
(176). For general fitness this requirement would suffice and can be slightly elevated to 1.0 
g/kg body weight / day. As seen in Potgieter et al. (2011), protein requirements are easily 
met when energy intake is sufficient (71).  
 
Timing the protein intake in relation to training sessions can also provide more benefit in 
terms of recovery and improved metabolic adaptations to training (175). The ISSN 
recommends that, depending on the individual’s exercise duration and fitness level, protein 
should be included with CHO in the pre-event meal (174). The addition of protein to CHO (at 
a CHO: protein ratio of 3-4:1) during exercise has shown some promise in recent literature. 
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For example, it has proven favourable in terms of increasing endurance performance and, 
increasing muscle glycogen stores, reducing muscle damage and promoting better training 
adaptations after resistance training (174, 177-180). Whether this addition of protein is due 
to the protein or due to the increased energy from the protein added to the supplement is still 
to be determined. There are studies showing no improvement in performance with the 
addition of protein (181, 182). Although recommended by the ISSN to add protein to CHO 
during endurance exercise, there is still insufficient evidence to unequivocally support this 
practice (175, 183).  
 
2.5.1.4 Fat 
The dietary fat recommendations of physically active individuals are mostly similar, slightly 
higher than their sedentary counterparts. Sufficient fat in the diet is essential to achieve 
optimal health and well-being, maintaining energy balance and the meeting requirements for 
essential fatty acids and the fat-soluble vitamins A, D, E and K. The importance of replacing 
intramuscular triacylglycerol (IMTAG) stores should not be overlooked in the context of sport 
performance. The fat requirements depend mostly on the athlete’s training program and 
goals for nutrition support. Moderate intake of fat (30% of total energy) is required, but this 
can be elevated to 50% of total energy for extreme training programs or athletes with a large 
body mass (170, 184).  
 
2.5.1.5 Micronutrients 
Essential micronutrients are important in terms of overall health and well-being. It is unclear 
whether most vitamins and minerals demonstrate an ergogenic effect, and further research 
into this is warranted. Both fat-soluble (A, D, E and K) and water-soluble (B and C) vitamins 
can assist athletes in their training programs and support overall health. Specific nutrients of 
concern in physically active individuals include vitamins C and E, which are known 
antioxidants and may help to reduce the oxidative damage caused by rigorous training and 
thereby support a healthy immune system. The wide range of B-vitamins might be 
ergogenic. A diet containing a variety of foods, and which is sufficient in energy –and 
macronutrients is likely to be sufficient in meeting the micronutrient requirements of athletes 
(170) .  
 
Minerals are important for all bodily functions. Deficiencies of certain minerals, in particular, 
have been found to negatively impact on exercise performance (170). These minerals 
include the following: 
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i) Calcium, which reduces the risk of developing premature osteoporosis and maintains 
body composition; 
ii) Iron, which is essential for transporting oxygen to the tissues from the lungs in the 
form of haemoglobin and especially for athletes who are prone to iron-deficiency; 
iii) Sodium phosphate, increases maximal oxygen uptake, anaerobic threshold and 
increase endurance capacity; 
iv) Sodium chloride, which maintains fluid and electrolyte balance; and 
v) Zinc, which decreases exercise-induced changes in immune functioning 
 
There is however little evidence linking improved sport performance to boron, chromium, 
magnesium or vanadium (170). Athletes at risk of developing micronutrient deficiencies 
should be identified; this includes athletes deliberately reducing energy intake to lose or 
maintain body weight; those with high volume intense training programs, and who have low 
appetite; athletes who are travelling; and those with special circumstances, such as 
vegetarians and diabetics. In these cases, low risk supplements such as combined multi-
vitamin and mineral or liquid meal replacements can be used (170). This should always be 
done in consultation with a dietitian and an optimal nutrition plan, as well as the athlete’s 
medical doctor.  
 
2.5.1.6 Supplements 
Supplements and sports foods are used extensively by athletes at various levels, as well as 
non-athletes. Although the use of some supplements may have added benefits in terms of 
improving body composition, sports performance and overall health, the risk/benefit ratio 
needs to be carefully considered before such supplements are used. There are several 
excellent reviews on supplements and sport performance, for example Maughan et al. 
(2007) and Burke et al. (2009) (185, 186).  
 
2.5.2 Body composition and bone mineral density 
Body composition “attempts to partition and quantify body weight or mass into its basic 
components” (187). The determination of body composition can be approached in a variety 
of ways. Historically, the two compartment model has been the model of choice for dividing 
body mass into meaningful components (187). This traditional approach has more recently 
evolved into complex models showcasing at least three or four compartments. The two-
compartment model measures fat mass and fat free mass by calculating body density. The 
three-compartment model allows for the simultaneous measurement of body density and 
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total body water to derive an estimate of the percentage of body fat. The four component 
model also includes body density, total body water and bone mineral content to estimate the 
percentage of body fat. Multicomponent models increase the accuracy of measurements, but 
due to high costs and technical constraints, the use of these are limited to clinical or 
laboratory settings (187). 
 
There are numerous ways in which body composition can be estimated, and some of these 
are complex (188). In vivo body composition analysis includes several different methods, 
such as the following: 
i) Direct or level I methods, for example neutron activation analysis; 
ii) Indirect or level II methods, such as underwater weighing and dual energy X-ray 
absorptiometry (DXA); and  
iii) Double indirect or level III methods, of which anthropometry and bio-electrical 
impedance analysis are examples.  
 
DXA, mentioned in (ii) above, is commonly used to determine bone mineral content and 
bone mineral density. Bone mineral content is used in the four compartment model to 
increase the accuracy of body composition estimates, and therefore DXA is often used to 
determine fat free mass, fat mass and the percentage of body fat (187). 
 
DXA is a method for determining body composition using the three-compartment model to 
estimate bone mineral density, fat mass and fat-free mass (189). It uses dual energies to 
differentiate the body into three compartments by only taking one measurement. This 
method is viewed as being reliable and the standard method for determining body 
composition in athletes, provided that the same DXA instrument is used in all the athletes. It 
is safe, non-invasive and convenient for those being assessed (189).  
 
Body composition is an important factor in exercise or more specifically triathlon 
performance. The appraisal of the human physique, better known as Kinanthropometry 
allows for interpration and monitoring of an athlete’s performance (190). In a sport such as 
triathlon, where body mass must be transported over a distance, a lean physique offers a 
competitive advantage (190). It is however important to note that ethnicity, heredity and the 
competitive environment should be taken into consideration in combination with body 
composition in order to relate it back to sport performance. It is possible for athletes to still 
be competitive without having the optimal physique; however, documentation of body 
composition is an important factor when conducting research in the field of exercise 
physiology / science.  
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2.6 Conclusion  
After careful consideration of the available literature, the researcher is of the opinion that 
supplementation with caffeine during an endurance event may elicit a different effect from 
that reported after laboratory-based trials, when subjects are asked to compete in a field trial 
and specifically during a triathlon. Research results from laboratory studies and single 
sports, such as swimming, cycling and running cannot be extrapolated to this arena. The 
effect of caffeine as a CNS stimulant and its effect on fatigue and the stress response, 
particularly when an athlete is placed in a competitive environment instead of a controlled 
laboratory experiment need to be taken into consideration. Placing an athlete in a real, 
competitive environment is likely to attenuate the effect of caffeine supplementation on 
endurance sport performance, as seen in the literature and summarized in Table 2.1. This is 
clearly a field that needs to be explored. When taking the pharmacokinetic and 
pharmacodynamic properties of caffeine into consideration, the potential of caffeine to 
improve sport performance is evident, but studying it in context is of critical importance.  
 
There is abundant evidence to support the ergogenic effect of caffeine during endurance 
exercise, but when considering the different conditions in and the physiological requirements 
of a triathlon, compared to single sporting events, the difference between laboratory –and 
field-based studies, as well as the other limitations of existing studies that were explored, the 
researcher identified the need for a double-blind, randomized, crossover, controlled clinical 
trial in a field setting. This may provide information that can be directly applied to the athletic 
arena.  
 
The researcher conducted a field study, utilising optimal performance assessment tools, to 
determine the effect of caffeine supplementation on triathletes and triathlon performance. 
The study controlled for and incorporated most confounding factors that are important when 
evaluating the effect of caffeine on sport performance. These include, abstinence from 
caffeine, withdrawal, caffeine habituation, genetics and menstrual history; as well as factors 
influencing triathlon performance such as nutritional intake before and during a triathlon, 
training, medical history, body composition, psychological factors, ratings of perceived 
exertion and physiological factors, for example the body’s response to stress and exhaustive 
exercise. 
 
Therefore, the main aims of this study were to i) investigate the performance-enhancing or 
ergogenic effect of caffeine supplementation during a real-life triathlon competition; ii) 
evaluate several parameters that could in part explain why caffeine supplementation is 
ergogenic, iii) investigate possible factors influencing the ergogenicity of caffeine 
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supplementation and iv) investigate possible confounding factors influencing Olympic-
distance triathlon performance. 
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CHAPTER 3: RESEARCH DESIGN AND METHODOLOGY 
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3.1 Research design 
A double-blind, randomized, crossover, controlled clinical field trial was conducted.  
 
A double-blind approach was chosen. The researcher, field workers and subjects were 
prevented from knowing who was receiving caffeine or placebo during T1 or T2. This 
approach was chosen to prevent conscious or subconscious bias and thereby invalidating 
the results. This was especially important due to the “placebo” effect of caffeine (93). The 
key distinguishing feature of a randomized clinical trial is that the subjects, after being 
screened according to the inclusion and exclusion criteria, before intervention are randomly 
allocated to receive one or other of the alternative treatments, this minimizes allocation bias. 
In this specific trial, the allocation was random and the study had a crossover design, in 
which subjects received both the treatments. The study was therefore also controlled, as 
each subject served as his/her own control, thereby increasing the reliability of the results.  
 
3.2 Study population 
3.2.1 Sampling 
Purposive sampling was used. The researcher targeted a particular group of people as 
described below. This approach was followed as the desired population for the study was 
rare and difficult to locate and recruit. All triathletes who were willing to participate in the 
research project, which gave written informed consent and adhered to the inclusion criteria, 
were included in the study group. The target population was athletes registered with the 
governing body for triathlon in the Western Cape region, the Western Province Triathlon 
Association (WPTA) and athletes who participated at the Western Province triathlon trials 
and championships during the 2010/2011 triathlon season were invited to participate in the 
study. A total of 197 senior registered triathletes participated in the 2010/2011 triathlon trials 
and championships, of which 137 athletes were male and 60 athletes female 
(http://www.triathlonsa.co.za). These figures were used by the biostatistician to estimate 
sample sizes that would enable sufficient statistical power for the proposed data analysis.   
 
After consultation with the biostatistician it was concluded that a sample size of Nm = 20 
male and Nf = 20 female participants would be representative of the target population. 
However, to detect statistically significant differences between males and females a larger 
sample size would have been required. As this was not one of the main aims of the study 
and because there are known marked differences in the physiology and performance times 
of male and female triathletes, the researcher did not compare results between these two 
groups. Even though comparison between males and females was not part of the statistical 
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analysis, a sample size of N = 20 per gender was estimated to be sufficient to yield an effect 
size of δ = 0.5 between males and females, with 75% power and at a level of significance of 
5%, using analysis of variance (ANOVA). The researcher thus set out to attain a sample size 
of N = 20 from each gender. 
 
Research in the field of sport nutrition/medicine is usually done on smaller sample sizes, as 
it is difficult to find athletes who meet inclusion criteria and because the original pool from 
which subjects can be recruited is often limited. Therefore, the current study, which sampled 
20% of the target population, compares favourably to other sports-related studies in the 
literature. 
 
The total sample size was N = 40 (N = 20 from each gender). However, due to withdrawals 
after triathlon 1 (T1), which was postponed due to poor weather conditions, the final sample 
size was N = 26, of which Nm = 14 were male and Nf = 12 were female. This was still a 
significant sample size in terms of power calculation as well as available research published 
on this topic, with the sample size comprising 13.2% of the target population.  
 
3.2.2 Recruitment of subjects 
An extensive marketing campaign was conducted to recruit subjects using an advertisement 
(Appendix 3.1). This advertisement was distributed at Western Province trials during 
December 2010, Western Province Championships during January 2011 and 11 Global 
standard distance triathlons during March 2011. The advertisement was also distributed at 
the Western Province Triathlon team meeting before the South African Championships in 
March 2011.  
 
The advertisement was placed on the WPTA website (http://www.wptriathlon.org.za) and 
electronically mailed to all WPTA members via the WPTA member database during 
December 2010 and February 2011. A reminder was sent out via this database during April 
2011. The advertisement was also sent out to all four registered triathlon clubs in the 
Western Cape, namely the Atlantic Triathlon Club, Multi-Sport Maniacs, Bike Marathon 
Triathlon and New Balance Multi-sport Club. The advertisement was also sent out through 
the Orca database; this is a leading wetsuit and triathlon apparel specialist retailer in the 
Western Cape.   
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3.2.3 Inclusion criteria 
The following inclusion criteria were developed for this study: 
 
i) Male and female triathletes, between the ages of 20-60 years, who gave written informed 
consent, were included.  
ii) Athletes registered with the WPTA or who competed at the 2010/2011 Western Province 
trials and championships competitions or any triathlete who had completed an Olympic-
distance triathlon in the year preceding data collection (2010/2011), were included.  
iii) All the triathletes had to finish both triathlon trials (T1 and T2) within 2% (± 3 minutes) of 
their usual time. This was to ensure that the athletes were competing at race intensity 
and that they were completing both triathlons at the same intensity. A previous study 
found that over a 19-month period, triathletes demonstrated a remarkably stable race 
performance, with differences of 1.1% being observed in the performance of elite 
athletes (i.e. the top 10% of the field) and 1.8% for the amateur triathletes (191).  
iv) Abstinence from caffeine or caffeine-containing products for 14 days prior to T1 and T2 
was required. Caffeine intake was allowed, however, after the races on the days of T1 
and T2, irrespective of whether caffeine supplementation was also used. 
 
3.2.4 Exclusion criteria 
The following triathletes were not included in the sample group: 
 
i) All triathletes not meeting the inclusion criteria; 
ii) All triathletes who participated in a race during the 14 days (two weeks) preceding either 
T1 or T2; and 
iii) Subjects with known prolactinoma (noncancerous pituitary tumour that produces 
prolactin) or hyperprolactinemia (elevated serum prolactin). 
 
Menopausal and post-menopausal females were not excluded from the study group. This 
was, though, documented and statistically analysed according to the known influence of 
menopause on caffeine metabolism (192). Likewise, females in the late luteal phase of their 
menstrual cycle were not excluded from the study, but this information was documented and 
statistically analysed according to the known influence on caffeine metabolism (62). Females 
who used oral contraceptives were also not excluded from the study. The use of such 
medication was documented and statistically analysed according to the known influence of 
these drugs on caffeine metabolism (63, 193).  
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3.3 Methods of data collection  
3.3.1 Data collection  
All data was collected by the researcher, Sunita Potgieter, a registered dietitian and lecturer 
in the Faculty of Medicine and Health Sciences, Stellenbosch University. Research 
assistants were used on the day of T1 and T2. Research assistants were fifteen BSc. 
Dietetic I-IV students, three BSc. Physiology students, -and four phlebotomists employed by 
Pathcare®, Somerset West who did most of the blood analysis as well.  
 
The research assistants performed different roles. The fifteen dietetic students, for example, 
were responsible for collecting data from the athletes before, during and after T1 and T2. 
These students were trained during a three-hour training session on the procedures for data 
collection on the day of T1 and T2 (Appendix 3.2). Each student received a checklist 
(Appendix 3.3) to ensure all the required data was collected on both days. It was the 
responsibility of these research assistants to ensure that the subjects completed all relevant 
questionnaires, handed in all relevant food and training logs and completed the time points 
without confusion. Fifteen BSc. Dietetic students were enlisted, to ensure an athlete: 
research assistant ratio of 2:1 in order for all data to be collected at the specific time points. 
The research assistants were randomly allocated to the athletes, but the same assistants 
who collected data from athletes during T1, collected their data again during T2.  
 
The role of the three physiology students, meanwhile, was to measure capillary lactate 
levels. These students were trained in a private session with the researcher prior to T1 to 
ensure correct finger prick technique. 
 
The four phlebotomists were responsible for drawing all blood samples before, during and 
after T1 and T2.  
 
All research assistants were clearly identifiable by wearing the same white T-shirt. The 
phlebotomists wore their Pathcare® uniforms and were thus easily distinguishable.  
 
Figure 3.1 below illustrates the flow of the research study. 
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Figure 3.1 Data collection and flow of the research study 
TP: Time point; POMS: Profile of mood state questionnaire; DXA: Dual energy X-ray absorptiometry; T1: Triathlon 1; TTC: 
Time to complete; RPE: Rating of perceived exertion; T2: Triathlon 2 
*Questionnaires included demographic, medical, training and menstrual history questionnaires, as well as habitual caffeine 
intake questionnaire 
 
3.3.2 Pilot study 
A pilot study was necessary to enable the researcher to manage and optimise the logistics 
regarding the organization and flow of the research study and to ensure that blood samples 
could be obtained from athletes during a triathlon. It was also important to establish how long 
it would take the phlebotomists to draw blood samples, because a blood sample needed to 
be taken during transition 2 (cycle →run). If the phlebotomists took too long (> 2-3 minutes) 
with the venipuncture/phlebotomy procedure, the amount of time the athlete had to rest 
would be increased and this could have possibly affected the outcome of the study.  
 
The pilot study was conducted on 4 December 2010. The participants included runners, 
cyclists and swimmers who were excluded from the study population. Six athletes (male Nm 
= 3, female Nf = 3) were recruited to participate in the pilot study (i.e. 23% of the total study 
population).  
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The pilot study consisted of a sprint distance triathlon. This was decided upon, as the actual 
distance raced was not important during the pilot study. The aim of the pilot study was to 
assess and implement all the logistic arrangements in order to collect all the necessary data. 
The pilot study consisted of a 750 m swim, 20 km cycle and 5 km run, held at a gym in the 
Helderberg area (Virgin Active gym®, Somerset West). The researcher obtained written 
informed consent from all six athletes before participating in the triathlon. Pilot study 
participants were given information on the RPE scale, a week before the pilot study so that 
they could be familiar with this. The weight of each athlete was measured and all four 
questionnaires (i.e. medical, demographic, habitual caffeine intake and exercise regime 
questionnaires) were piloted to ensure face and content validity. The research study 
checklist (Appendix 3.3) was also used during the pilot study to ensure the efficient flow of 
time points during the research study. 
 
The subjects were asked to complete a questionnaire regarding the simplicity of the 
questionnaires and whether these were easy to understand. Minor changes with regard to 
spelling and grammar were made to the questionnaires, following feedback from the 
subjects. 
 
The research assistants were asked to complete a questionnaire regarding the simplicity of 
the checklist and whether it was adequate to collect all the data. The research assistants all 
concluded that the checklist was sufficient to collect the necessary data and easy to use. 
 
The phlebotomists were asked to take blood samples before, during the transition from the 
cycle to the run and at the finish line of the sprint triathlon. They were also asked to complete 
a questionnaire on the ease of drawing the blood samples and the time taken to take the 
blood samples were timed by the research assistants. The phlebotomists from Pathcare® all 
indicated that it was easy to draw blood samples from all the subjects and that it took an 
average of 40 seconds to locate the vein and take the blood samples. The phlebotomists all 
concluded that this was an easy, safe and accurate way to draw blood samples from the 
subjects during a triathlon. 
 
3.3.3 Setting 
Data was collected during two triathlons which were held 14 days apart (22 May and 5 June 
2011) at Gordon’s Bay beach, Western Cape Province, South Africa. Both triathlons 
consisted of a sequential 1.5 km swim, 40 km cycle and 10 km run. The triathlons were 
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originally scheduled for 8 and 22 May 2011, but due to poor weather conditions (gale force 
wind; south-westerly at 60 km/hour), the first event was postponed. 
 
The WPTA was contacted to assist with the organization of the triathlons and logistical 
arrangements. Both triathlons were sanctioned by WPTA and adhered to the standard 
Triathlon South Africa (TSA) and International Triathlon Union (ITU) guidelines for a triathlon 
(8). This included all aspects regarding safety, rules and regulations. A race briefing session 
was held the morning before T1 and T2, in which the researcher explained the route of the 
triathlon to the participants. All ITU rules and regulations were discussed with the athletes by 
the triathlon referee from WPTA. The triathlons were non-draft legal races and the subjects 
were asked to race as hard and fast as they could.  
 
3.3.4 Weather 
Weather conditions on the days of both triathlons (22 May and 5 June 2011), were relatively 
similar, with little or no difference between the two days, as shown in Table 3.1. 
 
Table 3.1 Summary of actual weather conditions during T1 and T2 
 
Weather condition T1: 22 May 2011 T2: 5 June 2011 
Lowest temperature (ºC) 12ºC 10ºC 
Highest temperature (ºC) 17ºC 15ºC 
Wind speed 11-20 km/h 6-20 km/h 
Wind direction Gentle north-west (NW) North 
Humidity  35% 65% 
Dew point 4 10 
Comfort level 20ºC 15ºC 
Chance of rain 63% 35% 
Actual rain 0% 0.0mm 30% 4.0mm 
Sunrise  7:34AM 7:43AM 
Sunset 5:47PM 5:42PM 
Moonrise  10:49AM 10:33AM 
Moonset  11:51PM 9:18PM 
Moon phase Waning Gibbous Waxing Crescent 
Comments  Cloudy Cloudy with light rain throughout the day 
Tide*  Low tide: 00:27AM-6:32AM 
High tide: 6:32AM-12:38PM 
Low tide: 12:38PM-19:03PM 
Low tide: 05:16AM-11:23AM 
High tide: 11:23AM-17:42PM 
Low tide: 17:42PM-23:52PM 
Source: Weather 24 (http://www.weather24.com) and Weather SA (http://www.weathersa.co.za), South African Tide Tables 
(SA Navy) 2011 (http://www.sanho.co.za)  
*Tide influenced the swim start in ocean. Swim distance (1.5 km) was measured via GPS by the National Sea Rescue Institute 
(NSRI) Gordon’s Bay. Swim distance was equal for both T1 and T2. During low tide, the swim start (first buoy) was deeper in 
the sea than during high tide in T1. 
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3.3.5 Event plan 
An event plan (Appendix 3.4) was submitted to the City of Cape Town, Economic and 
Human Development; Film and Events Permit Office on 15 March 2011. Final approval to 
host the triathlons in Gordon’s bay was given by the City of Cape Town on 6 May 2011 
(Appendix 3.5).  
 
3.3.6 Caffeine habituation, washout and withdrawal 
All triathletes were instructed to abstain from using any caffeine or caffeine-containing 
products, including food and drinks, for 14 days prior to T1 and T2. This time period was 
regarded as being sufficient in allowing any withdrawal symptoms to pass. 
 
Although some studies (194) have reported enhanced exercise performance regardless of 
caffeine withdrawal, it has also been documented that with caffeine habituation, there is an 
increased amount of caffeine needed to elicit the same effect on the CNS. It is therefore 
important to control for subject habituation (195). Previous studies on caffeine 
supplementation involved subjects abstaining from caffeine for periods of between 2-4 days 
(Table 2.1). In the current study, subjects were asked to abstain from caffeine and caffeine-
containing products for 14 days prior to T1 and T2, in order to optimize the effect of caffeine 
and reduce the chance of any carry-over effect. 
 
Caffeine withdrawal during the period of caffeine abstinence was expected in subjects who 
habitually use > 300 mg caffeine per day. Symptoms of caffeine withdrawal include 
headaches, fatigue, lethargy and flu-like symptoms (26, 41, 100). Caffeine withdrawal 
symptoms were recorded during the study trial and are reported in Chapter 4.  
 
3.3.7 Recovery between T1 and T2 
There was a 14-day period between T1 and T2 to ensure athletes have fully recovered and 
were able to race at the same intensity for both trials. The athletes were not allowed to 
compete in another race for 14 days prior to T1 and they were instructed to schedule both 
events as races/competition in their training programmes. This was important in order for 
athletes to be fully recovered for the triathlons and to prevent race-fatigue.  
 
The athletes also completed the Profile of Mood States questionnaire in the week before T1 
and T2, as well as on the morning of and after T1 and T2. Any significant changes in mood 
state were documented and incorporated into the statistical analysis. 
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3.3.8 Blinding and randomization 
Each subject was given a subject number for the duration of the study. A computer was used 
to randomly select the subject numbers of the subjects to be in the caffeine and placebo 
groups during T1. Thirteen subjects was assigned to the caffeine and the placebo groups 
respectively during T1, while for T2 the groups crossed over and those receiving caffeine 
during T1 now received placebo and vice versa. 
 
Since this was a double blinded study, an independent laboratory (African Micronutrient 
Research Group, ward A10, Tygerberg Hospital) was contracted to randomize the groups, 
as well as to prepare the caffeine and placebo capsules. This ensured that both the 
researcher and the subjects were blinded as to who received caffeine or placebo. After T2, 
the list was made available to the researcher, who relayed the results to the subjects.  
 
3.3.9 Intervention 
Microencapsulated caffeine (70% caffeine concentration, certificate of purity, Appendix 3.6) 
was used for caffeine supplementation. “Microencapsulation is a process in which tiny 
pieces of an ingredient are packaged, or encapsulated, within another material in order to 
protect the active ingredient from the surrounding environment. Capsules can range in size 
from one-thousandth of a millimetre to seven millimetres” (Maxx Performance Inc.© 2005-
2009).  
 
In a recent systematic review by Ganio et al. (2009), the author concluded that caffeine 
supplementation was “equally ergogenic” and independent of the delivery mode of caffeine 
(41). Microencapsulation is effective for masking the taste of caffeine (pure caffeine has a 
bitter taste) and does not influence its bioavailability or the time taken to reach peak plasma 
concentrations. The microencapsulated caffeine and the placebo were placed in gelatin 
capsules, which are easily broken down in the stomach by the presence of hydrochloric acid, 
minimizing the effect of the capsule on the absorption of caffeine.  
 
The caffeine-containing capsules included an individually weighed dose of 6 mg/kg body 
weight caffeine, which was consumed as 8.6 mg/kg body weight microencapsulated caffeine 
to account for the fact that the microencapsulated caffeine contained 70% caffeine. The 
placebo contained an artificial sweetener (Canderel®) that resembled a white powder and did 
not contribute any caloric value. Due to the microencapsulation, the caffeine powder had no 
taste. The artificial sweetener tasted sweet. Both the caffeine and the artificial sweetener 
were placed in gelatin capsules so no taste could be observed. Both looked like a white 
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powder. The athletes were instructed not to open the capsules before consuming it and the 
research assistants monitored the athletes taking the supplementation as to ensure no one 
opened the capsules and they take it at the correct time before the race. The placebo was 
not able to influence triathlon performance. 
 
Using capsules of the same colour, shape and size, containing the white powder (either 
caffeine or artificial sweetener) ensured that neither the athletes nor the researcher were 
able to distinguish between the caffeine and placebo-containing formulations. The optimal 
concentration of plasma caffeine is seen 45 minutes to 1 hour after ingestion and therefore, 
both the caffeine- and placebo-containing capsules were administered to the athletes one 
hour prior to the start of T1 and T2. 
 
3.4 Research intruments and data analysis 
3.4.1 Ergogenic effect of caffeine supplementation 
Plasma caffeine levels were analyzed in order to determine if subjects adhered to the 
caffeine-abstinence protocol, as well as if peak plasma caffeine levels were reached during 
T1 and T2. Plasma caffeine levels were measured at baseline, transition (cycle → run) and 
at the finish line. Details of blood collection are summarized in section 3.4.2.1. 
 
3.4.1.1 Triathlon performance 
The time it took the subjects to complete the various components of the triathlon, as well as 
the overall time to complete T1 and T2 were recorded. The WPTA was contracted to record 
all the time-splits during T1 and T2, according to standard TSA and ITU guidelines. The 
subjects were each given a race number (identical to the subject number), which the subject 
wore around his/her waist during the triathlon with a race belt, which was provided by the 
researcher. Time splits were recorded for the swim + transition 1, cycle, run + transition 2 
and overall time to complete T1 and T2. The research assistants showed the subjects where 
to go to have the blood samples collected during transition 2 (cycle → run) and also 
recorded the time taken to draw the blood sample on the checklist provided. This time was 
subtracted from the run + transition 2 time (and the overall time), to give a time without blood 
sample collection. This was especially important when determining who had won the prize 
money.  
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3.4.1.2 Rating of perceived exertion 
Caffeine has been shown in various research studies to influence a subject’s rating of 
perceived exertion. This research study used the Borg Scale Rating of Perceived Exertion 
(RPE) to determine the RPE at various time points during T1 and T2. The scale rates how 
strenuous or heavy the exercise feels and depends mainly on the strain and fatigue felt in 
the muscles and the subject’s feeling of breathlessness or aches in the chest. It is a 15-point 
scale, in which “6” corresponds to very light exercise, such as walking slowly, and “20” 
corresponds to maximal exertion (196).  
 
During the initial visit, the week before T1, the researcher explained the Borg RPE scale to 
the subjects, who were each given a copy of the Borg scale RPE (Appendix 3.7) with which 
to familiarize themselves prior to T1 and T2. During T1 and T2, the research assistants 
prompted the subjects to rate their perceived exertion. The subjects were asked to rate their 
feelings as honestly as possible, without thinking about what the actual physical load is. 
These RPE values were given during transition 1 (swim → cycle), when the subjects were in 
the transition area, preparing for the cycle leg, during transition 2 (cycle →	   run), when the 
subjects were in the transition area, preparing for the run leg and directly after the race at the 
finish line, and were recorded on the checklist by the research assistants. 
 
Rating of perceived exertion was analysed as the scores given by subjects at the various 
time points before and during the triathlons. 
 
3.4.1.3 Mood state 
The profile of mood states (POMS) scale is a 65-item, self-assessment questionnaire using 
a Likert scale. In this study, the revised, shorter version of the POMS questionnaire was 
used; this is similar to the above questionnaire, but only 24 items are included. The POMS 
scales have been extensively used in sport psychology research (197). The original 
questionnaire was developed by McNair and Lorr in et al. (1971) (198) and revised in 1992 
(199). Questions are rated on a scale of 0 (not at all) to 4 (extremely) and measure mood 
disturbances and mood states, namely tension-anxiety, depression-dejection, anger-hostility, 
vigour-activity, fatigue-inertia and confusion-bewilderment. The shortened version of the 
POMS used in this study only assessed tension, vigour and fatigue.  
 
The subjects were asked to complete the POMS questionnaire (Appendix 3.8) at baseline 
and again immediately after T1 and T2 in order to determine the effect of caffeine 
supplementation on mood state.  
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All the emotions listed on the POMS questionnaire were scored. The original 65 item 
questionnaire was adapted to a shortened 24-item POMS questionnaire. The scoring system 
was thus adapted for this shortened questionnaire, as described below. 
Subscales were calculated for the parameters of tension, fatigue and vigour in the following 
manner:  
 
i) The tension subscale was scored by adding the awarded score that was circled for 
the following emotions: tense, shaky, on edge and panicky. The scores for relaxed, 
uneasy, restless, nervous and anxious were reversed (subtracted). 
ii) The fatigue subscale was scored by adding the awarded score that was circled for 
the following emotions; worn out, listless, fatigued, exhausted, sluggish, weary and 
bushed. 
iii) The vigour subscale was scored by adding the awarded score that was circled for the 
following emotions: lively, active, energetic, cheerful, alert, full of pep, carefree and 
vigorous. 
 
The total mood disturbance (TMD) was scored by adding all the raw scores from tension and 
fatigue, and subtracting the score from vigour. The TMD score was interpreted as the lower 
the score; the more positive the mood. 
 
3.4.2 Parameters that could in part explain the ergogenicity of 
caffeine supplementation 
3.4.2.1 Endocrine-stress response, oxidative stress and plasma lactate 
Collection of blood samples 
Subjects were instructed to arrive at T1 and T2 in the fasted state, as baseline blood 
samples needed to be taken in this state. The subjects were able to bring their pre-event 
meal with and were provided sufficient time before the start of T1 and T2 to eat this meal 
(baseline blood samples were collected 90 minutes before the start of T1 and T2). All blood 
samples were collected by registered phlebotomists from Pathcare®, Vergelegen Medi-
Clinic, Somerset West, South Africa. Four phlebotomists were available to collect blood 
samples during T1 and T2. 
 
Blood samples were collected according to the standard operating procedures of Pathcare®, 
South Africa. Table 3.2 summarizes when the blood samples were taken and the parameters 
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measured. The maximum amount of blood drawn during all time points (baseline, transition 
(cycle → run) and finish line) per triathlon was 90 ml.  
 
Table 3.2 Summary of blood parameters measured 
 
Parameter measured: Time points at which blood samples 
were taken (T1 and T2) 
Vacutainer used: 
Plasma caffeine (cold)  Baseline, Transition 2, Finish line EDTA purple top  
Full blood counta Baseline, Finish line EDTA purple top  
Plasma lactateb Baseline, Transition 2, Finish line 
(immediately, 3, 6, 9, 12 and 15 
minutes post-T1 and post-T2) 
Finger prick capillary sample  
Accutrend® Plus, Roche 
Serum cortisol Baseline, Finish line SST tube 
Serum albuminc Baseline, Transition 2, Finish line SST tube 
Total testosterone Baseline, Finish line SST tube 
DHEAs Baseline, Finish line SST tube 
Serum prolactin  Baseline, Finish line SST tube 
aA full blood count (FBC) sample was taken and analysed to determine the total and differential leukocyte count, the 
heamatocrit and haemoglobin. Leukocytes are the main cells of the immune system. Leukocytes can be divided into six groups, 
namely:  eosinophils, basophils (and mast cells), neutrophils, monocytes (and macrophages), lymphocytes (plasma cells and 
cytotoxic T cells) and dendritic cells (not found in the blood). 
bAccu-check® Safe-T-Pro Uno lancet (Roche) and Accutrend® Lactate (BM-Lactate, Roche®) test strips were used to test 
lactate levels. 
cSerum albumin is produced by the liver and exerts an osmotic effect to maintain water balance between blood and tissue. 
Serum albumin levels in the present study were determined to detect any changes in plasma volume that might occur due to 
exercise and to adjust other biochemical parameters accordingly.  
 
All blood samples, except for the full blood count sample, were collected and batched by a 
commercial pathology laboratory (Pathcare®) for analysis using standardised, accredited 
techniques and procedures. The full blood count sample, was collected and batched by 
Pathcare®, but sent to the Department of Physiological Sciences, Faculty of Science, 
Stellenbosch University for analysis. 
 
Plasma caffeine was analysed by high performance liquid chromatography (HPLC), using a 
Waters® instrument (Waters Corp®, Milford, Massachusetts). Serum Albumin was analysed 
by Roche® Bromocresol Green (BCG) with a Roche® Modular instrument (Roche 
Diagnostics®, Indianapolis, IN). Serum cortisol and prolactin were analysed by 
chemiluminescence with a Beckman® DXI 800 instrument (Beckman Coulter Inc., Fullerton, 
California) while total testosterone and DHEAs levels in serum were analysed by 
electrochemiluminescence with Roche® Elecsys 2010 (Roche Diagnostics®, Indianapolis, 
IN).  
 
The Accutrend® Plus instrument (Accu-Chek®, Roche Diagnostics®, Indianapolis, IN) was 
used for the quantitative assessment of blood lactate concentrations. The reflectance 
photometric measurement was performed using test strips for blood lactate. 
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The full blood count analysis was performed by a fully automated procedure (Celldyne 
3700CS, automated hemocytometer, Abbott Diagnostics®, Germany). Daily control 
repeatability tests were completed before each analysis. An experienced haematologist 
reviewed the data for validity 
 
The results of all the above mentioned blood analysis were interpreted using the standard 
reference values as shown in Table 3.3. 
 
Table 3.3 Reference values for different components of blood  
 
Parameter Reference value (Male) Reference value (Female) 
Plasma caffeine 5 – 25 mg/l 5 – 25 mg/l 
Serum albumin 35 – 50 g/l 35 – 50 g/l 
Serum cortisol 140 – 700nmol/l 140 – 700 nmol/l 
Serum prolactin 2.6 – 13.1 ug/l 3.3 – 26.7 ug/l 
Total testosterone 9.9 – 27.8 nm/l  0.22 – 2.0 nm/l 
DHEAs 0.95 – 11.7 umol/l 2.17 – 15.2 umol/l 
White blood cell count 4 – 11 X 109/l 4 – 11 X 109/l 
Relative neutrophil count (%) 40 – 75 % 40 – 75 % 
Absolute neutrophil count 2 – 8 X 109/l 2 – 8 X 109/l 
Relative lymphocyte count (%) 20 – 45 % 20 – 45 % 
Absolute lymphocyte count 1.0 – 4.0 X 109/l 1.0 – 4.0 X 109/l 
Relative monocyte count (%) 2 – 10 % 2 – 10 % 
Absolute monocyte count 0.0 – 1.0 X 109/l 0.0 – 1.0 X 109/l 
Relative eosinophil count (%) 1 – 6 % 1 – 6 % 
Absolute eosinophil count 0.0 – 0.5 X 109/l 0.0 – 0.5 X 109/l 
Relative basophil count (%) 0 – 1 % 0 – 1 % 
Absoulte basophil count 0.0 – 0.2 X 109/l 0.0 – 0.2 X 109/l 
Red blood cell count 4.5 – 6.6 X 1012/l 3.8 – 5.8 X 1012/l 
Hemoglobin 13.0 – 18.0 mg % 11.5 – 16.5 mg % 
Heamatocrit  40.0 – 54.0 % 38.0 – 47.0 % 
Platelets 150 – 400 X 109/l 150 – 400 X 109/l 
Plasma lactate 1.00 – 1.78 mmol/l 1.00 – 1.78 mmol/l 
Source: Ranges of normality. Department of Chemical Pathology, Tygerberg Hospital, Tyegerberg. South Africa, 2000 and 
Pathcare® 
All reference values refer to a sedentary person, 18 years or older  
 
3.4.3 Factors influencing the ergogenic effect of caffeine 
supplementation 
3.4.3.1 Caffeine habituation 
Habitual caffeine intake was determined by the subjects completing a habitual caffeine 
intake food frequency questionnaire (Appendix 3.9) via an Internet-based electronic survey 
(Survey Monkey®). The questionnaire was tested for face and content validity during the pilot 
study. The subjects completed this questionnaire during the initial research visit before T1.  
 
Habitual caffeine intake was described as low if it was ≤ 50 mg/day and as high if it was ≥ 
300 mg/day (72).  
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The subjects were instructed to refrain from all caffeine and caffeine containing products for 
two weeks prior to T1 and T2. The subjects were given a copy of these foodstuffs and it was 
verbally explained to them (Table 3.4). The subjects were allowed to ingest caffeine-
containing products after the races on the days of T1 and T2, irrespective of whether they 
had received caffeine or the placebo during the trial. This was only allowed as a reward, on 
the day of T1 and T2 as neither the subjects, nor the researcher knew who received 
caffeine. The subjects were asked to follow the same dietary patterns before T1 and T2. 
 
Table 3.4 Caffeine containing foodstuffs that the athletes were instructed to 
avoid for 14 days prior to T1 and T2 
 
• Any form of coffee (instant coffee, filter coffee, percolated etc.). Decaffeinated coffee was also not permitted, 
as this contains small amounts of caffeine. 
• Ceylon tea, black tea and green tea. Rooibos tea was permitted. 
• All soft drinks such as Coke®, iced tea etc. Only Tab® was allowed as it is caffeine free. All other soft drinks 
containing caffeine were excluded. 
• Chocolate bars as well as ice-cream containing coffee / chocolate. 
• Cocoa and drinks such as hot chocolate, Milo® and Horlicks®. 
• Energy gels and energy drinks containing caffeine (such as Gu®). If the subject was unsure of the caffeine 
content of a product, the subject was requested to ask the researcher to check this to ensure that it did not 
contain any caffeine. 
• Vitamin water® (energy flavour), which also contains caffeine, and was avoided. 
• Energy drinks such as Red Bull®. 
• Breathe fresheners and chewing gum containing caffeine. 
• Weight loss pills as well as pain relievers such as Grandpa®. 
 
3.4.3.2 Pre-event meal 
The pre-event meal may have influenced the ergogenic effect of caffeine supplementation. 
Therefore, it was important to note what the athletes ingested as their pre-event meal. The 
subjects arrived at the races in the fasted state in order to provide fasted baseline blood 
samples. Thereafter they had sufficient time to eat their pre-event meal. Details of the pre-
event meal were recorded as part of the food record described in Section 3.4.4.2. 
 
3.4.2.3 Menstrual cycle, oral contraceptive use and menopause 
The menstrual history questionnaire (Appendix 3.10) formed part of the demographic 
information questionnaire. Details of this questionnaire are described in Section 3.4.4.1. 
 
3.4.2.4 Genetic analysis 
Collection and extraction of genomic DNA for genetic analysis 
Because of the non-invasiveness and ease of obtaining and storing buccal samples, these 
were preferred for genomic DNA extraction in this study. Buccal swabs were collected from 
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each patient by the researcher, during the week before T1, using regular flocked 80 mm 
buccal swabs (Lasec SA® www.lasecsa.co.za) as described by the manufacturers (Table 
3.5). These collection instructions were explained to the subjects whilst obtaining written 
informed consent.  
  
The samples were transported immediately to the Department of Genetics, Faculty of 
AgriSciences, Stellenbosch University and were stored at room temperature for 1-2 weeks 
prior to DNA extraction. Thereafter, the samples were stored at -20ºC for re-extractions. The 
laboratory at the Department of Genetics extracted the DNA and analysed the samples 
according to the standard techniques and procedures outlined in the Invitrogen Purelink® 
Genomic DNA kit. 
 
Table 3.5 Collection instructions for buccal swab samples 
 
Step 1: Subjects abstained from eating or drinking for approximately 30 minutes prior to providing the sample 
Step 2: Alternatively, gently brush the inside surface of both cheeks with a toothbrush (without toothpaste) (Step 
1 above is preferred over step 2) 
Step 3: Thoroughly rinse the mouth twice with water 
Step 4: Roll the swab firmly on the inside of the cheek approximately 20 times on each side 
Step 5: Make sure to brush over the entire cheek 
Step 6: Allow the swab to dry at room temperature (±25⁰C) for 10-15 minutes, taking care not to touch the tip. 
Step 7: Place the swab in the original packaging for transportation 
Step 8: The swab is stable for up to one week stored at a temperature of between 22⁰C and 37⁰C 
Source: www.genediagnostics.co.za 
 
DNA extraction and purification were subsequently completed as recommended in the 
Laboratory Protocol for Manual Purification of DNA (Invitrogen PureLink® Genomic DNA kit) 
(Table 3.6). 
 
  
Stellenbosch University http://scholar.sun.ac.za
91 
 
Table 3.6 DNA extraction / purification 
 
Step 1: Preparing human buccal swab lysate: 
• Prepare lysate from human buccal cell swabs as described below 
• Set a water bath or heat block at 55ºC 
• Place the buccal swab in a sterile, 2 ml microcentrifuge tube 
• Add 400 µl (for cotton and Dacron swab) or 600 µl (for Omni swab) phosphate buffered saline (PBS) to the 
sample 
• Add 20 µl Proteinase K into a sterile micro centrifuge tube capable of holding three times the volume of 
lysate 
• Transfer 200-600 µl swab lysate to the micro centrifuge tube containing Proteinase K (Step 3). Mix well by 
pipetting 
• Add an equal volume of Purelink® Genomic Lysis/Binding Buffer to the lysate and mix well by brief vortexing. 
• Incubate at 55oC for at least 10 minutes 
• Centrifuge briefly to collect any lysate from the tube caps 
• Add 200 µl 96-100% ethanol to the tube 
• Mix well by vortexing for 5 seconds to yield a homogenous solution 
 
Step 2: Binding DNA 
• Remove a Purelink® spin Column in a Collection Tube from the package 
• Add the lysate (-640 µl) prepared with Purelink® Genomic Lysis/Binding Buffer and ethanol to the Purelink® 
Spin Column 
• Centrifuge the column at 10,000 x g for 1 minute at room temperature 
• Discard the collection tube and place the spin column into a clean Purelink® Collection Tube supplied with 
the kit 
 
Step 3: Washing DNA 
• Add 500 µl Wash Buffer 1 prepared with ethanol to the column 
• Centrifuge column at room temperature at 10,000 x g for 1 minute 
• Discard the collection tube and place the spin column into a clean Purelink” collection tube supplied with the 
kit 
• Add 500 µl Wash Buffer 2 prepared with ethanol to the column 
• Centrifuge the column at maximum speed for 3 minutes at room temperature 
• Discard the collection tube 
 
Step 4: Eluting DNA 
• Place the spin column in a sterile 1.5-ml micro centrifuge tube 
• Add 25-200 µl of Purelink® Genomic Elution Buffer to the column.  
• Parameters to choose the suitable elution volume for your needs 
• Incubate at room temperature for one minute. Centrifuge the column at maximum speed for one minute at 
room temperature. The tube contains purified genomic DNA 
• To recover more DNA, perform a second elution step using the same elution buffer volume as first elution in 
another sterile 1.5 ml micro centrifuge tube 
• Centrifuge the column at maximum speed for l-0.5 minutes at room temperature 
• The tube contains purified DNA 
• Remove and discard the column 
 
Step 5: Storing DNA 
• Store the purified DNA at -20ºC or use DNA for the desired downstream application. 
Source: Invitrogen PureLink® Genomic DNA 
 
Quality and quantity assessment of isolated genomic DNA 
After isolating the genomic DNA (gDNA) of each athlete from buccal swabs using the 
Invitrogen PureLink® Genomic DNA extraction kit, DNA concentrations were assessed by 
spectrophotometric analysis at an absorbance of 260 nm using Nanodrop technology 
(NanoDrop® ND-100, Nanodrop Technologies Inc., Wilmington, Delaware, USA). DNA 
integrity and quality was confirmed by loading approximately 100 ng of DNA on 0.6% 
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agarose gels and subsequent electrophoresis at 80 V for 30 minutes. Hyperladder V 
(Bioline, London, UK) was used as a molecular weight marker to facilitate estimation of 
gDNA size. Concentrations for the samples used in this study ranged between 20 ng/µl and 
60 ng/µl, and total yield from 500 to 1500 ng. DNA quality was satisfactory for all samples. 
Dilutions for all samples were prepared to yield a concentration of 25 ng/µl for use in all 
further analysis.   
 
Genomic DNA from all patients was analysed using the polymerase chain reaction (PCR) 
followed by restriction enzyme analysis to identify the presence of ancestral and/or variant 
CYP1A2 alleles.   
 
A total of five different polymorphisms were studied. PCR primers for CYP1A2*1F 
(rs762551) and CYP1A2*1D (rs35694136) were obtained from Tiwari et al. (2005) (200) and 
Sachse et al. (2003) (201), while primers for the SNPs between CYP1A1 and CYP1A2 
(rs2472297 and rs2470893) and the SNP near the AHR gene (rs6968865), discussed in 
Cornelis et al. (2011) (164) and Sulem et al. (2011) (163), were designed using 
PrimerQuest, incorporating Primer3 as described by Rozen et al. (2000) (202) 
(http://eu.idtdna.com/Scitools/Applications/Primerquest/). BLAStn was used to confirm 
primer specificity and homology (http://blast.ncbi.nlm.nih.gov/). Primer reaction mixtures, 
sequences and PCR product sizes are shown in Table 3.7 and 3.8. PCR amplifications were 
performed using a Geneamp PCR System 2700 (Applied Biosystems, Warrington, WA, 
USA). The PCR amplification conditions were as follows: initial denaturation at 94°C for 5 
min, followed by 30 cycles of 94°C for 30 s, annealing temperature for 30 s, 72°C for 30 s.  
 
Table 3.7 PCR reaction mixtures for all amplicons 
 
* Bioline, Randolph, MA, USA 
 
  
 Stock concentration Final concentration Volume per reaction (µl) 
DNA 15-30 ng/µl 15-30 ng/µl 1 
Buffer 10X 1X 2.5 
MgCl2 50 mM 2 mM 1 
dNTPs 10 mM 0.32 mM 0.8 
Forward Primer 10 pmol/µl 0.4 mM 1 
Reverse Primer 10 pmol/µl 0.4 mM 1 
BIOTAQTM polymerase* 5 U/µl 0.5 U 0.1 
dH2O   17.6 
Final Volume   25 
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Table 3.8 PCR primer sequences used to amplify gene variants 
An underlined nucleotide indicates a base change to incorporate a restriction enzyme site 
 
 
Restriction enzyme analysis: 
All SNPs were genotyped by PCR – restriction fragment length polymorphism (PCR-RFLP) 
analysis. The restriction enzyme digestion was performed in a total volume of 20 µl 
containing PCR product (10 µl), appropriate buffer and at least 2 units of the specific 
restriction enzyme (New England Biolabs Inc., Ipswich, Massachusetts, USA) (Table 3.6). 
Samples were incubated overnight at the optimum temperature of the enzyme and heat 
inactivated according to the enzyme specifications (Table 3.9). 
 
Restriction enzyme digested PCR products were analysed on a 2.5% (w/v) agarose gel 
containing ethidium bromide at 80 V for 3 hours. 1X TBE (0.089 M Tris, 0.089 M Boric acid 
and 20 mM EDTA, pH 8.0) was used as electrophoresis buffer and DNA fragments were 
visualised with UV light. The fragment sizes of the respective alleles detected are indicated 
in Table 3.9. 
 
  
Variant 
location 
rs number DNA sequence 
[Ancestral/ 
Variant base] 
Primer name Primer sequence 
(5’-3’) 
TA PCR 
Product 
size (bp) 
-163C>A 
(CYP1A2*1F) 
rs762551 tgggc[A/C]cagga CYP1A2*1FF TGGAGTGGTCAC
TTGCCTCT 
58°C 520 
CYP1A2*1FR CTGGCTCATCCTT
GACAGT 
 
-2467T/- 
(CYP1A2*1D) 
rs35694136 gcaca[T/-]gaaccc rs35694136 dTF TGAGCCATGATTG
TGGCATA 
54°C 167 
rs35694136 dTR AGGAGTCTTTAAT
ATGGACCCAG 
 
Between 
CYP1A1 & 
CYP1A2 
rs2472297 taatg[C/T]ctctt rs2472297 TF AGATGGAGGGCA
GTGGAGATGAAA 
60°C 384 
rs2472297 TR ACATTCTAACCAG
GGCGGAACACT 
 
Between 
CYP1A1 & 
CYP1A2 
rs2470893 ccagc[G/A]cctcc rs2470893 F TGTATTTGCGTGC
CTAGCTCAACC 
60°C 447 
rs2470893 R ATTCTTGACTCCA
CACTCCTGCCT 
 
Near AHR 
gene 
rs6968865 ggaga[A/T]atctc rs6968865 F ACCGGAAGCTGG
TAGATCAGAAGT 
60°C 228 
rs6968865 R ACACCACAGCAAT
CAACACAGCA 
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Table 3.9 Restriction enzyme assays for the genotype analysis 
 
rs number Recognition site Restriction 
enzyme 
Enzyme 
conditions 
Genotype Fragment sizes (bp) 
rs762551 GGGCC*C ApaI 25°C for 16 hr A/C A: 520 
65° for 20 min C: 373  and 147 
 
rs35694136 CA*TATG NdeI 37°C for 16 hr T/- T: 148 and 19  
65° for 20 min -: 167 
 
rs2472297 GTCTC(N)1* BsmAI 55°C for 16 hr C/T C: 384 
80° for 20 min T: 261  and 123 
 
rs2470893 RGCGC*Y 
R=A or G, Y=C or T 
HaeII 37°C for 16 hr G/A A: 447  
80° for 20 min G: 240  and 207  
 
rs6968865 GAT*ATC EcoRV 37°C for 16 hr A/T A: 228  
80° for 20 min T: 178  and 50  
 
3.4.4 Factors influencing triathlon performance 
3.4.4.1 General health (FBC, questionnaire, mood state) 
Components of the FBC detailed in section 3.4.2.1 were used to interpret the general health 
of the athletes. 
 
In the week before T1, the subjects were sent an e-mail by the researcher, in which an 
Internet link to the baseline questionnaires (Survey Monkey®) was provided. This was more 
convenient for subjects and simplified data collection and data capturing before both 
triathlons. The questionnaires were all completed in the week before T1 and data was 
directly exported to Microsoft Office Excel (2010) for Windows 7®, saving time and money. 
The questionnaires were tested for face and content validity during the pilot study. All the 
questionnaires were available in English and Afrikaans as this was the primary languages of 
the target population. Completing all the questionnaires did not take more than 30 minutes 
and all subjects had internet access.  
 
The following questionnaires were completed by means of this online survey: 
i) Demographic information (Appendix 3.11); 
ii) Training regime (Appendix 3.12); 
iii) Medical history (Appendix 3.13); and 
iv) Menstrual history (Appendix 3.10) 
 
The subjects were also asked to complete the POMS questionnaire (Appendix 3.8) in the 
week before T1 and T2. The questionnaire was used as a tool to establish whether or not 
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the athletes had recovered adequately between T1 and T2, as well as to determine the 
effect of mood state on overall triathlon performance.  
 
3.4.4.2 Energy- and nutrient intake two days before as well as dietary 
strategies followed on race day 
Dietary intake was determined two days before each triathlon, the morning of each triathlon 
(i.e. the pre-event meal) and during T1 and T2. The subjects were instructed to follow their 
normal dietary patterns before a race, with the exception of excluding all the caffeine-
containing products for 14 days prior to T1 and T2.  
 
To determine dietary intake two days before, as well as on the morning of and during T1 and 
T2, the subjects completed two three-day food records using a standardized food record 
form (Appendix 3.14). The three-day food records were completed during the two days 
before T1 and T2, as well as on race day. The subjects were instructed to complete the food 
records on race day (day three) for their pre-event meal/breakfast as well as what they 
ingested during the race. The research assistants checked each food record for completion. 
 
The food record form has been tested for face and content validity in a previous study by the 
same researcher on triathletes (71). The participants completed the food record prior to T1 
and T2 in order to monitor dietary intake before and during the event. Research assistants 
assisted and prompted the subjects before and after T1 and T2 to complete the record for 
the day. All subjects were trained by the researcher on how to keep a food record. The 
athletes were required to write down exactly what they ate and drank, and the amount of 
this, at the time of intake for two days before, the morning of and during T1 and T2.  
 
Portion sizes were either weighed with a small scale (Weigh-Less® Food Scale with 400 ml 
bowl, item code: FS02, capacity: 500 g/18 oz, graduation: 10 g or ¼ oz, www.Weigh-
Less.co.za) given to the subjects by the researcher, or quantified using standard household 
measurements and units, for example one egg, one can of a certain soft drink, or 250 ml of 
water. The quantities of supplements, such as energy gels- and bars, were recorded as the 
amounts indicated on the wrapper. Portion sizes of the pre-event meal on the day of the 
triathlons were weighed. Portion sizes of food and drink consumed during the triathlons were 
recorded directly after the triathlons. Quantities of sports drinks left over after the race was 
subtracted from the total amount the athlete took with during the race. Supplements and 
sports foods consumed were quantified as the portion sizes indicated on the wrapper. The 
researcher only provided water at the aid stations; therefore, the only sports drink or 
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supplements ingested were what the athletes brought with them. This was recorded on the 
food recorded after the race and quantified as explained above. 
 
On the day of each trial, the subjects were instructed to come to the trial in a fasted state, as 
fasted baseline blood samples needed to be taken in the fasted state. Therefore, they were 
instructed to bring their scales and food records to the race to include their pre-event meal 
and their intake during T1 and T2.  
 
The subjects completed the food records up to the end of T1 and T2 and handed these to 
the research assistants, who checked the records for completeness. Unclear and incomplete 
records were double-checked and completed with the athletes.  
 
The food record also contained a section on the daily use of supplements (i.e. the brand 
name, type of supplement, dose, when the supplement was taken and duration/frequency of 
use), as well as a section to complete on the training the athlete performed on the days of 
keeping the food record.  
 
Dietary data was analysed with the Food Finder TM3 for Windows® software application, 
Version 1 (Langenhoven 2002). This software application was developed by the Nutritional 
Intervention Research Unit (NIRU) and Biomedical Informatics Research Division (BIRD) of 
the South African Medical Research Council (MRC) in collaboration with WAMTechnology 
CC. The program analyses food intake of individuals or groups of individuals for energy, 
macro- and micronutrient content (http://www.foodfinder.mrc.ac.za/).  
 
Dietary data was analysed separately for habitual caffeine intake; and habitual dietary intake 
two days before, the morning of and during T1 and T2. If foodstuffs were not available on 
Food Finder®, the researcher searched for the nutritional information on the Internet, by 
looking at brand websites, and added the foodstuff to Food Finder®. Dietary supplements 
were quantified for macronutrients and added to the nutrient analysis. 
 
Habitual and training/racing specific dietary macronutrient intake was compared to nutritional 
requirements as stated in the latest International Olympic Committee (IOC) consensus 
documents and where applicable the recommendations of the American Dietetic Association 
(ADA) and the American College of Sports Medicine (ACSM), and the International Society 
of Sport Nutrition (ISSN) for total energy; estimated energy availability; and CHO, protein 
and fat intake for endurance athletes (4, 169, 170, 172, 174, 175, 183, 203). 
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To calculate estimated energy availability (estEA), expressed in kcal/kg FFM, the following 
formula was used (4): 
 
estEA = (average daily energy intake (kcal) - average daily exercise energy expenditure 
(EEE) (kcal)) / kg FFM 
EEE was calculated using the following formulas: 
i) EEE = (Metabolic equivalent (MET) X minutes exercised) – activity of daily living 
ii) Activity of daily living was calculated by multiplying the minutes exercised with a MET 
value of 2.3, which represented general daily living (i.e. sitting, walking, cleaning and 
transport).  
 
A low estEA was defined as < 30 kcal/kg FFM and a healthy estEA as 45 kcal/kg FFM  (4). 
 
The micronutrients that were analysed include habitual iron (mg) and calcium (mg) intake, 
measured with the food record completed two days before T1 and T2. These results were 
compared with the Dietary Reference Intakes (DRI) for iron and calcium and cut-off values of 
< 67% (inadequate) of the DRI was used to assess adequacy. The ratio of calcium:protein 
was also calculated and compared to the recommendation of at least 20 mg of calcium for 
every 1 g of protein (176, 204). Dietary supplements were not quantified for micronutrient 
content. 
 
3.4.4.3 Body composition and bone mineral density 
The height of the subjects was measured using a Seca® 767 Column Scale (Germany) with 
Height meter. The subjects stood barefoot with minimal clothing (shorts and a light T-shirt). 
The heels were placed together; the arms were to the side; legs were straight; the shoulders 
were relaxed; and the head positioned in the Frankfort horizontal plane (i.e. line extending 
from the most inferior point of the orbital margin to the left tragion, when the head is 
positioned correctly, the Frankfort horizontal plane is parallel to the fixed headpiece. For 
length measures, the Frankfort plane is aligned perpendicular to the plane of the measuring 
table and parallel to the headpiece). The heels, buttocks, scapulae and the back of the head 
rested against the vertical surface of the stadiometer. The subject inhaled deeply just before 
the measurement was taken. The breath was held and an erect posture was maintained 
while the headboard was lowered on the highest point of the head with enough pressure to 
compress the hair. Measurements were recorded to the nearest 0.1 cm, with the eye level 
with the headboard to decrease errors of parallax. Hair ornamentation was removed prior to 
taking the measurement (188).  
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The weight of the subjects was measured using the same Seca® 767 Column Scale with 
Height Meter. Each subject was instructed to stand still in the middle of the scale’s platform 
without touching anything and with the body weight equally distributed on both feet. The 
weight was recorded to the nearest 100 g. The subjects wore light clothing and no shoes 
(188).  
 
The body mass index (BMI) was interpreted according to the standard guidelines from the 
World Health Organizaion (WHO) (205) and calculated with the following formula: 
BMI (kg/m2) = weight (kg)/(height (m) x height (m)) 
 
For all anthropometrical measurements, the average of two measurements was used. If the 
two consecutive measurements differed significantly, the median of the three measurements 
were used as per guidelines from the International Society for the Advancement of 
Kinanthropometry (ISAK).  
 
All subjects underwent a DXA scan in the week before T1 at the Stellenbosch Osteoporosis 
Centre (Number 1, Oewerpark, Rokewood Avenue, Stellenbosch, 7600), to provide baseline 
body composition measurements. The subjects were instructed to arrive at the unit in the 
fasted state (overnight fast). A scan of the lumbar spine, left and right femoral neck and hip 
as well as whole body bone density and a whole body DXA scan was completed on each 
subject using a Hologic Discovery QDR-4500 DXA machine (12 December 1997). A 
qualified radiographer (CA Truebody, National Diploma in Diagnostic Radiography DXA, 
May 2009) operated the DXA machine. The total whole body reading of x-ray exposure was 
0.008 mGy, which can be described as minor, when comparing it with everyday background 
radiation levels.  
 
The following measurements were recorded from the DXA scan; bone mineral density 
(BMD) and calculation of T- and Z-scores of the anterior-posterior spine, left femoral neck, 
left total hip, total hip bilateral average and whole body BMD, as well as bone mineral 
content (BMC), percentage body fat (%BF), fat mass (kg), lean body mass (LBM) (kg), fat 
free mass (FFM = LBM + BMC) (kg) and total body mass. 
 
DXA scans were analysed and interpreted by a physician, Dr’ G. C. Ellis, Vergelegen Bone 
Scan (PTY) LTD 7 Arun Place, Sir Lowry’s Pass Road, Somerset West, 
grahamellis@helderbergmedical.co.za). 
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Various classification systems for the interpretation and classification of BMD exist. The 
WHO recommends using the T-scores to classify osteopenia and osteoporosis as these 
scores are compared to average peak BMD. This classification system was used in the 
current study to evaluate the bone mineral density of post-menopausal women and men 
over the age of 50, primarily due to the fact that the data from the WHO is predominantly 
based on Caucasian postmenopausal women (12). 
 
This classification identifies patients as: 
i) Normal, if the T-score is at or above -1.0; 
ii) Osteopenic, if the T-score is between -1.0 and -2.5; or  
iii) Osteoporotic, if the T-score is at or below -2.5 
 
The latest official positions from the International Society for Clinical Densitometry (ISCD) 
and the American College of Sports Medicine (ACSM) recommend that the classification 
system from the WHO be used for post-menopausal women and not applied to pre-
menopausal women and children (206).  
 
These populations should be classified according to Z-scores, where a Z-score of below -2.0 
is defined as “low bone density below the expected range for age” in pre-menopausal 
women and as “low bone density for chronological age” in children. These recommendations 
have been adopted by the American Society for Bone and Mineral Research, the 
International Osteoporosis Foundation and the American Association of Clinical 
Endocrinologists. The ACSM defines athletes at clinical risk with Z-scores between -1.0 and 
-2.0, together with a clinical history of fracture as well as nutritional deficiencies, hypo-
estrogenism and stress fractures. According to the ACSM, osteoporosis is defined as clinical 
risk factors as mentioned above with a BMD Z-score of below -2.0 (206).  
 
Therefore, both classification systems were used with the interpretation of the current study’s 
results. 
 
The percentage body fat was interpreted as appropriate for triathletes according to the 
ACSM and the ADA (183, 207). 
 
3.4.4.4 Training two days before race day 
Subjects were instructed to refrain from any exhaustive exercise for 48 hours prior to T1 and 
T2. If they did any exercise during this time, they were instructed to write it down on the food 
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record (Appendix 3.14) in the allocated space. The training record prompted the subjects to 
complete the type of exercise undertaken (for example, running-, or cycling), the duration of 
the exercise (in minutes) and the rating of self-perceived exertion (on a scale of 1-5, with 1 
being “easy” and 5 being “hard”). 
 
3.4.4.5 Caffeine withdrawal 
On the day of T1, the subjects were asked to complete a questionnaire administered by the 
research assistants regarding withdrawal symptoms experienced during the 14 days leading 
up to T1, in which caffeine-containing foodstuffs were excluded from their diet (Appendix 
3.15). 
 
3.4.4.6 Caffeine side-effects 
The side effects of caffeine supplementation include: nervousness, restlessness, shakiness, 
anxiety, heart palpitations, flushing, sleep alteration and headaches. Gastro-intestinal 
disturbances may also occur, although trials have shown no significant differences in 
gastroesophageal reflux, gastric pH or gastrointestinal transit time when caffeine 
supplements are used (44). The incidence of these side effects was recorded during T1 and 
T2 and is described in the results chapter. 
 
After completion of T1 and T2, the subjects were instructed by the research assistants to 
complete a questionnaire regarding any side effects of caffeine supplementation that were 
experienced during T1 or T2 (Appendix 3.16). 
 
3.4.4.7 Hydration status and changes in plasma volume 
Serum albumin is produced by the liver and exerts an osmotic effect to maintain water 
balance between blood and tissue. Serum albumin levels in the present study were 
determined to detect any changes in plasma volume that might occur due to exercise and to 
adjust other biochemical parameters accordingly. Serum albumin was measured at baseline, 
during transition (cycle → run) and at the finish line. Reference values for albumin are 35-50 
g/l for both males and females. Details of blood collection are described in section 3.4.2.1. 
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3.5 Ethics and legal aspects 
3.5.1 Ethics approval 
The protocol was approved by the Health Research Ethics Committee (HREC) of 
Stellenbosch University on 1 November 2010. After submission of amendments to the 
protocol, final approval was granted on 19 April 2011. Annual progress reports were 
submitted and approved for 2011 and 2012 (M10/08/030) (Appendix 3.17).  
 
3.5.2 Registration with the Medicines Control Council (MCC) 
Caffeine supplementation is not intended to treat or cure any medical condition and therefore 
not regarded as a medicine. It is, instead classified as a nutritional or sport supplement. The 
researcher, furthermore, used the supplement in healthy athletes at a dosage that did not 
pose any adverse effects to health. Registration with the MCC was therefore not required.  
 
3.5.3 Informed consent 
The researcher recognized autonomy and respect for persons and therefore participation in 
this study was completely voluntary. The pilot study- and research project were explained in 
detail by the researcher during the initial interview. Written informed consent was obtained 
from all subjects who participated in the pilot (Appendix 3.18), as well as in the research 
project (Appendix 3.19), and subjects were given a copy of the information leaflet and the 
written informed consent form. The written informed consent form also gave specific 
information regarding genetic analysis. All subjects also had to sign an indemnity waiver 
before T1 and T2 (Appendix 3.20). 
 
3.5.4 Anonymity 
All subjects were assigned a reference/subject number. The contact details of participants 
were only used to contact them before, and between T1 and T2. All personal and contact 
information was deleted from the computer after data collection was completed. All the 
information gathered during data collection was kept anonymous by using the assigned 
subject number. Only photos of subjects who gave consent for their photos to be used in this 
dissertation as well as future publications and presentations were used. 
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3.5.5 Incentive 
After T2, equal prize money was offered to the first five males and females who completed 
the triathlons in two age categories (Table 3.10). The finishing times for T1 and T2 were 
combined to determine the winners in each age category.  
 
Prize money is commonly awarded in all triathlon races, but, the amounts awarded can differ 
significantly between races and there is no known set standard. It is important to note that 
many athletes race as a source of income, apart from sponsorships. It was not intended that 
the prize money be a direct incentive for subjects to participate in the study, but rather that it 
would encourage the athletes to race at the same intensity as they would during a race and 
that the athletes would compete in both triathlons. The prize money was allocated from the 
research funds.  
 
Table 3.10 Prize money offered to the triathletes after triathlon 2 
 
 Male Female 
20-39 years 1. R 5 000.00 1. R 5 000.00 
 2. R 4 000.00 2. R 4 000.00 
 3. R 3 000.00 3. R 3 000.00 
 4. R 2 000.00 4. R 2 000.00 
 5. R 1 000.00 5. R 1 000.00 
40-60 years 1. R 5 000.00 1. R 5 000.00 
 2. R 4 000.00 2. R 4 000.00 
 3. R 3 000.00 3. R 3 000.00 
 4. R 2 000.00 4. R 2 000.00 
 5. R 1 000.00 5. R 1 000.00 
 
3.5.6 Insurance 
Insurance cover for the clinical field trial was provided by Stellenbosch University (Appendix 
3.21). 
 
3.5.7 Funding 
This study was supported by grants from the Harry Crossley Foundation; Subcommittee C of 
the Faculty of Health Sciences, Stellenbosch University; a National Research Foundation 
PhD scholarship; the Department of Physiology, Stellenbosch University; as well as the 
Mellon Early Research Career (MERC) Development Program. None of the funders had any 
vested interest in the outcome of the project and therefore there is no conflict of interest to 
be declared.  
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3.5.8 Dissemination of results 
Each subject received a confidential report directly from the Osteoporosis clinic regarding 
the DXA scans. The researcher also sent a summary of the main research findings to the 
subjects. 
 
Results from this dissertation will be submitted for publication as three to four original 
research articles in accredited scientific peer-reviewed journals. Journals considered by the 
researcher includes; Medicine and Science in Sports and Exercise, the International Journal 
of Sports Medicine, the International Journal of Sports Nutrition or the International Journal 
of Sports Nutrition and Exercise Metabolism, Current Sports Medicine Reports or the Journal 
of Applied Physiology. 
 
The researcher plans on submitting part or all of this original research for presentation at the 
American College of Sports Medicine (ACSM) 60th Annual Meeting and 4th World Congress 
on Exercise is Medicine® (May 28-June 1, 2013, Indianapolis, Indiana, USA). Further results 
eminating from this research may also be submitted for oral or poster presentation at other 
National and International Congresses. 
 
3.6 Statistical analysis 
Statistical analysis was completed with the assistance of a biostatistician from the Centre for 
Statistical Consultation (CSC), Stellenbosch University. 
 
3.6.1 Computer programs 
Data capturing and statistical analysis programs used included StatSoft, Statistica® (version 
10) and Microsoft Excel (2010) for Windows 7®. 
 
3.6.2 Descriptive statistics 
Descriptive statistics in the form of the mean ± standard deviation (SD)/standard error (SE) 
for continuous data or data that is normally distributed was used. Nonparametric statistics 
were used for ordinal/categorical data and for data that was not normally distributed. The 
data that is not normally distributed is presented as the median and quartile range, or the 
percentage of the total population.  
 
Some key assumptions made with parametric statistics are that data is normally distributed 
and that independent, unbiased samples with equal variances are used. 
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3.6.3 Comparing data between T1 and T2 
3.6.3.1 Normally distributed / continuous data 
To test the difference between two independent or two dependent groups, the t-test for 
independent and t-test for dependent samples were used respectively. To test the difference 
between multiple independent groups, analysis of variance (ANOVA) or multivariate analysis 
of variance (MANOVA), was performed. The difference between multiple dependent groups 
was assessed using repeated measures analysis of variance (RMANOVA).  
 
Relationships between variables were tested with the correlation coefficient.  
 
3.6.3.2 Ordinal and categorical and data that is not normally distributed  
For ordinal-, and categorical data, as well as data that is not normally distributed, the 
following non-parametric inferential statistical tests were used: 
i) The Mann-Whitney U test was used to test differences between independent groups; 
ii) Wilcoxon’s matched pairs test was used to test the difference between dependent 
groups; 
iii) McNemar’s Chi-square test was used when variables of interest were dichotomous in 
nature; and 
iv) The Spearman R test was used to test relationships between variables. If these 
variables of interest were categorical in nature, the Chi-squared test was used. 
 
3.6.3.3 Comparing data between caffeine and placebo groups 
The study design was a double-blind, randomized cross-over controlled clinical field trial, in 
which each subject was his/her own case and control. To compare data between the 
caffeine and placebo groups, variance estimation, precision and comparison (VEPAC) in 
STATISTICA® was used to do analysis of variance (ANOVA) with restricted maximum 
likelihood (REML). This allowed for the respondent to be nested within the treatment group 
(caffeine received during T1 or T2) and further analysis with the respondent group nested 
within gender. This approach allowed for the identification of a carry-over effect from whether 
or not the subject received caffeine during T1 or T2 as each participant was his/her own 
case (caffeine) and control (placebo). The researcher did not expect a carry-over effect to be 
present as the washout period between the two trials was 14 days and was deemed 
adequate in eliminating any possible carry-over effect. 
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To test differences between ordinal data obtained from the caffeine and placebo groups, the 
maximum likelihood (M-L) chi-squared test was used.  
 
3.6.3.4 Influence of variables on triathlon performance 
To determine the influence of various factors/paramaters on triathlon performance, the 
researcher performed a factorial ANOVA with VEPAC of the overall time to complete the 
triathlon, with factors group and caffeine and then gender and caffeine, with respondents 
nested firstly in group and then nested in gender. To investigate the influence of the various 
factors, these variables were one by one entered as covariates in a similar analysis of 
covariance (ANACOVA) with factors group and caffeine, and then gender and caffeine. 
 
3.6.3.5 Display of results (tables/figures) 
Tables are presented as the mean±SD for data that is normally distributed/continuous data. 
For data that is not normally distributed, the median or the percentage of the total population 
(frequency) is displayed. Relevant inferential statistics are displayed below each table. 
Graphs are displayed as least-square (LS) means and vertical bars denote 95% confidence 
intervals. Relevant inferential statistics are displayed below each graph. 
 
Statistical significance was set at p < 0.05* and is indicated with an * where relevant. Values 
that were statistically signficant from each other are marked with a and b.  
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CHAPTER 4: RESULTS 
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4.1 Demographic information 
The total number of subjects who participated in both T1 and T2 were N = 26, of which 54% 
(Nm = 14) were male and 46% (Nf = 12) were female. The mean age was 37.8 (±10.6) years, 
with the mean age of the males being 38.4 (±10.0) years and the mean age of the females 
being 37.2 (±11.6) years. All the subjects were Caucasian. 
 
The age distribution of the group was as follows: 
i) 18-29 years (31% of the sample size, N = 8); 
ii) 30-40 years (19%, N = 5); 
iii) 40-50 years (31%, N = 8); and 
iv) 50-60 years (19%, N = 5). 
 
4.2 Ergogenic effect of caffeine supplementation 
4.2.1 Plasma caffeine  
The researcher performed a RMANOVA with VEPAC on plasma caffeine levels with factors 
group, caffeine and stage (plasma caffeine levels measured at baseline, during transition 
(cycle → run) and at the finish line) and then gender, caffeine and stage with respondents 
nested firstly in group (p = 0.92) and then in gender (p = 0.17).  
 
Baseline plasma caffeine levels were taken 1 hour before caffeine supplementation and 
therefore caffeine supplementation had no influence on baseline caffeine levels (p = 0.85 for 
all; p = 0.68 for males and p = 0.88 for females). The plasma caffeine measurements taken 
during transition (cycle → run) (p = 0.00 for all; p = 0.00 for males and p = 0.00 for females) 
and at the finish line (all p = 0.00, male p = 0.00, female p = 0.00) were significantly 
increased by caffeine supplementation (Table 4.1).  
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Table 4.1 Caffeine supplementation and plasma caffeine levels in the caffeine 
and placebo groups 
 
 Caffeine Placebo Caffeine vs.  
Placebo 
 Mean±SD Mean±SD p-value 
All Nc = 28 Np = 28  
Caffeine supplementation (mg) 600.6±91.4   
Baseline (mg/l) 1.3±0.7 1.4±1.4 p = 0.85 
Transition (cycle-run) (mg/l) 7.0±3.1 1.3±1.2 p = 0.00* 
Finish line (mg/l) 8.6±2.8 1.3±1.2 p = 0.00* 
 
Male  Ncm = 14 Npm = 14  
Caffeine supplementation (mg) 652.4±76.7   
Baseline (mg/l) 1.5±0.9 1.7±1.9 p = 0.68 
Transition (cycle-run) (mg/l) 6.3±3.5a 1.6±1.6b p = 0.00*   
Finish line (mg/l) 8.1±2.9a 1.6±1.6b p = 0.00* 
 
Female  Ncf = 12 Npf = 12  
Caffeine supplementation (mg) 540.1±68.1   
Baseline (mg/l) 1.1±0.3 1.0±0.0 p = 0.88 
Transition (cycle-run) (mg/l) 7.9±2.5a 1.0±0.0b p = 0.00*  
Finish line (mg/l) 9.3±2.5a 1.0±0.0b p = 0.00*   
a differed significantly from b (p < 0.05) 
N = total sample; Nm = total male sample; Nf = total female sample; Nc = total caffeine; Ncm = total caffeine male; Ncf = total 
caffeine female; Np = total placebo; Npm = total placebo male; Npf = total placebo female 
 
In the placebo group, caffeine levels in the blood remained unchanged over the course of 
the event (p > 0.05). However, in the caffeine group, caffeine levels increased significantly 
throughout the triathlon and increased from baseline to transition (cycle → run) and at the 
finish line (p = 0.00*) (Figure 4.1). This was apparent in the male and female groups, 
although no statistically significant difference was found between the plasma caffeine levels 
of males and females (p = 0.17). 
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Figure 4.1 Influence of caffeine supplementation on plasma caffeine levels measured 
at baseline, transition (cycle → run) and at the finish line in the caffeine and placebo 
groups (Supplementation effect: p = 0.00*)  
 
4.2.2 Triathlon performance 
The researcher performed an ANOVA with VEPAC of the time taken to complete the swim 
(minutes), cycle (minutes), run (minutes), medical (minutes), overall with medical (minutes) 
and overall time to complete the triathlon without medical (minutes) respectively with factors 
group and caffeine and then gender and caffeine with respondents nested firstly in group 
and then nested in gender.  Although not always statistically significant, there was a definite 
trend toward faster overall times and individual sections of the triathlon in the caffeine group 
compared to the placebo group; this was also evident from the percentage reduction in time 
that was calculated, as described below.   
 
Caffeine supplementation had the most profound effect on the swim time, which is the first 
section of the triathlon. There was a 3.7% reduction in the time taken to complete the swim 
in all subjects (33.5±7.0 vs. 34.8±8.1) (p = 0.05*), a 4.5% reduction in the male subjects 
(32.2±4.6 vs. 33.7±6.3) (p = 0.07) and a 2.8% decrease in the female group (35.0±9.0 vs. 
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36.0±9.9) (p = 0.29). This effect was also observed in the overall time to complete the 
triathlon in all subjects, with a 1.3% reduction in the overall time to complete the triathlon 
(149.6±19.8 vs. 151.5±18.6) (p = 0.02*), a 1.7% decrease in the male subjects (142.6±11.9 
vs. 145.0±12.7) (p = 0.04*) and a 0.9% reduction in the female group (157.8±24.3 vs. 
159.2±21.9) (p = 0.29) (Table 4.2). Twenty of the triathletes (20/26) had decreased overall 
time to complete the triathlons, with only six (6/26) displaying either no or limited 
improvement in performance time (Figure 4.2). 
 
Table 4.2 Time to complete the various sections of the triathlon  
 
 All Caffeine Placebo Caffeine vs. 
Placebo 
% ↓ 
Mean±SD Mean±SD Mean±SD p-value  
All N = 52 Nc = 26 Np = 26   
Swim (minutes) 34.1±7.5 33.5±7.0a 34.8±8.1b p = 0.05* 3.7 % 
Cycle (minutes) 71.0±7.2 70.6±7.9 71.4±6.5 p = 0.33 1.1% 
Run with medical (minutes) 47.9±6.4 47.6±6.6 48.1±6.4 p = 0.18  
Medical* (minutes) 2.1±0.9 2.0±0.7 2.2±1.0 p = 0.43  
Run without medical (minutes) 45.8±6.3 45.6±6.4 45.9±6.3 p = 0.24 0.7% 
Overall with medical (minutes) 152.7±19.1 151.6±19.8a 153.8±18.7b p = 0.01*  
Overall without medical (minutes) 150.6±19.1 149.6±19.8a 151.5±18.6b p = 0.02* 1.3% 
 
Males Nm = 28 Ncm = 14 Npm = 14   
Swim (minutes) 32.9±5.5 32.2±4.6 33.7±6.3 p = 0.07 4.5% 
Cycle (minutes) 67.8±4.7 67.2±4.1 68.4±5.3 p = 0.29 1.8% 
Run with medical (minutes) 45.6±5.0 45.2±5.0 46.1±5.1 p = 0.10  
Medical* (minutes) 2.1±0.9 1.9±0.6 2.2±1.2 p = 0.29  
Run without medical (minutes) 43.6±4.9 43.3±4.9 43.8±5.0 p = 0.22 1.1% 
Overall with medical (minutes) 145.9±12.3 144.5±12.0a 147.2±12.9b p = 0.02*  
Overall without medical (minutes) 143.8±12.1 142.6±11.9a 145.0±12.7b p = 0.04* 1.7% 
 
Females Nf = 24 Ncf = 12 Npf = 12   
Swim (minutes) 35.5±9.2 35.0±9.0 36.0±9.9 p = 0.29 2.8% 
Cycle (minutes) 74.7±7.9 74.5±9.5 74.9±6.2 p = 0.78 0.5% 
Run with medical (minutes) 50.5±6.9 50.4±7.2 50.6±7.0 p = 0.78  
Medical* (minutes) 2.2±0.8 2.2±0.9 2.2±0.8 p = 0.94  
Run without medical (minutes) 48.3±6.9 48.2±7.1 48.4±7.0 p = 0.77 0.4% 
Overall with medical (minutes) 160.7±22.6 159.9±24.2 161.4±21.9 p = 0.22  
Overall without medical (minutes) 158.5±22.7 157.8±24.3 159.2±21.9 p = 0.24 0.9% 
a differed significantly from b (p < 0.05) 
*Medical: time taken to draw blood sample during transition from cycle-run 
N = total sample; Nm = total male sample; Nf = total female sample; Nc = total caffeine; Ncm = total caffeine male; Ncf = total 
caffeine female; Np = total placebo; Npm = total placebo male; Npf = total placebo female 
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Figure 4.2 Overall time to complete the triathlons in the caffeine and placebo groups 
(Supplementation effect: p = 0.02*) 
*indicates outliers, ∆	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  indicates	  mean	  and	  SD 
 
4.2.3 Rating of perceived exertion (RPE) 
4.2.3.1 RPE in the caffeine and placebo groups 
Ratings of perceived exertion were measured with the Borg scale RPE during transition 
(swim →	  cycle), transition (cycle →	  run) and again at the finish line. There were no significant 
differences in the RPE measured at all the time points in the caffeine and placebo groups, 
irrespective of gender. There was, however a tendency towards slightly decreased RPE 
values in the caffeine group compared to the placebo group, but this was not statistically 
significant (Table 4.3). 
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Table 4.3 Ratings of perceived exertion in the caffeine and placebo groups 
 
 All Caffeine Placebo Caffeine vs. 
Placebo 
Mean±SD Mean±SD Mean±SD p-value 
All N = 52 Nc = 26 Np = 26  
Transition (swim-cycle) 15.3±1.7 15.1±1.7 15.4±1.8 p = 0.45 
Transition (cycle-run) 15.8±1.7 15.8±1.7 15.8±1.8 p = 0.93 
Finish line 17.4±2.2 17.2±2.2 17.5±2.3 p = 0.50 
 
Males Nm = 28 Ncm = 14 Npm = 14  
Transition (swim-cycle) 15.8±1.4 15.7±1.5 15.8±1.4 p = 0.91 
Transition (cycle-run) 16.0±1.6 16.1±1.5 15.9±1.8 p = 0.65 
Finish line 17.7±2.3 17.5±2.5 17.9±2.2 p = 0.57 
 
Females Nf = 24 Ncf = 12 Npf = 12  
Transition (swim-cycle) 14.7±1.9 14.3±1.6 15.0±2.2 p = 0.33 
Transition (cycle-run) 15.5±1.8 15.3±1.8 15.8±1.8 p = 0.54 
Finish line 17.0±2.1 16.9±2.0 17.2±2.4 p = 0.71 
N = total sample; Nm = total male sample; Nf = total female sample; Nc = total caffeine; Ncm = total caffeine male; Ncf = total 
caffeine female; Np = total placebo;  
Npm = total placebo male; Npf = total placebo female 
 
The researcher performed a RMANOVA with VEPAC of the RPE with factors group, caffeine 
and stage (transition (swim → cycle), transition (cycle → run) and finish line) and then 
gender, caffeine and stage; with respondents nested firstly in group (p = 0.95) and then in 
gender (p = 0.80). 
 
There were no significant differences in the caffeine group between RPE measured during 
transition (swim → cycle) and during transition (cycle → run) in the combined male and 
female group (p = 0.13), and male (p = 0.49) and female (p = 0.14) groups. There were also 
no significant differences in the placebo group between RPE measured during transition 
(swim → cycle) and during transition (cycle → run) in the combined male and female group 
(p = 0.40), and male (p = 0.91) and female (p = 0.27) groups.  
 
There were however significant increases in RPE measured during transition (swim → cycle) 
and at the finish line in the combined male and female group (p = 0.00*), and male (p = 
0.00*) and female (p = 0.00*) groups and also between the RPE measured during transition 
(cycle → run) and at the finish line in the combined male and female group (p = 0.00*), and 
male (p = 0.03*) and female (p = 0.02*) groups with caffeine supplementation. 
 
There was also a significant increase in RPE measured during transition (swim → cycle) and 
at the finish line in the combined male and female group (p = 0.00*), and male (p = 0.00*) 
and female (p = 0.00*) groups and also between the RPE measured during transition (cycle 
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→ run) and at the finish line in the combined male and female group (p = 0.00*), and male (p 
= 0.00*) and female (p = 0.04*) groups in the placebo group.  
 
Although there was a trend toward lower RPE values in the caffeine vs. placebo group, this 
was not statistically significant (p = 0.87) (Figure 4.3).  
 
 
Figure 4.3 RPE measured at various time points in the caffeine and placebo groups 
(Supplementation effect: p = 0.87, significant difference between time points: p = 
0.00*) 
 
4.2.3.2 Influence of RPE on triathlon performance 
The researcher performed a factorial ANOVA with VEPAC of the overall time to complete the 
triathlon, the cycling and running times respectively, with factors group and caffeine and then 
gender and caffeine, with respondents nested firstly in group and then nested in gender. To 
investigate the influence of RPE measured during transition (swim → cycle), transition (cycle 
→ run) and at the finish line respectively, these variables were one by one entered as 
covariates in a similar analysis of covariance with factors (group and caffeine, and then 
gender and caffeine), as described above. 
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The introduction of RPE measured during transition (swim → cycle) (p = 0.35 with group and 
p = 0.49 with gender), transition (cycle → run) (p = 0.34 with group and p = 0.34 with gender) 
and at the finish line (p = 0.13 with group and p = 0.12 with gender) as a covariate had no 
significant effect on the overall time to complete the triathlon. 
 
The introduction of RPE measured during transition (swim → cycle) as a covariate had no 
significant effect on the time to complete the cycling section of the triathlon (p = 0.43 with 
group and p = 0.97 with gender). 
 
The introduction of RPE measured during transition (cycle → run) as a covariate also had no 
significant effect on the time to complete the running section of the triathlon (p = 0.93 with 
group and p = 0.74 with gender). 
 
4.2.3.3 Influence of RPE measured during transition (swim → cycle), transition 
(cycle → run) and at the finish line on plasma cortisol levels  
The researcher performed a factorial ANOVA with VEPAC of the plasma cortisol levels 
measured at the finish line, with factors group and caffeine and then gender and caffeine, 
with respondents nested firstly in group and then nested in gender. To investigate the 
influence of RPE measured during transition (swim → cycle), transition (cycle → run) and at 
the finish line respectively, these variables were one by one entered as covariates in a 
similar analysis of covariance with factors (group and caffeine, and then gender and 
caffeine), as described above. 
 
The introduction of RPE measured during transition (swim → cycle) (p = 0.46), transition 
(cycle → run) (p = 0.50) and at the finish line (p = 0.86) as a covariate had no significant 
effect on plasma cortisol levels measured at the finish line.  
 
4.2.4 Mood state 
The researcher performed a RMANOVA with VEPAC on the total POMS score with factors 
group, caffeine and stage (the week before, at baseline and at the finish line); and then 
gender, caffeine and stage; with respondents nested firstly in group (p = 0.92) and then 
nested in gender (p = 0.87). Caffeine supplementation made no difference in the total POMS 
score measured the week before, at baseline or at the finish line in the caffeine and placebo 
groups (p = 0.72), irrespective of gender (p = 0.87) (Figure 4.4). 
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Figure 4.4 Total POMS scores measured the week before, at baseline and at the finish 
line in the caffeine and placebo groups (Supplementation effect: p = 0.72) and 
according to gender (Gender effect: p = 0.87).  
 
The researcher performed a RMANOVA with VEPAC with factors group, caffeine and stage 
(the week before, at baseline and at the finish line); and then gender, caffeine and stage; 
with i) POMS tension score nested firstly in group (p = 0.32) and then gender (p = 0.90), ii) 
POMS vigour score nested firstly in group (p = 0.90) and then gender (p = 1.00) and iii) 
POMS fatigue score, nested firstly in group (p = 0.77) and then gender (p = 0.55).  
 
Caffeine supplementation made no difference in the differential POMS scores measured the 
week before, at baseline or at the finish line in the caffeine and placebo groups for i) POMS 
tension score (p = 0.19), irrespective of gender (p = 0.90), ii) POMS vigour score (p = 0.64), 
irrespective of gender (p = 1.00) and POMS fatigue score (p = 0.32), irrespective of gender 
(p = 0.55) (Table 4.4) 
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Table 4.4 POMS score between caffeine and placebo groups 
 
 All Male Female  
Caffeine 
(Nc = 26) 
Placebo 
(Np = 26) 
Caffeine 
(Nmc = 14) 
Placebo 
(Nmp = 14) 
Caffeine 
(Nfc = 12) 
Placebo 
(Nfp = 12) 
Caffeine 
vs. 
Placebo 
Male vs. 
Female 
Week before Mean±SD Mean±SD Mean±SD Mean±SD Mean±SD Mean±SD p-value p-value 
Total score -13.3±8.5 -12.3±7.6 -14.0±8.0 -12.0±8.1 -12.4±9.4 -12.6±7.4 p = 0.72 p = 0.87 
Tension -2.7±2.0 -2.5±1.8 -2.8±1.6 -2.8±1.6 -2.6±2.4 -2.2±2.0 p = 0.19 p = 0.90 
Vigor 17.0±4.2 17.2±3.2 17.6±3.7 17.3±3.6 16.2±4.7 17.2±2.9 p = 0.64 p = 1.00 
Fatigue 6.4±5.6 7.5±5.9 6.4±5.7 8.1±6.3 6.3±5.7 6.8±5.5 p = 0.32 p = 0.55 
 
Baseline Mean±SD Mean±SD Mean±SD Mean±SD Mean±SD Mean±SD p-value p-value 
Total score -13.7±9.1 -15.0±8.5 -15.9±6.7 -15.9±8.4 -11.0±11.0 -13.8±8.8 p = 0.72 p = 0.87 
Tension -2.6±2.6 -2.5±2.2 -2.9±2.1 -2.8±1.8 -2.3±3.2 -2.2±2.6 p = 0.19 p = 0.90 
Vigour 16.0±5.6 16.1±5.4 18.1±4.4 17.5±4.7 13.5±6.1 14.4±5.9 p = 0.64 p = 1.00 
Fatigue 4.9±5.2 3.6±4.1 5.0±5.3 4.4±5.1 4.8±5.3 2.8±2.4 p = 0.32 p = 0.55 
 
Finish line Mean±SD Mean±SD Mean±SD Mean±SD Mean±SD Mean±SD p-value p-value 
Total score -4.6±11.7 -4.7±9.2 -6.6±13.0 -6.7±10.7 -2.3±10.1 -2.3±6.5 p = 0.72 p = 0.87 
Tension -0.6±2.1 -1.7±2.3 -0.6±2.1 -1.6±1.6 -0.5±2.2 -1.8±3.0 p = 0.19 p = 0.90 
Vigour 15.5±6.6 14.4±6.0 18.3±6.6 16.6±6.0 12.3±5.1 11.8±5.1 p = 0.64 p = 1.00 
Fatigue 11.5±5.9 11.5±5.3 12.4±5.6 11.5±5.9 10.6±6.4 11.4±4.9 p = 0.32 p = 0.55 
a differed significantly from b (p < 0.05) 
N = total sample; Nm = total male sample; Nf = total female sample; Nc = total caffeine; Ncm = total caffeine male; Ncf = total 
caffeine female; Np = total placebo; Npm = total placebo male; Npf = total placebo female 
 
4.3 Parameters that could in part explain the ergogenicity of 
caffeine supplementation 
4.3.1 Endocrine-stress response 
Serum cortisol, DHEAs, prolactin and testosterone levels were measured at baseline and at 
the finish line in the caffeine and placebo groups (Table 4.5). 
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Table 4.5 Levels of various endocrine-stress hormones in the caffeine and 
placebo groups 
 
 All Caffeine Placebo Caffeine vs.  
Placebo 
Mean±SD Mean±SD Mean±SD p-value 
All N = 52 Nc = 26 Np = 26  
Cortisol 
Baseline (nmol/l) 569.9±140.6 570.5±142.6 569.3±141.5 p = 0.90 
Finish line (nmol/l) 604.0±193.1 664.9±199.7a 543.0±168.7b p = 0.00* 
DHEAS 
Baseline (umol/l) 6.6±3.3 6.7±3.4 6.6±3.3 p = 0.52 
Finish line (umol/l) 7.8±3.8 7.9±4.1 7.6±3.6 p = 0.16 
Prolactin 
Baseline (ug/l) 11.0±4.7 10.8±5.0 11.1±4.5 p = 0.93 
Finish line (ug/l) 20.6±12.8 21.8±13.5 19.4±12.2 p = 0.24 
Testosterone 
Baseline (nmol/l) 9.8±8.8 9.9±8.9 9.6±8.7 p = 0.59 
Finish line (nmol/l) 7.6±6.7 7.7±6.7 7.5±6.8 p = 0.77 
 
Male  Nm = 28 Ncm = 14 Npm = 14  
Cortisol 
Baseline (nmol/l) 523.4±88.9 511.0±88.2 535.9±91.1 p = 0.50 
Finish line (nmol/l) 615.3±185.6 675.4±201.1a 555.3±152.8b p = 0.00* 
DHEAS 
Baseline (umol/l) 8.3±3.4 8.4±3.6a 8.2±3.4b p = 0.01* 
Finish line (umol/l) 9.6±3.9 9.8±4.4 9.4±3.6 p = 0.16 
Prolactin 
Baseline (ug/l) 10.2±3.7 9.3±3.5 11.1±3.8 p = 0.50 
Finish line (ug/l) 17.3±6.5 18.5±6.5 16.2±6.4 p = 0.23 
Testosterone 
Baseline (nmol/l) 16.7±5.5 17.1±5.4 16.4±5.8 p = 0.34 
Finish line (nmol/l) 13.1±4.1 13.3±3.8 12.9±4.5 p = 0.70 
     
Female  Nf = 24 Ncf = 12 Npf = 12  
Cortisol 
Baseline (nmol/l) 624.2±169.9 640.0±165.0 608.4±180.5 p = 0.43 
Finish line (nmol/l) 590.8±204.6 652.8±206.2a 528.8±191.5b p = 0.00* 
DHEAS 
Baseline (umol/l) 4.7±1.8 4.7±1.7 4.7±2.0 p = 0.98 
Finish line (umol/l) 5.6±2.3 5.7±2.3 5.5±2.4 p = 0.59 
Prolactin 
Baseline (ug/l) 11.9±5.6 12.6±6.0 11.2±5.4 p = 0.62 
Finish line (ug/l) 24.3±16.9 25.5±18.2 23.1±16.2 p = 0.41 
Testosterone 
Baseline (nmol/l) 1.7±2.6 1.6±2.2 1.7±3.0 p = 0.85 
Finish line (nmol/l) 1.2±0.6 1.2±0.7 1.2±0.5 p = 0.97 
a differed significantly from b (p < 0.05) 
N = total sample; Nm = total male sample; Nf = total female sample; Nc = total caffeine; Ncm = total caffeine male; Ncf = total 
caffeine female; Np = total placebo; Npm = total placebo male; Npf = total placebo female 
 
The researcher performed a RMANOVA with VEPAC on serum cortisol levels with factors 
group, caffeine and stage (baseline and finish line) and then gender, caffeine and stage, with 
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respondents nested firstly in group (p = 1.00) and then in gender (p = 0.50). Similar analyses 
were completed for dehydroepiandrosterone sulphate (DHEAs) levels, nested firstly in group 
(p = 0.95) and then in gender (p = 0.96); prolactin, nested firstly in group (p = 0.46) and then 
in gender (p = 0.58); and testosterone levels, also nested firstly in group (p = 0.41) and then 
in gender (p = 0.70). 
 
4.3.1.1 Cortisol levels 
Serum cortisol levels measured in the caffeine group increased significantly from baseline to 
the finish line in all subjects (p = 0.00*) and the male (p = 0.00*) group, but not in the female 
group (p = 0.75). Serum cortisol levels measured in the placebo group, decreased from 
baseline to the finish line in all subjects (p = 0.27) and the female group (p = 0.05*) and 
increased slightly from baseline to the finish line in the male (p = 0.60) group.   
 
There was a significant increase in serum cortisol levels in the caffeine group compared to 
the placebo groups (p = 0.00*) (Figure 4.5).  
 
 
Figure 4.5 Serum cortisol levels measured at baseline and at the finish line in the 
caffeine and placebo groups (Supplementation effect: p = 0.00*) and according to 
gender (Gender effect: p = 0.50) 
 
There was a significant difference in serum cortisol levels measured at baseline and at the 
finish line between males and females (p = 0.00*). Males had lower baseline values, which 
increased at the finish line, whereas females had higher baseline serum cortisol levels that 
decreased at the finish line (Figure 4.6). 
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Figure 4.6 Serum cortisol levels measured at baseline and at the finish line in males 
and females (Gender effect: p = 0.00*)  
 
4.3.1.2 Dehydroepiandrosterone sulphate (DHEAs) levels 
DHEAs levels measured in the caffeine group increased significantly from baseline to the 
finish line in all subjects (p = 0.00*), and male (p = 0.00*) and female (p = 0.00*) groups. 
DHEAs levels measured in the placebo group were higher in all subjects (p = 0.00*), male (p 
= 0.00*) and female groups (p = 0.02*). The increase in DHEAs levels was thus not due to 
caffeine supplementation (p = 0.58) and did not differ between males and females (p = 0.17) 
(Figure 4.7).  
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Figure 4.7 DHEAs levels measured at baseline and at the finish line in the caffeine and 
placebo groups (Supplementation effect: p = 0.58) and according to gender (Gender 
effect: p = 0.96) 
 
4.3.1.3 Prolactin levels 
Prolactin levels measured in the caffeine group increased significantly from baseline to the 
finish line in all subjects (p = 0.00*), and male (p = 0.00*) and female groups (p = 0.00*). 
Prolactin levels measured in the placebo group were also higher in all subjects (p = 0.00*), 
and male (p = 0.00*) and female groups (p = 0.00*). Therefore, the increase in prolactin 
levels that was observed was not due to caffeine supplementation (p = 0.36), and did not 
differ between males and females (p = 0.07) (Figure 4.8). 
 
 
Figure 4.8 Prolactin levels measured at baseline and at the finish line in the caffeine 
and placebo groups (Supplementation effect: p = 0.36) and according to gender 
(Gender effect: p = 0.58)  
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4.3.1.4 Testosterone levels 
Testosterone levels measured in the caffeine group decreased significantly from baseline to 
the finish line in all subjects (p = 0.00*) and the male (p = 0.00*) group, but remained 
unchanged in the female group (p = 0.66). Similar results were found in the placebo group, 
with testosterone levels decreasing significantly from baseline to the finish line in all subjects 
(p = 0.00*) and the male group (p = 0.00*); this was not the case, however, in the female 
group (p = 0.51). Therefore, the change observed in testosterone levels was not due to 
caffeine supplementation (p = 0.88) (Figure 4.9). As expected, males had significantly higher 
testosterone levels at all the time points, compared to females (p = 0.00*) (Figure 4.10). 
 
 
Figure 4.9 Testosterone levels measured at baseline and at the finish line in the 
caffeine and placebo groups (Supplementation effect: p = 0.88) and according to 
gender (Gender effect: p = 0.70) 
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Figure 4.10 Testosterone levels measured at baseline and at the finish line in males 
and females (Gender effect: p = 0.00*) 
 
4.3.2 Oxidative stress (total and differential white blood cell count) 
The researcher performed a RMANOVA with VEPAC on total white blood cell count levels 
with factors group, caffeine and stage (baseline and finish line) and then gender, caffeine 
and stage, with respondents nested firstly in group (p = 0.56) and then in gender (p = 0.22) 
(Table 4.6). 
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Table 4.6 Total and differential white blood cell count 
 
 All Caffeine Placebo Caffeine vs. 
Placebo 
Mean±SD Mean±SD Mean±SD p-value 
All N = 52 Nc = 26 Np = 26  
White blood cells 
Baseline (X 109/l) 6.2±1.6 6.2±1.8 6.1±1.4 p = 0.88 
Finish line (X 109/l) 15.2±3.9 16.1±4.2a 14.2±3.5b p = 0.01* 
Neutrophils 
Baseline  3.2±1.5 3.2±1.7 3.2±1.2 p = 0.95 
Finish line  11.4±3.8 12.4±4.1a 11.0±3.3b p = 0.03* 
Baseline (%) 51.0±9.2 50.5±9.6 51.5±8.9 p = 0.54 
Finish line (%) 76.3±7.0 75.9±7.6 76.7±6.5 p = 0.51 
Lymphocytes 
Baseline  2.2±0.5 2.2±0.5 2.2±0.4 p = 0.73 
Finish line  2.5±0.8 2.7±0.8a 2.3±0.7b p = 0.00* 
Baseline (%) 36.9±8.3 37.3±8.9 36.5±7.9 p = 0.57 
Finish line (%) 17.2±6.3 17.7±7.0 16.8±5.8 p = 0.48 
Monocytes 
Baseline  0.5±0.1 0.5±0.1 0.5±0.1 p = 0.99 
Finish line  0.8±0.2 0.9±0.2a 0.8±0.3b p = 0.03* 
Baseline (%) 8.0±1.8 8.0±1.7 8.0±2.0 p = 1.00 
Finish line (%) 5.4±1.3 5.4±1.2 5.4±1.5 p = 0.99 
Eosinophil 
Baseline  0.2±0.1 0.2±0.1 0.2±0.1 p = 0.35 
Finish line  0.0±0.0 0.0±0.1 0.0±0.0 p = 0.60 
Baseline (%) 2.9±1.6 3.0±1.8 2.8±1.4 p = 0.43 
Finish line (%) 0.3±0.4 0.3±0.5 0.3±0.2 p = 0.75 
Basophils 
Baseline  0.1±0.0 0.1±0.0 0.1±0.0 p = 0.53 
Finish line  0.1±0.0 0.1±0.0 0.1±0.0 p = 0.54 
Baseline (%) 1.2±0.4 1.2±0.5 1.2±0.4 p = 0.39 
Finish line (%) 0.8±0.3 0.8±0.3 0.8±0.3 p = 0.34 
 
Male  Nm = 28 Ncm = 14 Npm = 14  
White blood cells 
Baseline (X 109/l) 6.1±1.3 6.1±1.4 6.1±1.3 p = 0.85 
Finish line (X 109/l) 16.1±4.0 17.6±4.2a 14.7±3.4b p = 0.00* 
Neutrophils 
Baseline  2.9±1.0 3.0±1.1 2.9±1.0 p = 0.97 
Finish line  12.4±3.8 13.5±4.2a 11.4±3.2b p = 0.01* 
Baseline (%) 47.4±7.2 47.2±7.7 47.5±7.0 p = 0.90 
Finish line (%) 76.2±7.0 75.7±7.5 76.7±6.7 p = 0.46 
Lymphocytes 
Baseline  2.4±0.4 2.4±0.4 2.4±0.4 p = 0.81 
Finish line  2.7±0.9 3.1±0.9a 2.4±0.9b p = 0.00* 
Baseline (%) 40.0±7.5 40.5±8.3 39.5±6.9 p = 0.64 
Finish line (%) 17.5±6.5 18.4±7.2 16.7±5.9 p = 0.30 
Monocytes 
Baseline  0.5±0.1 0.5±0.2 0.5±0.1 p = 0.74 
Finish line  0.9±0.3 0.9±0.3 0.8±0.3 p = 0.20 
Baseline (%) 8.4±1.8 8.2±1.6 8.6±2.0 p = 0.19 
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 All Caffeine Placebo Caffeine vs. 
Placebo 
Mean±SD Mean±SD Mean±SD p-value 
Finish line (%) 5.3±1.4 5.0±1.0 5.6±1.6 p = 0.18 
Eosinophil 
Baseline  0.2±0.1 0.2±0.1 0.2±0.1 p = 0.83 
Finish line  0.0±0.0 0.0±0.1 0.0±0.0 p = 0.71 
Baseline (%) 3.1±1.4 3.0±1.5 3.1±1.2 p = 0.86 
Finish line (%) 0.2±0.2 0.2±0.2 0.2±0.2 p = 0.86 
Basophils 
Baseline  0.1±0.0 0.1±0.0 0.1±0.0 p = 0.32 
Finish line  0.1±0.0 0.1±0.0 0.1±0.0 p = 0.45 
Baseline (%) 1.2±0.4 1.1±0.4 1.2±0.4 p = 0.14 
Finish line (%) 0.8±0.3 0.7±0.2 0.8±0.3 p = 0.39 
 
Female  Nf = 24 Ncf = 12 Npf = 12  
White blood cells 
Baseline (X 109/l) 6.2±1.9 6.3±2.3 6.1±1.6 p = 0.86 
Finish line (X 109/l) 14.1±3.6 14.5±3.8 13.7±3.6 p = 0.35 
Neutrophils 
Baseline  3.6±1.8 3.6±2.2 3.5±1.4 p = 0.95 
Finish line  11.0±3.6 11.3±3.9 10.7±3.5 p = 0.48 
Baseline (%) 55.2±9.5 54.4±10.4 56.1±8.8 p = 0.47 
Finish line (%) 76.4±7.2 76.1±8.1 76.6±6.6 p = 0.85 
Lymphocytes 
Baseline  2.0±0.4 2.0±0.5 1.9±0.4 p = 0.79 
Finish line  2.2±0.5 2.3±0.6 2.2±0.4 p = 0.54 
Baseline (%) 33.2±7.9 33.6±8.5 32.9±7.7 p = 0.73 
Finish line (%) 17.0±6.3 17.0±6.9 17.0±6.0 p = 0.99 
Monocytes 
Baseline  0.5±0.1 0.5±0.1 0.4±0.2 p = 0.75 
Finish line  0.8±0.2 0.8±0.2 0.7±0.2 p = 0.06 
Baseline (%) 7.5±1.8 7.8±1.9 7.3±1.8 p = 0.22 
Finish line (%) 5.5±1.2 5.7±1.2 5.2±1.3 p = 0.20 
Eosinophil 
Baseline  0.2±0.1 0.2±0.1 0.1±0.1 p = 0.14 
Finish line  0.0±0.0 0.0±0.1 0.0±0.0 p = 0.72 
Baseline (%) 2.8±1.9 3.0±2.1 2.5±1.7 p = 0.22 
Finish line (%) 0.3±0.5 0.4±0.7 0.3±0.3 p = 0.78 
Basophils 
Baseline  0.1±0.0 0.1±0.0 0.1±0.0 p = 0.95 
Finish line  0.1±0.0 0.1±0.0 0.1±0.0 p = 0.89 
Baseline (%) 1.2±0.5 1.2±0.5 1.2±0.5 p = 0.85 
Finish line (%) 0.8±0.4 0.8±0.4 0.9±0.4 p = 0.60 
a differed significantly from b (p < 0.05) 
% refer to relative counts; while other values refer to absolute counts 
N = total sample; Nm = total male sample; Nf = total female sample; Nc = total caffeine; Ncm = total caffeine male; Ncf = total 
caffeine female; Np = total placebo; Npm = total placebo male; Npf = total placebo female 
 
4.3.2.1 Total white blood cell count 
Total white blood cell count levels measured in the caffeine group increased significantly 
from baseline to the finish line in all subjects (p = 0.00*), and the male (p = 0.00*) and female 
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(p = 0.00*) groups. A similar increase was seen in the placebo group in all subjects (p = 
0.00*), as well as the male (p = 0.00*) and female (p = 0.00*) groups. Higher total white 
blood cell count values were observed at the finish line in the caffeine group compared to 
placebo (p = 0.05*) (Figure 4.11), as well as in the male group when compared to the female 
group (p = 0.01*) (Figure 4.12). 
 
 
Figure 4.11 Total white blood cell count measured at baseline and at the finish line in 
the caffeine and placebo groups (Supplementation effect: p = 0.05*) and according to 
gender (Gender effect: p = 0.22) 
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Figure 4.12 Total white blood cell count measured at baseline and at the finish line in 
males and females (Gender effect: p = 0.01*) 
 
4.3.2.2 Differential white blood cell count 
Absolute and relative (percentage) neutrophil counts measured in the caffeine, as well as in 
the placebo groups increased significantly from baseline to the finish line in all subjects (p = 
0.00*), and the male (p = 0.00*) and female (p = 0.00*) groups. Therefore, caffeine 
supplementation did not influence the absolute (p = 0.12) or relative count (p = 0.97). Higher 
neutrophil count values (p = 0.02*) were observed at the finish line in the male group 
compared to the female group. Lower relative baseline and finish line counts were observed 
in the male group compared to the female group (p = 0.00*) (Figure 4.13). 
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Figure 4.13  Absolute (p = 0.02*) and relative (p = 0.00*) neutrophil count at baseline 
and at the finish line in males and females (Gender effect: p < 0.05)  
 
Absolute lymphocyte count measured in the caffeine group increased significantly from 
baseline to the finish line all subjects (p = 0.00*) and in the male (p = 0.00*) group, but not in 
the female (p = 0.11) group. The absolute lymphocyte count measured in the placebo group 
did not differ significantly at baseline and at the finish line in all subjects (p = 0.31), and the 
male (p = 0.88) and female (p = 0.21) groups.  
 
The increase in the absolute lymphocyte count measured between baseline and at the finish 
line in all subjects and the male groups was due to caffeine supplementation (p = 0.05*) 
(Figure 4.14). There was no significant difference in the absolute lymphocyte count 
measured at baseline and at the finish line between males and females (p = 0.63).  
 
 
Figure 4.14 The absolute lymphocyte count at baseline and at the finish line in the 
caffeine and placebo groups (Supplementation effect: p = 0.05*) and according to 
gender (Gender effect: p = 0.10) 
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The relative lymphocyte count in the caffeine and placebo groups decreased significantly 
from baseline to the finish line in all subjects (p = 0.00*), and the male (p = 0.00*) and female 
(p = 0.00*) groups. This decrease was therefore not due to caffeine supplementation (p = 
0.92).  
 
There was a significant difference in the relative lymphocyte count at baseline and at the 
finish line between males and females (p = 0.01*). The count observed for males decreased 
more markedly from baseline to finish line, when compared to the female group (Figure 
4.15).  
 
 
Figure 4.15 The relative lymphocyte percentage at baseline and at the finish line in 
males and females (Gender effect: p = 0.01*)  
 
The absolute monocyte count measured in the caffeine and placebo groups increased 
significantly from baseline to the finish line in all subjects (p = 0.00*), and the male (p = 
0.00*) and female (p = 0.00*) groups. In contrast, the relative monocyte count measured in 
the caffeine and placebo groups decreased significantly from baseline to the finish line in all 
subjects (p = 0.00*), and the male (p = 0.00*) and female (p = 0.00*) groups. These 
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differences were not due to caffeine supplementation (p = 012 for absolute and p = 0.99 for 
relative monocyte count).  
 
There was no significant difference between the absolute monocyte count at baseline and at 
the finish line between males and females (p = 0.41). There was, however, a significant 
difference in the relative monocyte count at baseline and at the finish line between males 
and females (p = 0.01*) (Figure 4.16).  
 
 
Figure 4.16 The relative monocyte count at baseline and at the finish line in males and 
females (Gender effect: p = 0.01*)  
 
The absolute and relative eosinophil count in the caffeine and placebo groups decreased 
significantly from baseline to the finish line in all subjects (p = 0.00*), and the male (p = 
0.00*) and female (p = 0.00*) groups. There was no difference in the absolute (p = 0.77) or 
relative (p = 0.74) eosinophil count at baseline and at the finish line between the caffeine 
and placebo groups. There was also no significant difference in the absolute (p = 0.15) or 
relative (p = 0.28) eosinophil count measured at baseline and at the finish line between 
males and females.  
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The absolute basophil count in the caffeine and placebo group increased significantly from 
baseline to the finish line in all subjects (p = 0.00*), and the male (p = 0.00*) and female (p = 
0.00*) groups. In contrast to this, the relative basophil count in the caffeine and placebo 
groups, significantly decreased from baseline to finish line in all subjects (p = 0.00*), and the 
male (p = 0.00*) and female (p = 0.00*) groups. There was no difference in the absolute (p = 
0.38) or relative (p = 0.94) basophil count measured at baseline and at the finish line 
between the caffeine and placebo groups (p = 0.38). Furthermore, the absolute (p = 0.19) 
and relative (p = 0.83) basophil count did not differ significantly between males and females.  
 
4.3.3 Plasma lactate 
Lactate levels were measured at baseline, during transition (cycle → run) and 3, 6, 9, 12 and 
15 minutes after the end of the triathlon (Table 4.7). 
 
  
Stellenbosch University http://scholar.sun.ac.za
131 
 
Table 4.7 Lactate levels in the caffeine and placebo groups at baseline, during 
transition (cycle → run) and 3, 6, 9, 12 and 15 minutes after the finish line 
 
 All Caffeine Placebo Caffeine vs. 
Placebo 
N Mean±SD N Mean±SD N Mean±SD p-value 
All N = 52 Nc = 28 Np = 28  
Baseline (mmol/l) 41 2.2±0.7 22 1.9±0.5 19 2.6±0.6 p = 0.13 
Transition (cycle → run) 46 5.0±2.2 23 5.6±2.4a 23 4.4±1.9b p = 0.03* 
FL 3min (mmol/l) 38 5.3±2.4 18 5.9±2.3 20 4.7±2.5 p = 0.07 
FL 6min (mmol/l) 40 4.8±1.6 20 4.7±1.6 20 4.9±1.7 p = 0.76 
FL 9min (mmol/l) 45 4.6±1.9 25 5.0±1.4a 20 4.1±2.3b p = 0.04* 
FL 12min (mmol/l) 29 4.4±2.1 15 5.1±2.2a 14 3.7±1.6b p = 0.02* 
FL 15min (mmol/l) 42 4.4±1.8 21 4.7±1.6 21 4.2±1.9 p = 0.45 
 
Male  Nm = 28 Ncm = 14 Npm = 14  
Baseline (mmol/l) 23 2.1±0.6 12 1.8±0.5 11 2.5±0.5 p = 0.19 
Transition (cycle → run) 26 5.4±2.2 13 6.2±2.3a 13 4.6±1.7b p = 0.01* 
FL 3min (mmol/l) 22 5.5±2.7 10 6.3±1.8a 12 4.8±3.2b p = 0.03* 
FL 6min (mmol/l) 21 4.6±1.9 10 4.5±1.6 11 4.7±2.2 p = 0.95 
FL 9min (mmol/l) 24 4.5±2.2 13 5.0±1.4 11 4.0±2.8 p = 0.14 
FL 12min (mmol/l) 14 4.5±2.1 8 5.1±2.6 6 3.6±1.0 p = 0.10 
FL 15min (mmol/l) 20 4.5±1.9 10 4.8±1.5 10 4.3±2.3 p = 0.73 
 
Female  Nf = 24 Ncf = 12 Npf = 12  
Baseline (mmol/l) 18 2.4±0.7 10 2.0±0.6 8 2.8±0.7 p = 0.40 
Transition (cycle → run) 20 4.6±2.1 10 4.8±2.2 10 4.3±2.1 p = 0.48 
FL 3min (mmol/l) 16 5.0±2.1 8 5.3±2.8 8 4.6±1.0 p = 0.61 
FL 6min (mmol/l) 19 5.0±1.4 10 4.9±1.6 9 5.1±1.2 p = 0.71 
FL 9min (mmol/l) 21 4.7±1.6 12 5.1±1.4 9 4.2±1.7 p = 0.15 
FL 12min (mmol/l) 15 4.4±2.0 7 5.1±2.0 8 3.8±2.0 p = 0.13 
FL 15min (mmol/l) 22 4.3±1.7 11 4.6±1.7 11 4.1±1.7 p = 0.47 
a differed significantly from b (p < 0.05) 
FL: Finish line 
N = total sample; Nm = total male sample; Nf = total female sample; Nc = total caffeine; Ncm = total caffeine male; Ncf = total 
caffeine female; Np = total placebo; Npm = total placebo male; Npf = total placebo female 
 
The researcher performed a RMANOVA with VEPAC on lactate levels with factors group, 
caffeine and stage (baseline, transition (cycle → run) and at 3, 6, 9, 12 and 15 minutes after 
the finish line) and then gender, caffeine and stage, with respondents nested firstly in group 
(p = 0.61) and then in gender (p = 0.92).  
 
There was a significant difference in the lactate levels measured at baseline, during the 
transition (cycle → run) and at 3, 6, 9, 12 and 15 minutes after the finish line between the 
caffeine and placebo groups (p = 0.04*) (Figure 4.17). There were, however, no significant 
differences in lactate levels measured at baseline, during transition (cycle → run) and at 3, 6, 
9, 12 and 15 minutes after the finish line between males and females (p = 0.56) 
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Figure 4.17 Lactate levels measured at baseline, during transition (cycle → run) and at 
3, 6, 9, 12 and 15 minutes after the finish line in the caffeine and placebo groups 
(Supplementation effect: p = 0.04*)  
 
4.3.3.1 Influence of lactate levels on the overall time to complete the triathlon 
Basic statistics, by means of correlations dialog, was used to determine which of the lactate 
measurements at the various time points, influenced the overall time to complete the 
triathlon. None of the lactate measurements influenced the overall time to complete the 
triathlon according to the correlations dialog and therefore a factorial ANOVA with VEPAC 
and lactate levels as covariate was not conducted.  
 
4.4 Factors influencing the ergogenic effect of caffeine 
supplementation 
4.4.1 Habitual caffeine intake 
The habitual caffeine intake, shown in Table 4.8 did not influence the baseline caffeine 
levels before T1 (p = 0.88) or T2 (p = 0.60), as determined by the non-parametric Spearman 
R test. 
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Table 4.8 Habitual caffeine intake 
 
 All (N = 26) Male (Nm = 14) Female (Nf = 12) 
Mean±SD Mean±SD Mean±SD 
Habitual caffeine intake (mg/day)* 412.7±504.8 337.1±345.7 501.0±649.7 
N = total sample; Nm = total male sample; Nf = total female sample 
 
4.4.2 Effect of the pre-event meal on plasma caffeine levels 
Details of the pre-event meal of the caffeine and placebo groups are displayed in Table 4.9. 
There were no statistically significant differences between the caffeine and placebo groups 
with regard to components of the pre-event meal, except for protein intake measured in g/kg 
BW in the male group (p = 0.01*). However, when comparing the protein intake measured in 
g, there were no statistically significant difference between the caffeine and placebo groups 
(p = 0.34) (Table 4.9). 
 
Table 4.9 Pre-event meal of the caffeine and placebo groups 
 
 Recommendation Caffeine Placebo Caffeine 
vs. 
Placebo  
All (N = 52) Mean±SD Mean±SD p-value 
Total energy intake (kcal) N/A 323.1±239.2 302.6±234.4 p = 0.76 
Total energy intake (kcal/kg BW) N/A 4.6±3.0 4.3±3.2 p = 0.73 
Protein intake (g) N/A 9.2±8.5 7.5±6.7 p = 0.43 
Protein intake (g/kg BW) 0.15-0.25 g/kg BW* 0.1±0.1 0.1±0.1 p = 1.00 
CHO intake (g)  48.0±32.3 46.4±42.0 p = 0.88 
CHO intake (g/kg BW) 1-4 g/kg BW  
(Pre-event fuelling, 
exercise > 60 minutes) 
0.7±0.4 0.7±0.5 p = 1.00 
Fat intake (g) N/A 9.1±10.8 8.3±11.1 p = 0.79 
Fat intake (g/kg BW) N/A 0.1±0.1 0.1±0.2 p = 1.00 
 
Male (Nm = 28) Mean±SD Mean±SD p-value 
Total energy intake (kcal) N/A 429.5±263.3 375.7±254.5 p = 0.59 
Total energy intake (kcal/kg BW) N/A 5.6±3.3 5.0±3.2 p = 0.63 
Protein intake (g)  12.2±10.3 8.8±8.2 p = 0.34 
Protein intake (g/kg BW) 0.15-0.25 g/kg BW* 0.2±0.1a 0.1±0.1b p = 0.01* 
CHO intake (g)  62.6±33.4 59.4±49.4 p = 0.84 
CHO intake (g/kg BW) 1-4 g/kg BW  0.8±0.4 0.8±0.6 p = 1.00 
Fat intake (g) N/A 12.7±13.4 9.4±13.3 p = 0.52 
Fat intake (g/kg BW) N/A 0.2±0.2 0.1±0.2 p = 0.20 
 
Female (Nf = 24) Mean±SD Mean±SD p-value 
Total energy intake (kcal) N/A 207.0±145.5 216.2±188.0 p = 0.89 
Total energy intake (kcal/kg BW) N/A 3.4±2.4 3.5±3.1 p = 0.11 
Protein intake (g)  5.9±4.5 5.8±4.0 p = 0.95 
Protein intake (g/kg BW) 0.15-0.25 g/kg BW* 0.1±0.1 0.1±0.1 p = 1.00 
Carbohydrate intake (g)  32.0±23.2 31.1±25.4 p = 0.93 
CHO intake (g/kg BW) 1-4 g/kg BW  0.5±0.4 0.5±1.6 p = 1.00 
Fat intake (g) N/A 5.1±5.0 6.9±8.0 p = 0.52 
Fat intake (g/kg BW) N/A 0.1±0.1 0.1±0.1 p = 1.00 
Sources: (4, 169, 170, 172, 174, 175, 183, 203) 
a differed significantly from b (p < 0.05) 
kcal: calories; kcal/kg BW/day: calories per kilogram body weight per day; kcal/kg FFM: calories per kilogram fat free mass; 
g/kg BW: gram per kilogram body weight; N/A: not applicable; N = total sample; Nm = total male sample; Nf = total female 
sample 
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There were no statistically significant correlations between any of the listed dietary 
components of the pre-event meal and plasma caffeine levels in the group receiving caffeine 
supplementation, suggesting that the pre-event meal did not influence the absorption of 
caffeine after supplementation. 
 
4.4.3 Menstrual history (females) 
4.4.3.1 Menstrual patterns and oral contraceptive use 
Currently only 50% (N = 6) of the females in the sample group have regular menstrual 
cycles. Forty two percent of the females (N = 5) were post-menopausal. Of all the females, 
42% (N = 5) had gone more than three months without menstruation during the previous 12 
months, all of which reported loss of menstruation due to menopause. Fifty eight percent (N 
= 7) of the females used oral contraceptive medication (Table 4.10). 
 
Table 4.10 Menstrual patterns and oral contraceptive use  
 
 % (Nf = 12) 
General information   
Age of menarche (mean±SD) 12.9±1.8 
Menarche reached before onset of sport 75% (N = 9) 
Gynecological age (mean±SD) 24.3±12.1 
 
Menstrual cycle information % (Nf = 12) 
Eumenorrhea 50% (N = 6) 
Oligomenorrhea  8% (N = 1) 
Amenorrhea  0% (N = 0) 
No cycles preceding 12 months 42% (N = 5) 
No cycle due to menopause 42% (N = 5) 
 
Changes in response to training (can be more than one) % (Nf = 12) 
Shorter cycle 17% (N = 2) 
Longer cycle 8% (N = 1)  
Lighter bleeding 17% (N = 2) 
No cycle > 3 months 17% (N = 2) 
 
Contraceptive use % (Nf = 12) 
Yes 58% (N = 7) 
No  42% (N = 5) 
 
Self-reported menstrual phase during triathlon 1 % (Nf = 12) 
Luteal phase 50% (N = 6) 
Follicular phase 8% (N = 1) 
 
Self-reported menstrual phase during triathlon 2 % (Nf = 12) 
Luteal phase 8% (N = 1) 
Follicular phase 50% (N = 6) 
Nf = total female sample 
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4.4.3.2 The influence of the phase of menstrual cycle on plasma caffeine levels 
during transition (cycle → run) and at the finish line in the caffeine and placebo 
groups  
This analysis could not be performed as there were no/limited observations, when the small 
female subject sample was further sub-divided into the different phases of the menstrual 
cycle. 
 
4.4.3.3 The influence of oral contraceptive use on plasma caffeine levels 
during transition (cycle → run) and at the finish line in the caffeine and placebo 
groups  
The researcher did a factorial ANOVA with variance, estimation, precision and comparison 
(VEPAC) of plasma caffeine levels during transition (cycle → run) and at the finish line with 
factors group (whether or not subjects received caffeine supplementation during T1 or T2) 
and caffeine, with respondents nested in group. To investigate the influence of oral 
contraceptive use on plasma caffeine levels during transition (cycle → run) and at the finish 
line respectively, these variables were one by one entered as covariates in a similar analysis 
of covariance with factors (group and caffeine) as described above.  
 
The introduction of oral contraceptive use as a covariate had no significant effect on plasma 
caffeine levels measured during transition (cycle → run) (p = 0.63 with group) or the plasma 
caffeine levels measured at the finish line (p = 0.06 with group) (Figure 4.18). 
  
 
Figure 4.18 Plasma caffeine levels measured during transition (cycle → run) (p = 0.63) 
and at the finish line (p = 0.06) according to oral contraceptive use and caffeine 
supplementation.  
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4.4.3.4 Descriptive information on the phase of menstrual cycle and oral 
contraceptive use on the overall time to complete the triathlon in the caffeine 
and placebo groups 
The researcher did a factorial ANOVA with VEPAC of the overall time to complete the 
triathlon with factors group (whether or not subjects received caffeine supplementation 
during T1 or T2) and caffeine, with respondents nested in group. To investigate the influence 
of the phase of the menstrual cycle and oral contraceptive use respectively, on the overall 
time to complete the triathlon, these variables were one by one entered as covariates in 
similar analysis of covariance with factors (group and caffeine) as described above.  
 
The introduction of the self-reported phase of the menstrual cycle as a covariate had no 
significant effect on the overall time to complete the triathlon (p = 0.29 with group). The 
introduction of oral contraceptive use as a covariate also had no significant effect on the 
overall time to complete the triathlon (p = 0.73 with group).   
 
As mentioned above, the self-reported phase of the menstrual cycle did not significantly 
affect the overall time to complete the triathlons, irrespective of whether subjects were 
supplemented with caffeine or placebo, and irrespective of oral contraceptive use (Table 
4.11, Figure 4.19). Although not statistically significant, it may be of clinical importance that 
time to completion was slightly faster (4%) in the follicular phase when compared to the 
luteal phase, in the caffeine group only. For both the caffeine and placebo groups, average 
overall time to complete the triathlon was increased in post-menopausal women when 
compared to pre-menopausal women. The average overall time to complete the triathlon 
was ≈25 minutes (14%) slower for the post-menopausal females, when compared to the 
females in the luteal phase of the menstrual cycle, independent of supplementation, while it 
was 28.83 (±14.16) minutes and 21.77 (±8.28) minutes slower for the caffeine and placebo 
post-menopausal groups respectively, when compared to the females in the follicular phase 
of the menstrual cycle. Although this finding was not statistically significant, in our opinion 
these differences of 16% and 13% respectively are indeed of clinical significance.   
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Table 4.11 Overall time to complete the triathlons (minutes) according to the 
phase of the menstrual cycle and oral contraceptive use 
 
 Caffeine (Ncf  = 12) Placebo (Npf  = 12) Caffeine vs. 
Placebo 
 Mean (±SE) N Mean (±SE) N p-value 
All (Nf = 24) 155.75 (±6.23) 12 157.39 (±6.23) 12 p = 0.48 
Luteal phase 149.08 (±4.44) 3 148.15 (±4.40) 4 p = 0.96  
Post-menopausal 173.49 (±14.48) 5 172.89 (±12.85) 5 p = 0.84 
Follicular phase 144.66 (±2.16) 4 151.12 (±4.57) 3 p = 0.76 
Oral contraceptive (Yes) 157.07 (±9.17) 7 156.73 (±9.14) 7 p = 0.95 
Oral contraceptive (No) 158.78 (±10.81) 5 162.65 (±10.81) 5 p = 0.57 
Nf = total female sample; Ncf = total caffeine female; Npf = total placebo female 
 
 
Figure 4.19 The effect of the phase of the menstrual cycle (p = 0.66) and oral 
contraceptive use (p = 0.16) on the overall time to complete the triathlon (minutes) in 
the caffeine and placebo groups. 
 
4.4.4 Genetic analysis  
4.4.4.1 CYP1A2 genotype and allele frequencies 
The CYP1A2*1F allele (rs762551-C) is common with highly comparable frequencies in 
various populations (160). The frequency of the variant C allele was 0.29 in the study 
population in the present study. Caffeine metabolism is the same for heterozygotes and CC 
homozygotes. Triathletes were therefore grouped as AA homozygous (62%, N = 16) and C-
allele carriers (38%, N = 10); the latter group including both heterozygotes and CC 
homozygotes (Table 4.12) as done in previous studies (158, 165, 208). 
 
The allelic frequency of the CYP1A2*1D (rs35694136delT) allele in the 5’-flanking region 
(160) is 0.08, with 15% (N = 4) of the study group being heterozygous for this genotype 
(Table 4.12). 
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The frequency of the T-allele of the SNP located at 15q24 between CYP1A1 and CYP1A2 
(rs2472297-T) (163) is 0.27 in the study population, with 23% (N = 6) being heterozygous, 
and 15% (N = 4) being homozygous for the T/T genotype (Table 4.12). 
 
The frequency of the A allele of the SNP mapped to 15q24 within the bidirectional promoter 
of the CYP1A1-CYP1A2 locus (164) (rs2470893-A) was 0.31, with 31% (N = 8) being 
heterozygous, and 15% (N = 4) being homozygous for the A/A genotype (Table 4.12). 
 
Variant rs6968865-T is located within a linkage disequilibrium (LD) block of 240kb on 7p15. 
The gene encoding the aryl hydrocarbon receptor (AHR) is the only gene located within this 
LD block. AHR plays a central role in xenobiotic metabolism and induces members of the 
CYP1 family of genes (CYP1A1, CYP1A2 and CYP1B1) (163). The frequency of the T allele 
in the study population was 0.60, with 58% (N = 15) being heterozygous and 31% (N = 8) 
being homozygous (Table 4.12). 
 
Table 4.12 Genotype and allele frequencies: 
 
 All (N =26) Male (Nm=14) Female (Nf=12) 
Genotype 
frequency 
% (N) 
Allele 
frequency 
Genotype 
frequency 
% (N) 
Allele 
frequency 
Genotype 
frequency 
% (N) 
Allele 
frequency 
CYP1A2*1F (rs762551-C) 
C/C 19% (N = 5) C = 0.29 21% (N = 3) C = 0.29 17% (N = 2) C = 0.29 
A/C 19% (N = 5)  14% (N = 2)  25% (N = 3)  
A/A 62% (N = 16) A = 0.71 65% (N = 9) A = 0.71 58% (N = 7) A = 0.71 
 
CYP1A2*1D (rs35694136delT) 
T/T 85% (N = 22) T = 0.92 86% (N = 12) T = 0.93 83% (N = 10) T = 0.92 
-/T 15% (N = 4)  14% (N = 2)   17% (N = 2)  
-/- 0%  - = 0.08 0% - = 0.07 0% - = 0.08 
 
Between CYP1A1-CYP1A2 (rs2472297-T) 
C/C 62% (N = 16) C = 0.73 72% (N = 10) C = 0.79 50% (N = 6) C = 0.67 
C/T 23% (N = 6)  14% (N = 2)  33% (N = 4)  
T/T 15% (N = 4) T = 0.27 14% (N = 2) T = 0.21 17% (N = 2) T = 0.33 
 
Between CYP1A1-CYP1A2 (rs2470893-A) 
G/G 54% (N = 14) G = 0.69 65% (N = 9) G = 0.75 41.5% (N = 5) G = 0.63 
G/A 31% (N = 8)  21% (N = 3)  41.5% (N = 5)  
A/A 15% (N = 4) A = 0.31 14% (N = 2) A = 0.25 17% (N = 2) A = 0.37 
 
Near AHR gene (rs698865-T) 
T/T 31% (N = 8) T = 0.60 36% (N = 5) T = 0.64 25% (N = 3) T = 0.54 
A/T 58% (N = 15)  57% (N = 8)  58% (N = 7)  
A/A 12% (N = 3) A = 0.40 7% (N = 1) A = 0.36 17% (N = 2) A = 0.46 
N = total sample; Nm = total male sample; Nf = total female sample 
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4.4.4.2 Influence of genotype on plasma caffeine levels 
The researcher did a RMANOVA with VEPAC on plasma caffeine levels with factors group 
(whether subjects received caffeine supplementation during T1 or T2), caffeine 
supplementation and genotype frequency and then gender, caffeine supplementation and 
genotype frequency with respondents nested firstly in group and i) CYP1A2*1F (rs762551-C) 
(p = 0.08), ii) CYP1A2*1D (rs35694136delT) (p = 0.54), iii) CYP1A1-CYP1A2 (rs2472297-T) 
(p = 0.46), iv) CYP1A1-CYP1A2 (rs2470893-A) (p = 0.11), iv) the variant near the AHR gene 
(rs 6968865-T) (p = 0.10) and then in gender and i) CYP1A2*1F (rs762551-C) (p = 0.51), ii) 
CYP1A2*1D (rs35694136delT) (p = 0.33), iii) CYP1A1-CYP1A2 (rs2472297-T) (p = 0.78), iv) 
CYP1A1-CYP1A2 (rs2470893-A) (p = 0.91) and v) the variant near the AHR gene (rs 
6968865-T) (p = 0.12). Therefore, no carry-over effects from whether or not the subject 
received caffeine during T1 or T2 was observed when analysing the influence of the 
genotype frequency on plasma caffeine levels. 
 
There were no significant interaction between plasma caffeine levels measured at baseline, 
during transition (cycle → run) and at the finish line and the genotype frequency of i) 
CYP1A2*1F (rs762551-C) (p = 0.61), ii) CYP1A2*1D (rs35694136delT) (p = 0.88),  iii) 
CYP1A1-CYP1A2 (rs2472297-T) (p = 0.27), iv) CYP1A1-CYP1A2 (rs2470893-A) (p = 0.21) 
or v) the variant near the AHR gene (rs 6968865-T) (p = 0.39) in the caffeine and placebo 
groups. 
 
There were no significant interaction between plasma caffeine levels measured at baseline, 
during transition (cycle → run) and at the finish line and the genotype frequency of i) 
CYP1A2*1F (rs762551-C) (p = 0.69), ii) CYP1A2*1D (rs35694136delT) (p = 0.51),  iii) 
CYP1A1-CYP1A2 (rs2472297-T) (p = 0.78), iv) CYP1A1-CYP1A2 (rs2470893-A) (p = 0.91) 
or v) the variant near the AHR gene (rs 6968865-T) (p = 0.12) in the male or female group. 
 
4.4.4.3 Influence of genotype frequency on the overall time to complete the 
triathlon 
The researcher did a factorial ANOVA with VEPAC on the overall time to complete the 
triathlon with factors group and caffeine and then gender and caffeine with respondents 
nested firstly in group and then nested in gender. 
 
The introduction of i) CYP1A2*1F (rs762551-C) (p = 0.71 with group and p = 0.26 with 
gender), ii) CYP1A2*1D (rs35694136delT) (p = 0.99 with group and p = 0.96 with gender), 
iii) CYP1A1-CYP1A2 (rs2472297-T) (p = 0.85 with group)), iv) CYP1A1-CYP1A2 
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(rs2470893-A) (p = 0.32 with group and p = 0.44 with gender) and v) the variant near the 
AHR gene (rs 6968865-T) (p = 0.63 with group) had no significant effect on the overall time 
to complete the triathlon. Due to the limited number of observations when divided into 
gender, the effect of covariates CYP1A1-CYP1A2 (rs2472297-T) and the variant near the 
AHR gene (rs 6968865-T) on overall time to complete the triathlon according to gender could 
not be established. 
 
4.5 Factors influencing triathlon performance 
4.5.1 Medical history and over-the-counter supplement use 
The subjects were, overall, in excellent health with few chronic diseases evident (Table 4.9). 
Supplement use was rife among the subjects, with 85% (N = 22) using supplements. All the 
females reported using supplements (100%, Nf = 12), while this was the case with only 75% 
(Nm = 10) of the males. The supplements most commonly used were multivitamin and 
mineral supplements (85%, N = 22), as well as energy drinks and bars (85%, N = 22) (Table 
4.13). 
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Table 4.13 Medical history and supplement use 
 
 All  
(N =26) 
Male 
(Nm=14) 
Female 
(Nf=12) 
Medical history % N % Nm % Nf 
Injury or illness 12% 3 21% 3 0% 0 
History of stress fractures 0% 0 0% 0 0% 0 
Chronic illnessa 12% 3 14% 2 8% 1 
Allergiesb 19% 5 14% 2 25% 3 
OTC medicationc 35% 9 21% 3 50% 6 
Prescribed medicationd 23% 6 14% 2 33% 4 
Inhaler  8% 2 0% 0 17% 2 
High blood pressure 0% 0 0% 0 0% 0 
Heart disease 0% 0 0% 0 0% 0 
High total cholesterol 8% 2 14% 2 0% 0 
Diabetes mellitus 0% 0 0% 0 0% 0 
 
 % N % Nm % Nf 
Supplement use 85% 22 71% 10 100
% 
12 
Multivitamin & mineral 85% 22 79% 11 92% 11 
Individual vitamins 50% 13 50% 7 50% 6 
Individual minerals 27% 7 21% 3 33% 4 
Protein supplements 42% 11 29% 4 58% 7 
Herbal supplementse 12% 3 14% 2 8% 1 
Energy drinks & bars 85% 22 71% 10 100
% 
12 
Creatine  12% 3 14% 2 8% 1 
Single amino acids 19% 5 14% 2 25% 3 
 
Frequency  % N % Nm % Nf 
Daily 31% 8 29% 4 33% 4 
Specific times 35% 9 14% 2 58% 7 
Occasionally  31% 8 29% 4 33% 4 
Several times a week 8% 2 7% 1 8% 1 
 
Reasons  % N % Nm % Nf 
Inadequate diet 35% 9 29% 4 42% 5 
Treat illness / injury 8% 2 7% 1 8% 1 
Increase muscle mass 8% 2 7% 1 8% 1 
Prevent illness 46% 12 57% 8 33% 4 
Weight loss 0% 0 0% 0 0% 0 
Increased energy 35% 9 21% 3 50% 6 
Enhance exercise performance 31% 8 21% 3 42% 5 
No reason 4% 1 0% 0 8% 1 
aChronic illness: any condition requiring long term prescription treatment ; bAllergies: food or non-food related; cOTC Over the 
counter medication; dPrescribed medication: any medication used on a repeated basis; prescribed by a medical doctor; eHerbal 
supplements: includes all herbal preparations  
N = total sample; Nm = total male sample; Nf = total female sample 
 
4.5.2 Full blood count 
A full blood count was measured at baseline and again at the finish line (Table 4.14).  
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Table 4.14 Full blood count values in the caffeine and placebo groups 
 
 All Caffeine Placebo Caffeine vs. 
Placebo 
Mean±SD Mean±SD Mean±SD p-value 
All N = 52 Nc = 26 Np = 26  
White blood cells 
Baseline (X 109/l) 6.2±1.6 6.2±1.8 6.1±1.4 p = 0.88 
Finish line (X 109/l) 15.2±3.9 16.1±4.2a 14.2±3.5b p = 0.01* 
Red blood cell count 
Baseline (X 1012/l) 4.6±0.4 4.6±0.4 4.6±0.4 p = 0.57 
Finish line (X 1012/l) 4.5±0.4 4.5±0.4 4.5±0.3 p = 0.30 
Hemoglobin 
Baseline (mg %) 14.6±1.2 14.7±1.4 14.6±1.0 p = 0.86 
Finish line (mg %) 14.4±1.4 14.3±1.5 14.4±1.2 p = 0.77 
Heamatocrit 
Baseline (%) 41.4±2.6 41.5±2.7 41.3±2.7 p = 0.48 
Finish line (%) 40.4±2.8 40.2±2.9 40.7±2.8 p = 0.24 
Platelets 
Baseline (X 109/l) 295.7±51.7 295.1±51.0 296.3±53.4 p = 0.87 
Finish line (X 109/l) 380.1±69.2 383.6±70.9 376.7±68.7 p = 0.44 
 
Male  Nm = 28 Ncm = 14 Npm = 14  
White blood cells 
Baseline (X 109/l) 6.1±1.3 6.1±1.4 6.1±1.3 p = 0.85 
Finish line (X 109/l) 16.1±4.0 17.6±4.2a 14.7±3.4b p = 0.00* 
Red blood cell count 
Baseline (X 1012/l) 4.9±0.3 4.9±0.3 4.9±0.3 p = 0.87 
Finish line (X 1012/l) 4.8±0.3 4.8±0.4 4.8±0.3 p = 0.93 
Hemoglobin 
Baseline (mg %) 15.3±0.9 15.4±1.1 15.2±0.7 p = 0.60 
Finish line (mg %) 15.0±1.1 15.2±1.2 14.9±1.1 p = 0.39 
Heamatocrit 
Baseline (%) 43.1±1.7 43.0±1.9 43.3±1.6 p = 0.61 
Finish line (%) 42.2±2.0 42.0±2.1 42.5±2.0 p = 0.43 
Platelets 
Baseline (X 109/l) 286.3±50.1 285.6±53.4 287.0±48.5 p = 0.89 
Finish line (X 109/l) 369.4±63.9 375.0±69.2 364.2±60.7 p = 0.34 
 
Female  Nf = 24 Ncf = 12 Npf = 12  
White blood cells 
Baseline (X 109/l) 6.2±1.9 6.3±2.3 6.1±1.6 p = 0.86 
Finish line (X 109/l) 14.1±3.6 14.5±3.8 13.7±3.6 p = 0.35 
Red blood cell count 
Baseline (X 1012/l) 4.4±0.3 4.4±0.3 4.3±0.2 p = 0.35 
Finish line (X 1012/l) 4.2±0.3 4.2±0.3 4.3±0.2 p = 0.17 
Hemoglobin 
Baseline (mg %) 13.8±1.0 13.8±1.2 13.9±0.9 p = 0.80 
Finish line (mg %) 13.6±1.2 13.3±1.3 13.9±1.1 p = 0.22 
Heamatocrit 
Baseline (%) 39.4±2.0 39.7±2.4 39.0±1.6 p = 0.16 
Finish line (%) 38.4±2.2 38.2±2.4 38.7±2.0 p = 0.37 
Platelets 
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 All Caffeine Placebo Caffeine vs. 
Placebo 
Mean±SD Mean±SD Mean±SD p-value 
Baseline (X 109/l) 306.8±52.4 306.3±47.7 307.3±58.8 p = 0.93 
Finish line (X 109/l) 392.2±74.1 393.0±74.6 391.3±77.0 p = 0.88 
a differed significantly from b (p < 0.05) 
% refer to relative counts; while other values refer to absolute counts 
N = total sample; Nm = total male sample; Nf = total female sample; Nc = total caffeine; Ncm = total caffeine male; Ncf = total 
caffeine female; Np = total placebo; Npm = total placebo male; Npf = total placebo female 
 
The researcher performed a RMANOVA with VEPAC on total white blood cell count levels 
with factors group, caffeine and stage (baseline and finish line) and then gender, caffeine 
and stage, with respondents nested firstly in group (p = 0.56) and then in gender (p = 0.22). 
Similar analyses were done for red blood cell count, nested firstly in group (p = 0.23) and 
then in gender (p = 0.22); haemoglobin, nested firstly in group (p = 0.06) and then in gender 
(p = 0.50); heamatocrit, nested firstly in group (p = 0.23) and then in gender (p = 0.29); and 
platelet count, nested firstly in group (p = 0.33) and then in gender (p = 0.68). The following 
section explains the results of this analysis. 
 
The red blood cell count in the caffeine group decreased significantly from baseline to the 
finish line in all subjects (p = 0.00*), and the male (p = 0.04*) and female (p = 0.00*) groups. 
The red blood cell count in the placebo group decreased significantly from baseline to the 
finish line in all subjects (p = 0.04*) and the male group (p = 0.03*), but not in the female 
group (p = 0.43). These differences were not due to caffeine supplementation (p = 0.25) and 
there were no differences between gender (p = 0.96). 
 
Haemoglobin levels in the caffeine group at baseline and at the finish line did not differ 
significantly in all subjects (p = 0.29), and the male (p = 0.39) and female (p = 0.29) groups. 
Haemoglobin levels in the placebo group did not differ significantly at baseline and at the 
finish line in all subjects (p = 0.55), and the male (p = 0.44) and female (p = 0.92) groups. 
There was no difference in haemoglobin levels at baseline and at the finish line between the 
caffeine and placebo groups (p = 0.74), nor between gender (p = 0.97). 
 
Heamatocrit levels in the caffeine group decreased significantly from baseline to the finish 
line in all subjects (p = 0.00*), and the male (p = 0.05*) and female (p = 0.00*) groups. 
Heamatocrit levels in the placebo group also decreased significantly from baseline to the 
finish line in the male group (p = 0.00*), but not in all subjects (p = 0.10) or in the female 
group (p = 0.50). These decreases were not due to caffeine supplementation (p = 0.18). 
Heamatocrit levels did not differ significantly between males and females (p = 0.91). 
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The platelet count in the caffeine and placebo groups increased significantly from baseline to 
the finish line in all subjects (p = 0.00*), and in the male (p = 0.00*) and female (p = 0.00*) 
groups. This increase was not due to caffeine supplementation (p = 0.50). Platelet counts 
did not differ significantly between males and females (p = 0.82). 
 
4.5.3 Mood state 
The POMS questionnaire was completed during the week before T1 and T2, at baseline the 
morning of T1 and T2, as well as at the finish line after T1 and T2. There were no differences 
in the total POMS scores, tension or vigour scores measured at all the time points in the 
male and female groups (Table 4.15). There were however significantly higher fatigue 
scores in the week before T1 vs. T2 in the male group, and significantly lower fatigue scores 
in the week before T1 vs. T2 in the female group (Figure 4.20). These values changed at 
baseline and there were no differences observed in the fatigue scores measured at baseline 
in males and females before T1 or T2. The fatigue scores were higher in the male group 
when measured at the finish line, and lower in the female group, when compared to 
baseline, but these differences were not statistically significant.  
 
Table 4.15 POMS scores the week before, at baseline and the finish line of T1 
and T2* 
 
 All (N = 26) Males (Nm = 14) Females (Nf = 12)  
T1 T2 T1 T2 T1 T2 T1 vs. T2 
Week before Mean±SD Mean±SD Mean±SD Mean±SD Mean±SD Mean±SD p-value* 
Total POMS score -13.2±8.1 -12.3±8.0 -14.6±8.1 -11.4±7.8 -11.7±8.3 -13.3±8.5 p = 0.11 
Tension -2.3±1.8 -2.9±1.9 -2.4±1.7 -3.1±1.4 -2.2±2.0 -2.6±2.4 p = 0.28 
Vigor 17.8±3.9 16.3±3.4 18.6±3.9 16.3±2.9 16.9±3.7 16.4±4.1 p = 0.27 
Fatigue 6.9±5.4 6.9±6.1 6.5±5.5a 8.0±6.4b 7.4±5.5a 5.7±5.6b p = 0.04* 
 
Baseline Mean±SD Mean±SD Mean±SD Mean±SD Mean±SD Mean±SD p-value* 
Total POMS score -15.2±8.9 -13.5±8.6 -16.6±7.5 -15.2±7.6 -13.4±10.5 -11.4±9.5 p = 0.88 
Tension -2.4±2.8 -2.7±1.9 -2.9±2.3 -2.8±1.4 -1.9±3.3 -2.5±2.4 p = 0.49 
Vigor 16.8±5.1 15.3±5.8 18.5±3.7 17.1±5.2 14.8±5.9 13.2±6.0 p = 0.94 
Fatigue 4.0±4.5 4.5±4.9 4.7±5.2 4.6±5.2 3.3±3.7 4.3±4.7 p = 0.62 
 
Finish line Mean±SD Mean±SD Mean±SD Mean±SD Mean±SD Mean±SD p-value* 
Total POMS score -5.6±10.8 -3.6±10.1 -8.9±13.1 -4.4±10.1 -1.8±5.7 -2.7±10.5 p = 0.18 
Tension -1.5±2.4 -0.8±2.1 -1.4±1.9 -0.9±2.0 -1.5±3.0 -0.8±2.4 p = 0.93 
Vigor 16.0±6.6 13.9±5.8 18.8±6.4 16.1±6.0 12.8±5.5 11.3±4.6 p = 0.55 
Fatigue 11.8±5.6 11.1±5.6 12.3±6.2 12.6±5.1 12.5±4.9 9.5±6.0 p = 0.06 
a differed significantly from b (p < 0.05) 
*RMANOVA 
Nm = total male sample; Nf = total female sample 
 
Stellenbosch University http://scholar.sun.ac.za
145 
 
 
Figure 4.20 POMS fatigue score(s) during the week before T1 and T2 in males and 
females (Gender effect: p = 0.04*)  
 
The researcher used the Spearman rank-order correlation test to determine the effect of the 
total and differential POMS score during the week before T1 and T2, and at baseline and the 
effect of this on the overall time to complete the triathlons. The POMS scores measured 
during the week before and at baseline before T1 and T2 were able to influence the overall 
time to complete the triathlons. There were no significant correlations between the overall 
time to complete T1 and the total POMS score (p = 0.28), POMS tension score (p = 0.17), 
POMS vigour score (p = 1.00) or the POMS fatigue score (p = 0.06) during the week before 
T1. There was however a significant positive correlation between the total POMS score 
measured at baseline before T1 and the overall time to complete T1 (p = 0.02*) (Figure 
4.21). There were no relationship between the POMS tension (p = 0.17), POMS vigour (p = 
0.10) and POMS fatigue (p = 0.22) scores measured at baseline before T1 and the overall 
time to complete T1.  
 
Likewise, there were no significant correlations between the overall time to complete T2 and 
the total POMS score (p = 0.33), POMS tension score (p = 0.42), POMS vigour score (p = 
0.67) or the POMS fatigue score (p = 0.39) during the week before T2. There were no 
significant correlations between the total POMS score (p = 0.38), POMS tension (p = 0.47), 
POMS vigour (p = 0.80) and POMS fatigue (p = 0.14) scores measured at baseline before 
T2 and the overall time to complete T2.  
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Figure 4.21 Relationship between total POMS scores measured at baseline and the 
overall time to complete T1 (p = 0.02*) and T2 (p = 0.38) (minutes) 
 
The researcher used the Spearman rank order correlation test to determine the effect of the 
total and differential POMS scores at baseline and the effect of these scores on the time to 
complete the swim sections of T1 and T2. The POMS scores measured at baseline before 
T1 and T2 were able to influence the time to complete the swim sections of T1 and T2. 
There were no significant correlations between the time to complete the swim section of T1 
(minutes) and the total POMS score (p = 0.08), POMS tension score (p = 0.09), POMS 
vigour score (p = 0.41) or the POMS fatigue score (p = 0.33) measured at baseline the 
morning before T1. There were also no significant correlations between the time to complete 
the swim section of T2 (minutes) and the total POMS score (p = 0.49), POMS tension score 
(p = 0.17), POMS vigour score (p = 0.86) or the POMS fatigue score (p = 0.69) measured at 
baseline the morning before T2.  
 
4.5.4 Dietary intake 
4.5.4.1 Dietary intake two days before triathlon 1 (T1) and triathlon 2 (T2) 
A Wilcoxon matched pairs test was completed to determine differences between the dietary 
intake two days before T1 and T2. As illustrated in Table 4.16, there was no significant 
difference in the dietary intake of the subjects two days before T1 and T2, except for alcohol 
intake, which was significantly higher two days before T2 in the whole group (p = 0.05*) and 
in the male group (p = 0.02*). It was concerning to note that amongst the total group the 
energy intake (36.5±17.6 and 38.9±18.2), estEA (27.9±28.0 and 28.8±25.6) and CHO intake 
(4.1±1.6 g/kg BW and 4.6±2.5 g/kg BW) before T1 and T2 respectively, were below the 
recommendations. 
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Table 4.16 Dietary intake two days before T1 and T2  
 
 Recommendation T1 T2 T1 vs. T2 
All (N = 26) Mean±SD Mean±SD p-value 
Total energy intake (kcal/day) 2500-8000 kcal/day 2472.1±1034.5 2641.2±1119.0 p = 0.51 
Total energy intake (kcal/kg BW/day) 50-80 kcal/kg BW/day 
(Moderate levels of intense training 
2-3 hours/day, 5-6 X week) 
36.5±17.6 38.9±18.2 p = 0.51 
estEA (kcal/kg FFM) 30-45 kcal/kg FFM 27.9±28.0 28.8±25.6 p = 0.90 
Protein intake (g/kg BW/day) 1.0-1.5 g/kg BW 1.6±0.9 1.7±1.6 p = 0.97 
CHO intake (g/kg BW/day) 6-10 g/kg BW  
(Endurance program, moderate-
high intensity, 1-3 hours/day) 
7-12 g/kg BW 
(General fuelling up (CHO-loading) 
for events > 90 minutes) 
4.1±1.6 4.6±2.5 p = 0.28 
Fat intake (g/kg BW /day) 0.8-1.5 g/kg BW  1.4±1.1 1.2±0.5 p = 0.95 
Alcohol intake (g/day) 10-20 g/day  5.9±10.6a 11.0±14.2b p = 0.05* 
Fibre intake (g/day) 20-30 g/day 22.7±7.9 25.4±10.2 p = 0.14 
Calcium (mg/day) 1000 mg/day (RDA/AI) – 2500 
mg/day (UL) 
1051.8±1258.9 
(105% of DRI) 
1571.8±3630.2 
(157% of DRI) 
p = 0.34 
Calcium: Protein ratio 20 mg calcium per 1 g protein 9.5±4.9 10.7±6.8 p = 0.41 
Iron (mg/day) Male & female reference 
values 
16.6±11.6 
 
17.6±8.8 p = 0.09 
 
Male (Nm = 14) Mean±SD Mean±SD p-value 
Total energy intake (kcal/day) 2500-8000 kcal/day 2520.9±708.8 2692.3±701.8 p = 0.28 
Total energy intake (kcal/kg BW/day) 50-80 kcal/kg BW/day 33.8±9.5 35.9±7.6 p = 0.28 
estEA (kcal/kg FFM) 30-45 kcal/kg FFM 20.8±14.2 24.7±19.7 p = 0.55 
Protein intake (g/kg BW/day) 1.0-1.5 g/kg BW 1.4±0.6 1.4±0.4 p = 0.65 
CHO intake (g/kg BW/day) 6-10 g/kg BW or 7-12 g/kg BW 3.9±1.5 3.9±1.2 p = 0.20 
Fat intake (g/kg BW /day) 0.8-1.5 g/kg BW  1.1±0.3 1.2±0.3 p = 0.31 
Alcohol intake (g/day) 10-20 g/day  7.4±12.1a 17.2±16.9b p = 0.02* 
Fibre intake (g/day) 20-30 g/day 23.1±6.5 27.6±11.3 p = 0.18 
Calcium (mg/day) 1000 mg/day (RDA/AI) – 2500 
mg/day (UL) 
844.0±377.9 958.3±446.8 p = 0.15 
Calcium: Protein ratio 20 mg calcium per 1 g protein 8.7±4.4 9.3±4.6 p = 0.65 
Iron (mg/day) 6-8 mg/day (EAR-RDA/AI), - 
45 mg/day (UL) 
19.5±14.4 
(244% of RDA) 
20.5±10.7 
(256% of RDA) 
p = 0.13 
 
Female (Nf = 12) Mean±SD Mean±SD p-value 
Total energy intake (kcal/day) 2500-8000 kcal/day 2415.1±1353.5 2585.9±1479.3 p = 0.88 
Total energy intake (kcal/kg BW/day) 50-80 kcal/kg BW/day 39.6±24.1 42.1±25.2 p = 0.94 
estEA (kcal/kg FFM) 30-45 kcal/kg FFM 36.3±37.4 33.5±31.4 p = 0.82 
Protein intake (g/kg BW/day) 1.0-1.5 g/kg BW 1.7±1.2 2.0±2.3 p = 0.69 
CHO intake (g/kg BW/day) 6-10 g/kg BW or 7-12 g/kg BW 4.4±1.7 5.3±3.3 p = 0.69 
Fat intake (g/kg BW /day) 0.8-1.5 g/kg BW  1.6±1.6 1.2±0.6 p = 0.43 
Alcohol intake (g/day) 10-20 g/day  4.2±8.8 4.3±5.9 p = 1.00 
Fibre intake (g/day) 20-30 g/day 22.3±9.6 23.0±8.8 p = 0.50 
Calcium (mg/day) 1000 mg/day (RDA/AI) – 2500 
mg/day (UL) 
1294.3±1820.5 2236.5±5254.3 p = 0.94 
Calcium: Protein ratio 20 mg calcium per 1 g protein 10.5±5.4 12.3±8.5 p = 0.53 
Iron (mg/day) 8.1-18 mg/day (EAR-RDA/AI), 
- 45 mg/day (UL) 
13.2±5.9 
(73% of RDA) 
14.5±6.5 
(81% of RDA) 
p = 0.39 
Sources: (4, 169, 170, 172, 174, 175, 183, 203) 
a differed significantly from b (p < 0.05) 
kcal: calories; kcal/kg BW/day: calories per kilogram body weight per day; kcal/kg FFM: calories per kilogram fat free mass; 
g/kg BW: gram per kilogram body weight; TE: total energy; EAR: Estimated Average Requirement; RDA: Recommended 
Dietary Allowance; AI: Adequate Intake; UL: Upper Limit; N = total sample; Nm = total male sample; Nf = total female sample 
 
 
Although the alcohol intake differed significantly two days before T1 and T2 in the whole 
group and in the male group, it did not influence the overall time to complete T1 (p = 0.64 
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and p = 0.43 respectively) or T2 (p = 0.81 and p = 0.40 respectively). However, a higher fibre 
intake was associated with a shorter/decreased overall time to complete T1 (p = 0.02*) and 
T2 (p = 0.04*) (Figure 4.22) and an increased CHO intake two days before T2 in the male 
group significantly decreased the overall time to complete T2 in this group (p = 0.05*) 
(Figure 4.23).  
 
 
Figure 4.22 Relationship between the overall time to complete and the total fibre 
intake (g/day) two days before T1 (p = 0.02*) and T2 (p = 0.04*) in the whole group (N = 
26) as determined by the Spearman R rank-order correlation. 
 
 
Figure 4.23 Relationship between the overall time to complete and the total CHO 
intake (g/kg body weight (BW)) two days before T1 (p = 0.74) and T2 (p = 0.05*) in the 
male group (Nm = 14) as determined by the Spearman R rank-order correlation. 
 
The mean number of meals (meal frequency) of the subjects two days before T1 and T2 
(data combined) was 6.7 (±2.2) meals. The top 15 food choices include the following: oats 
(77.4±60.3 g), Rooibos tea (267.8±50.7 ml), brown bread (71.1±35.3 g), low-fat milk or 
yogurt (108.1±96.0 ml), chicken (112.7±83.5 g), peanut butter (18.8±11.7 g), tuna (96.8±57.5 
Stellenbosch University http://scholar.sun.ac.za
149 
 
g), avocado pear (80.8±62.8 g), fruit (apples (130.7±45.8 g) and bananas (96.6±21.0 g)), red 
meat (beef) (153.9±106.9 g), eggs (2.1±0.7 eggs), honey (17.6±8.6 g), spaghetti bolognaise 
(259.1±119.6 g), rusks (40.3±24.5 g) and pizza (347.2±195.3 g)  The food groups most 
athletes chose from included the starch, protein (including milk and dairy) and fat  
(unsaturated) groups. 
 
The combined (T1 and T2) estEA of the subjects were 25.5(±22.9) for all; and 17.9(±10.7) 
and 34.3(±30.0) for males and females, respectively, which is low.  
 
4.5.4.2 Pre-event dietary intake before T1 and T2 
A Wilcoxon matched pairs test was used to determine differences between pre-event dietary 
intakes on the morning of T1 and T2. There were no significant differences in the dietary 
intake of the subjects on the morning of the race between T1 and T2, except for higher total 
energy intake (p = 0.04*) in the females and higher fat intake (g) (p = 0.04*) in the whole 
subject group prior to T1 when compared to T2 (Table 4.16). Carbohydrate is the most 
important nutrient in the pre-event meal. In the present study, the pre-event meal was not 
adequate in terms of carbohydrate content (0.7±0.4 and 0.7±0.5 g/kg BW) (Table 4.17). 
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Table 4.17 Dietary intake the morning of T1 and T2 (i.e. the pre-event meal) 
 
 Recommendation T1 T2 T1 vs. T2 
All (N = 26) Mean±SD Mean±SD p-value 
Total energy intake (kcal) N/A 377.1±242.5 298.8±230.7 p = 0.26 
Total energy intake (kcal/kg BW) N/A 4.7±3.3 4.2±2.9 p = 0.22 
Protein intake (g/kg BW) 0.15-0.25 g/kg BW* 0.1±0.1 0.1±0.1 p = 0.20 
CHO intake (g/kg BW) 1-4 g/kg BW  
(Pre-event fuelling, 
exercise > 60 minutes) 
0.7±0.4 0.7±0.5 p = 0.74 
Fat intake (g) N/A 10.0±11.2a 7.4±10.5b p = 0.04* 
Fat intake (g/kg BW) N/A 0.1±0.2 0.1±0.1 p = 0.95 
 
Male (Nm = 14) Mean±SD Mean±SD p-value 
Total energy intake (kcal) N/A 418.3±259.6 386.1±256.9 p = 0.69  
Total energy intake (kcal/kg BW) N/A 5.5±3.4 5.1±3.1 p = 0.64 
Protein intake (g/kg BW) 0.15-0.25 g/kg BW* 0.2±0.1 0.1±0.1 p = 0.16 
CHO intake (g/kg BW) 1-4 g/kg BW  0.8±0.4 0.8±0.5 p = 0.64 
Fat intake (g) N/A 12.8±13.1 9.4±13.5 p = 0.06 
Fat intake (g/kg BW) N/A 0.2±0.2 0.1±0.2 p = 0.31 
 
Female (Nf = 12) Mean±SD Mean±SD p-value 
Total energy intake (kcal) N/A 227.5±185.4a 195.7±147.0b p = 0.04*  
Total energy intake (kcal/kg BW) N/A 3.7±3.1 3.2±2.5 p = 0.07 
Protein intake (g/kg BW) 0.15-0.25 g/kg BW* 0.1±0.1 0.1±0.1 p = 0.89 
CHO intake (g/kg BW) 1-4 g/kg BW  0.5±0.4 0.5±0.4 p = 0.21 
Fat intake (g) N/A 6.9±8.2 5.1±4.8 p = 0.40 
Fat intake (g/kg BW) N/A 0.1±0.1 0.1±0.1 p = 0.43 
Sources: (4, 169, 170, 172, 174, 175, 183, 203) 
a differed significantly from b (p < 0.05) 
kcal: calories; kcal/kg BW/day: calories per kilogram body weight per day; kcal/kg FFM: calories per kilogram fat free mass; 
g/kg BW: gram per kilogram body weight; N/A: not applicable; N = total sample; Nm = total male sample; Nf = total female 
sample 
 
 
Although the total energy content (kcal/meal) of the pre-event meal in the female group 
differed significantly between T1 and T2 it did not influence the overall time to complete T1 
and T2 in the female group (p = 0.10).  
 
However, as expected the total energy content of the pre-event meal (kcal/meal) inversely 
correlated with the overall time to complete T1 and T2 in the whole group (p = 0.02* and p = 
0.02* respectively) (Figure 4.24).  
 
The CHO content (g/kg BW) of the pre-event meal in the whole group also showed a 
negative correlation with the overall time to complete T1 and T2 (p = 0.00* and p = 0.00* 
respectively) (Figure 4.25). 
 
Although the fat intake in the whole group differed significantly between T1 and T2 it did not 
seem to influence the overall time to complete T1 and T2 (p = 0.22 and p = 0.54 
respectively). 
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Figure 4.24 Relationship between the overall time to complete and the total energy 
content (kcal/meal) of the pre-event meal the morning of T1 (p = 0.02*) and T2 (p = 
0.02*) in the whole group (N = 26) as determined by the Spearman R rank-order 
correlation. 
 
 
Figure 4.25 Relationship between the overall time to complete and the CHO content 
(g/kg BW) of the pre-event meal the morning of T1 (p = 0.00*) and T2 (p = 0.00*) in the 
whole group (N = 26) as determined by the Spearman R rank-order correlation. 
 
Most of the subjects (N = 22) ate a pre-event meal before T1 and T2 (combined data). The 
most commonly consumed meals were oats (68.2±57.8 g) and brown bread (60.5±21.4 g) 
with peanut butter (33.3±22.5 g) and banana (108.3±45.6 g). The most commonly consumed 
drink was rooibos tea (250.0±26.7 ml)) and their carbohydrate-electrolyte solution of choice 
(215.0±105.5 ml), which included, but is not limited to, Energade®, PVM Octane® or 32 GI®. 
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4.5.4.3 Dietary intake during T1 and T2 
A Wilcoxon matched pairs test was used to determine differences between dietary intake 
during T1 and T2. There were no significant difference in the dietary intake of the subjects 
during T1 and T2, except for total energy (p = 0.02*) and CHO intake (p = 0.02*) in male 
subjects (Table 4.18), which was higher during T1 when compared to T2 (total energy 
intake; 488.5±721.3 vs. 208.8±105.6 kcal and CHO intake; 1.6±2.3 vs. 0.7±0.4 g/kg BW). 
 
Table 4.18 Dietary intake during T1 and T2  
 
 Recommendation T1 T2 T1 vs. T2 
All (N = 26) Mean±SD Mean±SD p-value 
Total energy intake (kcal) N/A 467.9±613.7 262.6±138.0 p = 0.13 
Total energy intake (kcal/kgBW) N/A 6.8±8.6 4.0±2.4 p = 0.15 
Protein intake (g/kg BW) N/A 0.1±0.1 0.0±0.1 p = 0.21  
CHO intake (g/kg BW) 0.7 g/kg BW CHO (ACSM) 
30-60 g/hour* 
1.6±2.3 0.9±0.5 p = 0.16 
Fat intake (g/kg BW) N/A 1.5±2.8 0.9±2.0 p = 0.17 
CHO: Protein ratio CHO:Protein ratio of 3-4:1 10.8±8.2 24.7±42.7 p = 0.50 
 
Male (Nm = 14) Mean±SD Mean±SD p-value 
Total energy intake (kcal) N/A 488.5±721.3a 208.8±105.6b p = 0.02* 
Total energy intake (kcal/kgBW) N/A 6.2±8.5a 2.8±1.5b p = 0.02* 
Protein intake (g/kg BW) N/A 0.0±0.0 0.0±0.0 p = 0.29 
CHO intake (g/kg BW) 0.7 g/kg BW CHO (ACSM) 
30-60 g/hour* 
1.6±2.3a 0.7±0.4b p = 0.02* 
Fat intake (g/kg BW) N/A 0.7±2.1 0.3±1.0 p = 0.65 
CHO: Protein ratio CHO:Protein ratio of 3-4:1 9.9±9.2 9.0±6.3 p = 0.72 
 
Female (Nf = 12) Mean±SD Mean±SD p-value 
Total energy intake (kcal) N/A 449.1±533.0 321.7±150.1 p = 0.96 
Total energy intake (kcal/kgBW) N/A 7.4±9.1 5.3±2.6 p = 0.96 
Protein intake (g/kg BW) N/A 0.1±0.1 0.1±0.1 p = 0.50 
CHO intake (g/kg BW) 0.7 g/kg BW CHO (ACSM) 
30-60 g/hour* 
1.6±2.4 1.1±0.6 p = 0.96 
Fat intake (g/kg BW) N/A 2.3±3.2 1.6±2.6 p = 0.27 
CHO: Protein ratio CHO:Protein ratio of 3-4:1 9.9±9.2 9.0±6.3 p = 0.72 
Sources: (4, 169, 170, 172, 174, 175, 183, 203) 
a differed significantly from b (p < 0.05) 
kcal: calories; kcal/kgBW/day: calories per kilogram body weight per day; kcal/kgFFM: calories per kilogram fat free mass; g/kg 
BW: gram per kilogram body weight; N = total sample; Nm = total male sample; Nf = total female sample 
 
Although the total energy (kcal) and CHO intake (g/kg BW) during T1 and T2 differed 
significantly in the male group it did not show any correlation with the overall time to 
complete T1 and T2 (p = 0.55 and p = 0.10) as determined by the Spearman R rank-order 
correlation.  
 
Only 16 of the subjects ingested a food or drink during the triathlon (when combining data 
from T1 and T2). Most of the subjects ingested a form of carbohydrate-electrolyte solution 
(539.5±178.3 ml), such as Energade®, PVM Octane® or 32 GI®. Subjects also chose PVM® 
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energy bars (32.5±11.5 g)) and GU® energy gels (35.4±17.1 g) as food to be consumed 
during the triathlons. 
 
4.5.5 Body composition and anthropometry 
4.5.5.1 Bone densitometry 
Bone densitometry was determined by means of DXA. It was alarming to note that in the 
female group, the whole body BMD revealed that 72% (Nf pre-men = 5) and 40% (Nf post-men = 2) 
was classified as low BMD (Z-scores used according to ACSM criteria for pre-menopausal 
women) and osteopenic (T-scores used according to WHO criteria for post-menopausal 
women) respectively. It was also noted that according to this whole body classification, 14% 
(Nf pre-men = 1) and 20% (Nf post-men = 1) was classified as osteoporotic according to above 
mentioned classification systems (Table 4.19). 
 
There were no statistically significant correlations found between BMD and the following 
parameters in all, males and females respectively: estEA (p = 0.53, p = 0.29, p = 0.90), BMI 
(p = 0.54, p = 0.49, p = 0.57), body weight (p = 0.09, p = 0.20, p = 0.56), age (p = 0.40, p = 
0.31, p = 0.92) and height in males (p = 0.22) and females (p = 0.87).  
 
There was however, a significant positive correlation between BMD and height in the total 
subject group (p = 0.04*) (Figure 4.26). 
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Table 4.19 Bone densitometry  
 
*Classification for pre-menopausal women and men < 50 years based on ACSM criteria (Z-scores), classification for post-
menopausal women and men > 50 years based on WHO criteria (T-scores). 
N = total sample; Nm < 50 years = total male sample < 50 years; Nm > 50 years = total male sample > 50 years; Nf pre-men = total female 
sample pre-menopause; Nf pre-men = total female sample post-menopause 
 
 Nm < 50 years = 11 Nm > 50 years = 3 Nf pre-men = 7 Nf post-men = 5 
Anterior-posterior spine: Mean±SD Mean±SD Mean±SD Mean±SD 
Bone mineral density (g/cm2) 1.1±0.1 1.0±0.1 1.0±0.1 1.1±0.2 
T-score  -0.7±1.0  0.1±2.1 
Z-score -0.2±1.2  -0.6±1.0  
Classification* % (Nm < 50 years ) % (Nm > 50 years ) % (Nf pre-men ) % (Nf post-men ) 
Normal 82% (9) 67% (2) 57% (4) 60% (3) 
Osteopenic (WHO), Low BMD (ACSM) 18% (2) 33% (1) 43% (3) 40% (2) 
Osteoporotic 0% (0) 0% (0) 0% (0) 0% (0) 
 
Left femoral neck: Mean±SD Mean±SD Mean±SD Mean±SD 
Bone mineral density (g/cm2) 0.9±0.1 0.8±0.0 0.8±0.1 0.8±0.1 
T-score  -0.8±0.4  -0.0±1.0 
Z-score 0.0±0.9  -0.1±0.6  
Classification* % (Nm < 50 years ) % (Nm > 50 years ) % (Nf pre-men ) % (Nf post-men ) 
Normal 100% (11) 67% (2) 86% (6) 80% (4) 
Osteopenic (WHO), Low BMD (ACSM) 0% (0) 33% (1) 14% (1) 20% (1) 
Osteoporotic 0% (0) 0% (0) 0% (0) 0% (0) 
 
Left total hip: Mean±SD Mean±SD Mean±SD Mean±SD 
Bone mineral density (g/cm2) 1.0±0.1 1.0±0.0 1.0±0.1 1.0±0.1 
T-score  0.1±0.3  0.2±0.9 
Z-score 0.1±0.7  0.2±0.6  
Classification* % (Nm < 50 years ) % (Nm > 50 years ) % (Nf pre-men ) % (Nf post-men ) 
Normal 100% (11) 100% (3) 100% (7) 100% (5) 
Osteopenic (WHO), Low BMD (ACSM) 0% (0) 0% (0) 0% (0) 0% (0) 
Osteoporotic 0% (0) 0% (0) 0% (0) 0% (0) 
 
Total hip bilateral average: Mean±SD Mean±SD Mean±SD Mean±SD 
Bone mineral density (g/cm2) 1.0±0.1 1.0±0.1 1.0±0.1 1.0±0.1 
T-score  0.0±0.4  0.1±1.0 
Z-score 0.0±0.7  0.1±0.7  
Classification* % (Nm < 50 years ) % (Nm > 50 years ) % (Nf pre-men ) % (Nf post-men ) 
Normal 100% (11) 100% (3) 86% (6) 100% (5) 
Osteopenic (WHO), Low BMD (ACSM) 0% (0) 0% (0) 14% (1) 0% (0) 
Osteoporotic 0% (0) 0% (0) 0% (0) 0% (0) 
 
Whole body: Mean±SD Mean±SD Mean±SD Mean±SD 
Bone mineral density (g/cm2) 1.1±0.1 1.1±0.1 1.0±0.1 1.0±0.1 
T-score  -1.1±0.6  -1.3±1.2 
Z-score 0.0±0.0  -1.1±1.1  
Classification* % (Nm < 50 years ) % (Nm > 50 years ) % (Nf pre-men ) % (Nf post-men ) 
Normal 100% (11) 67% (2) 14% (1) 40% (2) 
Osteopenic (WHO), Low BMD (ACSM) 0% (0) 33% (1) 72% (5) 40% (2) 
Osteoporotic 0% (0) 0% (0) 14% (1) 20% (1) 
 
Bone mineral content (g) Mean±SD Mean±SD Mean±SD Mean±SD 
Total 2451.4±444.2 2543.53.5 1925.0±239.2 2020.6±258.4 
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Figure 4.26 Relationship between whole body BMD (g/cm2) and height (m) in the total 
subject group (p = 0.04*) 
 
4.5.5.2 Body composition and anthropometry 
Table 4.20 summarizes the body composition and anthropometrical measurements of the 
triathletes. The ACSM recommends that triathletes should aim for a percentage body fat of 
between 6-15%, males aiming for the lower and females for the upper range. The current 
study population falls within this range (14.5±7.2 %), with the males 10.7±3.8 % and females 
above the recommendation at 19.0±7.7 %.  
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Table 4.20 Body composition measurements and anthropometry 
 
 All (N = 26) Male (Nm = 14) Female (Nf = 12) 
Body compositiona Mean±SD Mean±SD Mean±SD 
Percentage body fat (%) 14.5±7.2 10.7±3.8 19.0±7.7 
Fat (kg) 9.5±5.0 7.7±3.2 11.5±5.9 
Lean body mass (LBM) (kg) 53.8±9.6 61.0±6.5 45.4±4.0 
Fat free mass (lean + BMC) (kg) 56.±9.9 63.5±6.8 47.4±4.1 
Body mass (kg) 65.5±10.0 71.2±8.4 58.9±7.5 
 
Anthropometryb Mean±SD Mean±SD Mean±SD 
Height (cm) 172.5±8.3 178.0±6.2 166.2±5.4 
Body weight (kg) 69.2±10.6 75.3±8.8 62.2±7.8 
BMI (kg/m2) 21.9±2.0 22.4±1.8 21.3±2.1 
aMeasured with DXA 
bMeasured with Seca® 767 column scale with height meter 
N = total sample; Nm = total male sample; Nf = total female sample 
BMI: Body mass index (kg/m2) 
 
4.5.6 Training regime 
4.5.6.1 Usual training habits / regime 
The workloads for exercise sessions completed per week by the subjects as part of their 
usual training regime are presented in Table 4.21. While males and females spent similar 
times training for swimming and cycling, females spent significantly more time running than 
males (4.3 (±1.3) vs. 2.8 (±1.2) hours per week) (p = 0.01*). The average amount of training 
per week was 12.8 (±4.8) hours for the whole group.  
 
Table 4.21 Usual training regime 
 
 All (N = 26) Male (Nm = 14) Female (Nf = 12) Male vs. Female 
Mean±SD Mean±SD Mean±SD p-value 
Exercise sessions / week 6.5±0.5 6.1±3.1 7.1±2.1 p = 0.35 
Exercise sessions / day 1.5±2.7 1.4±0.5 1.7±0.5 p = 0.14 
Swimming / week (hours) 2.5±1.2 2.1±1.3 2.9±1.0 p = 0.10 
Swimming / week (km) 5.8±3.9 5.6±4.5 6.0±3.4 p = 0.80 
Cycling / week (hours) 5.3±2.2 5.3±2.5 5.3±2.0 p = 1.00 
Cycling / week (km) 153.1±103.0 166.8±122.7 137.1±76.0 p = 0.47 
Running / week (hours) 3.5±1.4 2.8±1.2a 4.3±1.3b p = 0.01* 
Running / week (km) 37.1±15.0 30.7±13.1a 44.6±14.0b p = 0.02* 
Gym / week (hours) 0.9±1.1 0.8±0.8 1.0±1.5 p = 0.67 
Other / week (hours)a 0.9±1.2 1.1±1.2 0.6± 1.1 p = 0.28 
OD tri’s completed in 2010/11 4.5±4.7 4.7±6.4 4.3±1.8 p = 0.84 
OD tri PB (minutes) 144.8±18.3 139.0±14.0 153.0±21.7 p = 0.06 
OD tri PB (hours) 2h25m±18.3m 2h19m±14.0 2h33m±21.7 p = 0.06 
a differed significantly from b (p < 0.05) 
km: kilometers; OD: Olympic-distance; tri: triathlon; PB: personal best; aOther: includes aerobic exercise other than running; 
swimming and cycling (e.g. rowing; canoeing); N = total sample; Nm = total male sample; Nf = total female sample 
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4.5.6.2 Training characteristics two (2) days before T1 and T2  
As determined with the t-test for independent samples, there were no differences in the type 
and volume of training completed before T1 vs. T2 (Table 4.22). However, the rating of 
exertion in running was significantly higher before T2, when compared to T1 in the male 
group (p = 0.04*).  
 
Table 4.22 Training completed two days before T1 and T2 
 
 T1 T2 T1 vs. T2 
All (N = 26) N Mean±SD N Mean±SD p-value 
Swimming (minutes) 13 35.7±11.5 12 35.8±19.0 p = 0.98 
Swimming (km) 13 1.6±0.5 12 1.6±0.9 p = 0.96 
Swimming (exertion) 13 3.1±0.8 13 3.1±0.9 p = 0.98 
Cycling (minutes) 10 56.0±49.2 11 67.5±49.1 p = 0.62 
Cycling (km) 10 26.2±25.0 11 27.0±18.6 p = 0.94 
Cycling (exertion)c 10 2.6±0.5 11 3.0±0.8 p = 0.24 
Running (minutes) 12 27.8±14.3 5 27.0±20.2 p = 0.93 
Running (km) 12 5.3±2.7 5 4.8±2.9 p = 0.72 
Running (exertion) 12 2.5±0.7 5 3.1±1.1 p = 0.15 
Other (minutes)d 5 49.0±29.2 5 59.0±23.0 p = 0.56 
 
Male (Nm = 14) N Mean±SD N Mean±SD p-value 
Swimming (minutes) 9 36.0±12.4 7 35.0±22.7 p = 0.91 
Swimming (km) 9 1.5±0.6 7 1.5±0.9 p = 0.89 
Swimming (exertion)c 9 3.4±0.7 7 3.6±0.8 p = 0.74 
Cycling (minutes) 6 38.7±27.9 6 51.3±35.2 p = 0.51 
Cycling (km) 6 18.2±14.1 6 22.0±12.4 p = 0.63 
Cycling (exertion) 6 2.7±0.5 6 3.2±0.8 p = 0.21 
Running (minutes) 8 26.9±15.6 3 28.3±28.4 p = 0.91 
Running (km) 8 5.4±3.2 3 4.7±4.0 p = 0.76 
Running (exertion) 8 2.5±0.5a 3 3.7±1.2b p = 0.04* 
Other* (minutes)d 4 50.0±33.7 3 63.3±30.6 p = 0.61 
 
Female (Nf = 12) N Mean±SD N Mean±SD p-value 
Swimming (minutes) 4 35.0±10.8 5 37.0±14.8 p = 0.83 
Swimming (km) 4 1.6±0.6 5 1.7±0.8 p = 0.86 
Swimming (exertion)c 4 2.4±0.5 5 2.5±0.5 p = 0.72 
Cycling (minutes) 4 82.0±66.8 5 87.0±60.2 p = 0.91 
Cycling (km) 4 38.3±34.9 5 33.0±24.2 p = 0.80 
Cycling (exertion) 4 2.5±0.8 5 2.7±0.8 p = 0.70  
Running (minutes) 4 29.5±13.2 2 25.0±0.0 p = 0.67 
Running (km) 4 5.3±1.9 2 5.0±0.0 p = 0.18 
Running (exertion) 4 2.5±1.0 2 2.3±0.4 p = 0.33 
Other* (minutes)d 1 45.0±0.0 2 52.5±10.6 p = 0.67 
a differed significantly from b (p < 0.05) 
cExertion measured on a 5 point scale; dOther: includes aerobic exercise other than running; swimming and cycling (e.g. 
rowing; canoeing); N = total sample; Nm = total male sample; Nf = total female sample 
 
Although the rating of exertion for running two days before racing was higher before T2, 
when compared to T1 in the male group it did not influence the overall time to complete T1 
(143.0±12.0 minutes) or T2 (144.6±12.7 minutes) (p = 0.45 and p = 0.60 respectively) 
according to the Pearson correlation coefficient. 
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4.5.7 Caffeine withdrawal symptoms 
A questionnaire was completed before T1 to determine any subjective caffeine withdrawal 
symptoms experienced during the first two weeks of caffeine abstinence. The most common 
withdrawal symptom experienced were headaches (46%, N = 12), followed by flu-like 
symptoms (38%, N = 10) (Table 4.23). 
 
 
Table 4.23 Prevalence of caffeine withdrawal symptoms   
 
 All (N = 26) Male (Nm = 14) Female (Nf = 12) 
 % (N) % (Nm) % (Nf) 
Headaches 46% (12) 21% (3) 75% (9) 
Fatigue 31% (8) 14% (2) 50% (6) 
Lethargy 35% (9) 21% (3) 50% (6) 
Flu-like symptoms 38% (10) 14% (2) 67% (8) 
N = total sample; Nm = total male sample; Nf = total female sample 
 
According to the Mann-Whitney U test, headaches experienced in the two weeks before T1 
increased the overall time to complete T1 in the male and female groups, as well as in the 
combined group (Table 4.24). 
 
 
Table 4.24 Influence of headaches experienced during the two weeks before T1 
on the overall time to complete T1  
 
 Time to complete 
(minutes) 
 Yes vs. No 
All (N = 26) Mean±SD N p-value  
Headaches (Y) 160.5±20.7a 12 p = 0.00* Headaches (N) 141.5±11.7b 14 
 
Male (Nm = 14) Mean±SD N p-value  
Headaches (Y) 146.4±10.9a 3 p = 0.05* Headaches (N) 142.1±12.6b 11 
 
Female (Nf = 12) Mean±SD N p-value  
Headaches (Y) 165.2±21.5a 9 p = 0.04* Headaches (N) 139.3±9.4b 3 
a differed significantly from b (p < 0.05) 
N = total sample; Nm = total male sample; Nf = total female sample; Y = yes; N = no 
 
4.5.8 Side effects of caffeine supplementation 
The subjects were asked to complete a subjective questionnaire to determine which of the 
most common side-effects of caffeine supplementation were experienced and how these 
may have affected the subject’s overall time to complete the triathlon in the caffeine and 
placebo groups respectively.  When comparing the caffeine and placebo groups with the M-L 
chi-squared test, the whole group experienced shakiness (p = 0.00*), heart palpitations (p = 
0.01*) and GIT disturbances (p = 0.01*) when receiving caffeine supplementation. In the 
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female group, shakiness (p = 0.05*) and heart palpitations (p = 0.05*) were more prevalent 
while GIT disturbances (p = 0.01*) were more prevalent in the male caffeine vs. placebo 
group.  
 
It is interesting to note that, although the values did not reach statistical significance, 
nervousness was less prevalent in both males (7% reduction) and females (25% reduction) 
in the caffeine group compared to the placebo group (Table 4.25).  
 
Table 4.25 Prevalence of subjective symptoms of the side-effects of caffeine 
experienced in the caffeine and placebo groups 
 
 Caffeine & 
placebo 
combined 
Caffeine Placebo Caffeine vs. 
Placebo 
 % (N) % (N) % (N) p-value 
All N = 52 Nc = 26 Np = 26  
Nervousness 54% (28) 38% (10) 54% (14) p = 0.26 
Shakiness 27% (14) 42%a (11) 12%b (3) p = 0.00* 
Anxiety 23% (12) 23% (6) 23% (6) p = 1.00 
Heart palpitations 23% (12) 38%a (10) 8%b (2) p = 0.01* 
Flushing  10% (5) 15% (4) 4% (1) p = 0.15 
GIT disturbances 23% (12) 38%a (10) 8%b (2) p = 0.01* 
Headaches 17% (9) 12% (3) 23% (6) p = 0.27 
 
Male  Nm = 28 Ncm = 14 Npm = 14  
Nervousness 32% (9) 29% (4) 36% (5) p = 0.69 
Shakiness 25% (7) 43% (6) 7% (1) p = 0.23 
Anxiety 18% (5) 21% (3) 14% (2) p = 0.62 
Heart palpitations 21% (6) 36% (5) 7% (1) p = 0.06 
Flushing  11% (3) 14% (2) 7% (1) p = 0.54 
GIT disturbances 14% (4) 29%a (4) 0%b (0) p = 0.01* 
Headaches 18% (5) 14% (2) 21% (3) p = 0.62 
 
Females Nf = 24 Ncf = 12 Npf = 12  
Nervousness 63% (15) 50% (6) 75% (9) p = 0.20 
Shakiness 29% (7) 42%a (5) 17%b (2) p = 0.05* 
Anxiety 29% (7) 25% (3) 33% (4) p = 0.65 
Heart palpitations 25% (6) 42%a (5) 8%b (1) p = 0.05* 
Flushing  8% (2) 17% (2) 0% (0) p = 0.09 
GIT disturbances 33% (8) 50% (6) 17%(2) p = 0.08 
Headaches 17% (4) 8% (1) 25%(3) p = 0.26 
a differed significantly from b (p < 0.05) 
N = total sample; Nm = total male sample; Nf = total female sample; Nc = total caffeine; Ncm = total caffeine male; Ncf = total 
caffeine female; Np = total placebo; Npm = total placebo male; Npf = total placebo female 
 
4.5.8.1 Influence of the symptoms of the side-effects of caffeine supplementation on 
the overall time to complete the triathlon 
The researcher did a factorial ANOVA with VEPAC of the overall time to complete the 
triathlon with factors group and caffeine and then gender and caffeine with respondents 
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nested firstly in group and then nested in gender. To investigate the influence of the different 
symptoms of the side-effects of caffeine, these variables were one by one entered as 
covariates in a similar analysis of covariance with factors (group and caffeine and then 
gender and caffeine) as described above. 
 
Of all the side effects considered, heart palpitations were the only covariate which 
significantly affected the overall time to complete the triathlon (p = 0.03*) (Figure 4.27). In 
the caffeine and placebo groups, irrespective of gender, the prevalence of heart palpitations 
led to a slower time to complete the triathlon. 
 
 
Figure 4.27 Overall time to complete the triathlon according to the prevalence of heart 
palpitations experienced (Time effect: p = 0.03*).  
 
4.5.9 Hydration status and changes in plasma volume (serum 
albumin) 
The researcher performed a RMANOVA with VEPAC on serum albumin levels with factors 
group, caffeine and stage (baseline, during transition (cycle → run) and at the finish line); 
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and then gender, caffeine and stage; with respondents nested firstly in group (p = 0.26) and 
then in gender (p = 0.12) (Table 4.26).  
Table 4.26 Serum albumin levels in the caffeine and placebo groups  
 
 All Caffeine Placebo Caffeine vs. 
Placebo 
Mean±SD Mean±SD Mean±SD p-value 
All N = 52 Nc = 26 Np = 26  
Baseline (g/l) 48.6±2.4 48.6±2.2 48.6±2.6 p = 1.00 
Transition (cycle-run) (g/l) 49.9±2.6 50.0±2.6 49.8±2.7 p = 0.72 
Finish line (g/l) 48.7±2.5 48.8±2.2 48.7±2.7 p = 0.72 
 
Male  Nm = 28 Ncm = 14 Npm = 14  
Baseline (g/l) 48.9±1.9 48.5±1.7 49.4±2.0 p = 0.12 
Transition (cycle-run) (g/l) 51.1±2.2 51.2±2.0 51.0±2.4 p = 0.70 
Finish line (g/l) 49.2±2.5 49.4±2.3 49.1±2.9 p = 0.61 
 
Female  Nf = 24 Ncf = 12 Npf = 12  
Baseline (g/l) 48.3±2.8 48.8±2.7 47.8±2.9 p = 0.10 
Transition (cycle-run) (g/l) 48.5±2.4 48.6±2.5 48.5±2.3 p = 0.90 
Finish line (g/l) 48.2±2.3 48.2±2.0 48.2±2.6 p = 1.00 
N = total sample; Nm = total male sample; Nf = total female sample; Nc = total caffeine; Ncm = total caffeine male; Ncf = total 
caffeine female; Np = total placebo; Npm = total placebo male; Npf = total placebo female 
 
Serum albumin levels measured during transition (cycle → run) increased significantly from 
serum albumin levels measured at baseline (p = 0.00*). Thereafter, serum albumin levels 
measured at the finish line decreased significantly from serum albumin levels measured 
during transition (cycle → run) (p = 0.00*). The serum albumin levels measured at baseline 
did not differ significantly from the serum albumin levels measured at the finish line (p = 
0.70) in the whole group.  
 
The difference observed between the various stages of the triathlon was not due to caffeine 
supplementation in males or females (p = 0.12). Although there were no overall observed 
effects between gender, caffeine supplementation and serum albumin levels (at all three 
time points) (p = 0.12), there was a significant difference in serum albumin levels measured 
at the three time points for males and females (p = 0.00*), with males having consistently 
higher values than females (Figure 4.28).  
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Figure 4.28 Serum albumin levels measured at baseline, during transition (cycle → 
run) and at the finish line in the caffeine and placebo groups (Supplementation effect: 
p = 0.96) and according to gender (Gender effect: p = 0.00*) 
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CHAPTER 5: DISCUSSION 
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This research study provides a comprehensive assessment of the performance enhancing or 
ergogenic effect of caffeine supplementation during a real life triathlon competition, an 
evaluation of several parameters that could in part explain why caffeine supplementation is 
ergogenic during endurance exercise and it describes in detail factors influencing the 
ergonicity of caffeine supplementation as well as factors influencing triathlon performance. 
The researcher demonstrated that double-blind, randomized, crossover, controlled, clinical 
field trials, and not only laboratory experiments, are necessary to establish the real effect of 
caffeine supplementation on triathlon performance. It was shown that caffeine 
supplementation during an Olympic-distance triathlon has a performance enhancing effect 
on male and female provincial level triathletes in the Western Cape, South Africa. However, 
this effect was not as pronounced as seen in previous laboratory trials and the effect was not 
significantly related to a reduction in rating of perceived exertion or positive changes in mood 
state. Further results discussed in this chapter indicated that caffeine supplementation acts 
mainly as an ergogenic aid through its affect on the central as well as autonomic nervous 
system. Factors such as lifestyle, gender and genetics may influence the ergogenicity of 
caffeine supplementation although this remains to be substantiated in larger cohorts. 
General health, dietary intake, body composition and bone mineral density, side effects of 
caffeine withdrawal and acute caffeine supplementation and hydration status may influence 
Olympic-distance triathlon performance. 
  
5.1 Ergogenic effect of caffeine supplementation 
The present study investigated the effect of 6 mg/kg BW microencapsulated caffeine (70% 
caffeine concentration,© 2005-2009 Maxx Performance Inc.) on triathlon performance.  
 
The reference range for plasma caffeine concentrations is 5-25 mg/l. In the current study, 
the baseline plasma caffeine levels were < 1 mg/l, indicating that the athletes adhered to the 
research protocol by abstaining from caffeine supplementation.  
 
The peak plasma caffeine concentration to have an ergogenic effect (8-10 mg/l) for doses of 
5-8 mg/kg body weight is typically reached in the blood after 15-120 minutes (57), and 
therefore the caffeine supplementation was given to the subjects in the present study 45-60 
minutes prior to the start of the triathlon. Peak plasma caffeine concentrations (7-10 mg/l) 
were reached in the caffeine group during transition (cycle → run) and at the finish line. The 
supplementation was therefore effective in elevating plasma caffeine concentrations to levels 
which have been shown to be ergogenic in the literature.  
 
Stellenbosch University http://scholar.sun.ac.za
165 
 
5.1.1 Triathlon performance (time to complete) 
Most studies evaluating the effect of caffeine supplementation on endurance performance 
showed an improved performance when using a TTE protocol, followed by a TT or only a 
TTE protocol (13-16, 19-22, 25-30, 41, 45, 75, 82, 83, 85, 100-105, 107, 111, 114, 115, 
209).  
 
No improvement in performance was found in studies evaluating the effect of caffeine 
supplementation on endurance exercise, during various extreme environmental and exercise 
conditions (37, 53, 76, 86, 90, 92, 98, 106, 109, 110, 115).  
 
In the current study, the researcher found statistically significant differences in the time to 
complete the swim and the overall time to complete the triathlon in the caffeine group (a 
3.7% and 1.3% reduction respectively) when considering the group as a whole. The time to 
complete all the other components, including cycle time and run time, was not reduced to a  
statistically significantly extent, although there was a 1.1% and 0.7% decrease in the time to 
complete the cycle and run, respectively. When considering the times in a gender-specific 
manner, the overall time to complete the triathlon was significantly reduced (1.7%) in the 
male group receiving caffeine. Although the time to complete the swim improved by 4.5%, 
the cycle by 1.8% and the run by 1.1%, these decreases in time were also not statistically 
significant. The females also showed a percentage reduction in the swim (2.8%), cycle 
(0.5%) and run (0.4%) times, as well as the overall time to complete the triathlon (0.9%), but 
this too was not statistically significant.  
 
The fact that the abovementioned decreases in time were not found to be statistically 
significant may be due to the small sample size used. However, studies (Table 2.1) that 
showed a significant improvement used smaller sample sizes, suggesting rather that this 
non-significant effect was rather due to the effect of competing in a real-life triathlon than 
only the sample size employed. A triathlon encompasses three disciplines and cannot be 
compared to studies completed solely on swimming, cycling and running. Furthermore, a 
field study cannot readily be compared to studies conducted in a laboratory environment. 
 
It is evident from the results, that caffeine supplementation taken 45-60 minutes before an 
Olympic-distance triathlon, exerted the greatest effect on performance in the swimming 
section of the triathlon, as well as on the overall time to complete the triathlon, in the whole 
subject group.  
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The effect of caffeine supplementation on swim performance in the present study is 
interesting. Swimming is not regularly chosen as an exercise protocol when evaluating the 
ergogenic effect of caffeine (Table 2.1). A reason for this may be that the intensity of 
exercise cannot be regulated in the same manner as cycling or running and pacing 
strategies may differ whilst swimming (15). The few studies that have examined the effect of 
caffeine supplementation on swim performance either evaluated the effect  during short 
distance swimming (100 m or less) (210, 211) or the combination of caffeine and sodium 
bicarbonate on repeated short distance (200 m) swim performance (212). The only study to 
the author’s knowledge that evaluated the effect of caffeine supplementation on 1 500 m 
swim performance was conducted in 1995 (15). The authors concluded that supplementation 
with 6 mg/kg caffeine, two and a half hours prior to the 1 500 m swim significantly reduced 
the time to complete the 1 500 m swim. The authors suggested that this ergogenic effect 
may have been due to altered electrolyte balance and improved glucose availability (15). In 
the present study, the researchers also found the most profound decrease in the time to 
complete the swim section of the triathlon. The present study did not evaluate the same 
mechanisms in terms of electrolyte balance and glucose availability, but found that caffeine 
supplementation continually increased plasma caffeine levels from baseline, with the highest 
values recorded at the finish line. This would suggest that caffeine supplementation would 
have a beneficial effect, even before peak plasma caffeine levels have been reached. Rating 
of perceived exertion was also lower in the caffeine compared to placebo group (although 
not statistically significant) and lowest during the transition from the swim → cycle. This 
suggests that caffeine has a beneficial effect before maximal exertion or fatigue is reached, 
such as experienced at the end of the cycle or run leg of the triathlon. The importance of an 
increased swim performance during a triathlon is of paramount importance, especially when 
applying the results to elite triathletes who race in draft-legal triathlon races. The evaluation 
of caffeine supplementation on swim performance warrants further research. 
 
The practical application of these results for triathletes is that caffeine supplementation 
decreases time to complete an Olympic-distance triathlon in the field setting. Even though 
we had a relative small sample size, this effect was evident in both males and females. The 
greatest effect was seen on the overall time to complete the triathlon, as well as the swim 
section of the triathlon. It was the shortest discipline of the three and also the first. Although 
not always statistically significant, the percentage decrease in time to complete the various 
sections (swim, cycle, and run) of the triathlon is important to note. One to two minutes 
decreased time to swim can make a significant practical/clinical difference in triathlon 
performance. This would be even more important in races where the cycling section of the 
triathlon is draft legal and making the lead pack from the swim to the cycle is of critical 
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importance. Although the present study was not draft legal, this is of practical value for draft 
legal races.  
 
5.1.2 Rating of perceived exertion (RPE) 
RPE is one of the well-studied outcomes when evaluating the literature on the effect of 
caffeine supplementation. Various studies have found no change in RPE with caffeine 
supplementation (75, 77, 83, 85, 87, 102, 116). However, most studies have shown 
decreased RPE with caffeine supplementation (14, 15, 22, 27, 29, 31, 32, 37, 45, 81, 91, 92, 
96, 97, 99, 100, 104, 109, 110, 112, 117).  
 
In all studies evaluating the mechanism of action of the ergogenic effect of caffeine 
supplementation, or the relationship of caffeine to improved exercise performance, the 
enhanced effect of caffeine on a person’s perceptual responses remains constant (31). In a 
meta-analysis conducted by Doherty and Smith et al. (2005), it was concluded that there 
was a 6% reduction in RPE during constant load exercise, but no difference in RPE values 
after exhaustive exercise. The author concluded that this was a normal physiological 
response, as exercise would be stopped when the individual was exhausted or at the end of 
exercise. This is the main reason for most studies reporting an improvement in RPE when 
determining time to exhaustion (31).  
 
The abovementioned meta-analysis, along with another meta-analysis by Doherty and Smith 
et al. (2004), concluded an 11% reduction in RPE and improved exercise performance 
following caffeine ingestion (28, 31). The decrease in the RPE during endurance exercise 
enables athletes to manage fatigue, which allows the athletes to complete longer TTE 
protocols. The difference in perceptual response allows subjects to recruit and use more 
motor units and improve power output, which can also be beneficial for time trial 
performance (31). However, in the current study, none of the RPE measures influenced the 
time to complete any single component of the triathlon or the overall time to complete the 
triathlon. 
 
The meta-analysis conducted by Doherty et al. (2005) concluded that the effect of caffeine 
on RPE was present, irrespective of caffeine withdrawal, or the timing or dosage of caffeine 
supplementation, and that there was a more pronounced decrease in RPE with advanced 
levels of fitness (31).  
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The current study showed no statistically significant differences in the RPE measured at 
baseline, transition (swim → cycle), transition (cycle → run) and at the finish line between the 
caffeine and placebo groups, but there was a clear trend towards lower RPE values in the 
caffeine group. This concurs with research conducted by Tarnopolsky et al. (1989) and Trice 
et al. (1995), who found a 16% and 6% reduction, respectively, in RPE, although these 
results were also not statistically significant (22, 112).  
 
The reason for the abovementioned studies and others showing little or no improvement in 
RPE can, according to Doherty et al. (2005) be attributed to the small sample sizes used 
(31). However, in the current study, the sample size was the same, if not greater, than the 
sample sizes used in most of these studies. A further explanation for the lack of statistical 
significance can be that the current study was a field study, not a laboratory-based study. In 
field studies, various additional physiological factors may be involved, and these can affect 
perceptual responses and levels of fatigue. Moreover, the current study involved studying 
the effect of caffeine supplementation during and after a triathlon, which has not been 
studied previously. Physiological responses during and after competing in a triathlon are also 
different from responses during and after only cycling or running and can have an effect on 
the athlete’s perceptual response to exercise. It is also important that during a time trial 
event, RPE cannot be interpreted in the same manner as during a time to exhaustion or 
constant exercise at submaximal intensity. During a time trial, even though the athlete is less 
fatigued from the exhaustive exercise due to caffeine supplementation, the athlete will push 
him/herself harder and RPE will remain the same. Performance time is therefore a greater 
indicater in a time trial event than measures of RPE. There is, nevertheless, a clear trend in 
most studies, including the current study, suggesting that caffeine supplementation reduces 
RPE, although, the percentage decrease in outcomes measured, is not always statistically 
significant.  
 
5.1.3 Mood state 
Subjects also completed the POMS questionnaire at baseline and again at the finish line of 
the triathlons, in order to determine the effect of caffeine supplementation on the mood state 
of the subjects. It has been reported that caffeine significantly improves mood (195), 
although this has not been measured consistently with the POMS questionnaire. Caffeine 
has been found to be positively associated with mood, contributing to individuals feeling 
more energetic, imaginative, efficient and motivated to work and socialize (57).  
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Caffeine supplementation in the current trial had no effect on the total or differential POMS 
scores in all subjects, and the male and female groups. This is in contrast to other studies 
that examined the effect of caffeine-containing energy capsules on mood and psychomotor 
performance in fatigued individuals. Childs et al. (2008), who also used a POMS 
questionnaire, found that the ingestion of a caffeine-containing food supplement improved 
the subjective state and cognitive performance of fatigued individuals, and also that caffeine 
had a stimulant-like effect in improving mood and reaction times (213). Possible reasons 
why caffeine supplementation did not improve POMS scores could be that the baseline 
POMS questionnaire was completed before caffeine supplementation and that 
supplementation could not have had an effect and that the POMS score at the finish line was 
after the triathlon, which is exhaustive exercise. The effect of caffeine supplementation on 
the POMS score may not have been big enough to detect. It could also be that in the 
present study, the sample size was too small to detect changes in the POMS score due to 
caffeine supplementation.  
 
The mood state of the athletes was not influenced by caffeine supplementation. We can 
therefore conclude that either the athletes were not sufficiently mentally fatigued for caffeine 
to have a measurable beneficial effect or the mechanism by which caffeine elicits its 
ergogenic effect is not clear from the current study’s results, as mood state was unchanged 
regardless of caffeine supplementation.  
 
It is clear from the present study that caffeine supplementation significantly improves the 
time to complete an Olympic-distance triathlon. However, the mechanism by which caffeine 
elicits its ergogenic effect is not clear from the current study’s results as rating of perceived 
exertion and mood state was statistically unchanged due to supplementation with caffeine. 
The researcher did however observe a general trend toward lower RPE values in the 
caffeine when compared to the placebo group. If these results can be substantiated in a 
larger cohort and significantly reduced RPE values observed, the effect of caffeine 
supplementation can be attributed to one of two suggested mechanisms of action. First, the 
antagonism of adenosine receptors, which leads to a reduction of pain, improving arousal 
and motivation and thus reducing pain and RPE or to the stimulation of the HPA-axis, which 
leads to the release of β-endorphins and cortisol, both of which has been shown to decrease 
RPE . 
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5.2 Parameters that could in part explain the ergogenic effect of 
caffeine supplementation 
5.2.1 Endocrine-stress response 
5.2.1.1 Serum cortisol levels 
In the current study, all the measured serum cortisol values (at baseline, 1 hour before the 
triathlon and again at the finish line) were within the recommended reference range (140-700 
nmol/l). Cortisol levels follow a circadian rhythm in the body, levels peak at about 8 a.m. and 
then decrease during the day. The serum cortisol level measured at the finish line was 
significantly higher in the caffeine group, compared to the placebo group. This was 
particularly evident in the male group.  
 
As discussed in the literature overview, cortisol levels are increased independently due to 
caffeine, the mental stress of competing in a race environment and the exertion of exercising 
at the high intensity required during a triathlon (140). Several studies have found increased 
cortisol levels after marathon running (136, 142-146). Balthazar et al. (2012) found that 
salivary cortisol were greater on the day of a short triathlon, compared to a rest day, in eight 
male triathletes, and that exercise performance was positively associated with salivery 
cortisol concentration in the early morning on race day. The authors concluded that early 
morning salivary cortisol levels could be used to predict performance during a triathlon (214).   
 
Exercise is also a metabolic stressor and the response of cortisol to stress varies widely 
between individuals (148), between genders and between various durations of exercise 
(136, 145, 147). The elevated cortisol levels seen after exercise may be a largely metabolic 
effect, which lead to increased gluconeogenesis and lipolysis. Our results are therefore in 
agreement with the sports literature in this context. 
 
There was a difference between male and female cortisol levels, with males reaching a 
significantly higher serum cortisol level at the finish line, compared to females. This is also 
supported by previous studies that have shown that in females, caffeine supplementation 
has a smaller effect on cortisol levels than in males. In the current study, differences 
between cortisol levels in males and females were observed, irrespective of whether caffeine 
supplementation was administered or not. Cortisol levels in males were increased after 
exercise, whereas these levels decreased in the female group. The serum cortisol levels 
measured at baseline also influenced the overall time to complete the triathlon, with faster 
times being observed in males and slower times in females.  
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Studies found that the cortisol response to mental stress is less pronounced in females 
compared to males (140, 215). This author also found that 30 minutes of steady state 
exercise on a cycle ergometer had no effect on cortisol levels, but when caffeine was given 
before exercise, serum cortisol levels were elevated in both males and females (140). 
Caffeine has been shown to elevate cortisol levels at rest and after exercise (51, 131, 140, 
216). It therefore appears that the release of cortisol in response to stress or caffeine is 
dependent on the type of stressor, as well as gender. It was also concluded that caffeine 
increases cortisol secretion by stimulating the CNS, especially in males, but in females it 
may interact with peripheral metabolic mechanisms (140).  
 
The augmented increase in cortisol levels seen after exercise with caffeine supplementation 
suggests that one of the main mechanism of action of caffeine having an ergogenic effect is 
the indirect stimulation of the HPA-axis and the effect on the autonomic nervous system (in 
addition to the effect on the CNS). This leads to cortisol levels being elevated above that 
would occur after prolonged or endurance exercise. The increased cortisol can positively 
affect cognitive performance and mood, thereby decreasing the perception of pain and 
improving sport performance.  
 
5.2.1.2 DHEAs levels 
In the present study, there was a significant difference between baseline DHEAs levels in 
the caffeine and placebo groups. This was, however not due to caffeine supplementation as 
this was given after the baseline blood samples were taken. DHEAs levels were consistently 
within the reference ranges (i.e. 0.95-11.7 umol/l for males and 2.17-15.2 umol/l for 
females). There were significant increases between baseline and finish line DHEAs levels in 
all subjects, and the male and female groups, irrespective of whether or not caffeine 
supplementation was given. There were no statistically significant differences between 
DHEAs levels in males and females, although there were lower baseline and finish line 
levels observed in females compared to males. According to the literature and as discussed 
in the literature review, DHEAs levels increase during endurance exercise (136, 150). It is 
also known that women, who regularly enjoy endurance exercise, such as the females in our 
study group, have decreased resting DHEAs levels as a result of decreased ACTH following 
an endurance training program (135). When introducing DHEAs levels as a covariate to 
triathlon performance, no significant influence was found.  
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5.2.1.3 Prolactin levels 
Prolactin levels measured at baseline and at the finish line, also consistently fell within the 
recommended reference ranges (2.6-13.1 ug/l for males and 3.3-26.7 ug/l for females). In 
the caffeine and placebo groups, baseline and finish line serum prolactin levels increased 
significantly in all subjects, and the male and female groups. There were no differences 
observed between the caffeine and placebo groups. There was also no difference observed 
between the male and female group, although the average baseline and finish line values 
were slightly higher in the female group. The finish line levels in the female group also 
increased more markedly from baseline than in the male group (51% increase for females, 
compared to 41% increase for males). Karkoulias et al. (2008) reported an increase in 
prolactin levels due to physical stress, such as endurance exercise (136). This is particularly 
evident in female athletes following endurance exercise as described by Enea et al. (2011) 
(135).   
 
The introduction of serum prolactin as a covariate to influence triathlon performance showed 
no effect on the overall time to complete the triathlon. It has been hypothesized that prolactin 
secretion could be reduced during an exercise trial following caffeine ingestion as prolactin is 
under control of the central serotonergic system. Without caffeine supplementation, prolactin 
increases serotonin synthesis and decreases dopamine synthesis. Caffeine has the opposite 
effect and therefore decreased levels of prolactin could be observed. However, this was not 
observed in the present study as levels between caffeine and placebo groups remained the 
same. This may suggest that the physical stress of strenuous exercise in near real life 
conditions increase prolactin (with increased cortisol levels) and caffeine decreases 
prolactin, therefore, the net effect is no/little change in prolactin levels. However this remains 
to be substantiated by further research. 
 
5.2.1.4 Testosterone 
In the present study, all the testosterone values fell within the reference range (9.9-27.8 nm/l 
for males and 0.22-2.0 nm/l for females). In the caffeine and placebo groups, significantly 
lower values were obtained at the finish line, compared to baseline values in the whole 
group and in the male group. This is in keeping with studies reporting decreased 
testosterone levels during and after endurance exercise (136).  
 
As expected, however there was a significant difference in the testosterone levels between 
males and females. Males had significantly higher baseline and finish line values, with the 
values at the finish line significantly lower than the value measured at baseline.  
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In the female group, there was no difference between baseline and finish line values. Enea 
et al. (2011) found that females had increased testosterone levels during and after 
endurance exercise (135). This was not supported by the current study, in which there was 
no statistically significant difference in the testosterone levels of the female group between 
the baseline and the finish line, although a slight decrease was noted in testosterone levels 
at the finish line. This could in part be due to triathlon being more intensive exercise than 
those described by Enea et al. (2011) (135).    
 
There were also no differences in values between the caffeine and placebo groups. During 
resistance training, caffeine have been found to increase testosterone levels after training, 
although the effect may be diminished by an increased release of cortisol due to physical 
activity and caffeine as a metabolic stressor (152). The introduction of testosterone as a 
covariate had no influence on triathlon performance.  
 
The increased DHEAs levels are consistent with literature indicating that prolonged exercise 
can increase DHEAs and consequently decrease testosterone levels, the observed effect in 
the present study. In addition, in the present study it was observed that testosterone levels 
decreased and cortisol levels increased. Therefore, the effect of caffeine supplementation on 
cortisol is greater than the effect thereof on testosterone levels, suggesting the stimulation of 
the HPA-axis being a primary mechanism of action of caffeine supplementation (in addition 
to the effect on the CNS). If the primary effect was only on the CNS, testosterone levels 
would have increased irrespective of increased cortisol levels. However, due to stimulation 
of the HPA-axis, cortisol levels increased and negated the effect of caffeine supplementation 
on testosterone levels, suggesting that the latter is not the only mechanism of action. 
 
In conclusion, caffeine did not seem to have major effects on the endocrine-stress response 
to exercise, except for cortisol, which increased beyond that of the effect observed from 
endurance exercise in the caffeine, compared to placebo group. Other markers displayed 
gender differences as expected, but no differences were observed in the caffeine and 
placebo groups. Exercise stress resulted in increased levels of cortisol, DHEAs and prolactin 
and decreased testosterone levels. Furthermore, caffeine supplementation exacerbated this 
response by further elevating levels of cortisol, suggesting a combined effect of the central 
and autonomic nervous system on the ergogenicity of caffeine supplementation.  
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5.2.2 Oxidative-stress 
Fifty to sixty per cent of circulating leukocytes are neutrophils, which are known as the first 
line of defence against infectious agents. Neutrophils release reactive oxygen species (ROS) 
and antimicrobial enzymes (133). Strenuous exercise, for example a triathlon race, can 
promote oxidative stress. It was therefore important to measure the total and differential 
leukocyte count to assess whether caffeine supplementation had an effect on this first line of 
defence after exercise.  
 
5.2.2.1 White blood cell (WBC) count  
White blood cells, also known as leukocytes, are mainly responsible for defending the body 
against foreign entities, such as bacteria, parasites and viruses. White blood cells can be 
divided further into the differential white cell count, which includes lymphocytes, monocytes, 
neutrophils, eosinophils and basophils. Lymphocytes are also termed immunocytes and are 
primarily responsible for the body’s immune response against infections. Monocytes leave 
the circulation, enter tissues and develop into macrophages. Macrophages, monocytes and 
neutrophils are known as phagocytes, due to their ability to engulf and ingest foreign 
particles and thereby destroy these. Neutrophils, eosinophils and basophils form part of the 
granulocytes, as the cytoplasmic content of these cells gives it a granular appearance (5).  
 
Both the absolute number of WBC and the relative proportions of the different types of WBC 
in the circulation will change when the body is called to fight foreign entities (5). 
 
The total WBC count should not be interpreted in isolation. The absolute counts of individual 
cell types comprising the WBC count should also be taken into consideration (217). The 
normal reference range for the total WBC count is 4 – 11 X 109/l for males and females. In 
the current study, all the WBC count values (all subjects, males and females) increased from 
baseline to the finish line. All the baseline values fell within the recommended reference 
ranges, but all values measured at the finish line exceeded 11 X 109/l. This increase was 
significantly higher in the caffeine group in all subjects and in the male group. Although not 
statistically significant, there was a trend towards higher WBC count values at the finish line 
in the female group as well. In general, the males also had significantly higher WBC values 
at the finish line, compared to the female group. This increased WBC count observed at the 
finish line and due to caffeine supplementation could be due to exercise and caffeine 
independently being stressors. The WBC count increases when acute inflammation or 
infection is present, as well as in dehydration states. This increased leukocytosis is observed 
primarily due to increased neutrophils and lymphocytes and is a result of the effect of 
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caffeine on the central nervous system or as a result of the effect of caffeine on the 
autonomic nervous system (133), whereby caffeine increases cortisol release after exercise 
(as seen in the present study), the increased cortisol leads to increased neutrophils being 
recruited from bone marrow to the circulation, resulting in leukocytosis and neutrophillia 
(133). 
 
Studies on resistance exercise have found that, with caffeine supplementation, leukocyte 
counts did not increase any more than that resulting from exercise alone (218). Walker et al. 
(2007) also found that caffeine supplementation had no effect on leukocyte count following 
time trial cycling performance (133). 
 
5.2.2.2 Neutrophils 
Neutrophils comprise approximately 70% of the total WBC count. Neutropenia, a low 
neutrophil count, can arise from viral infections, autoimmune diseases, idiopathic causes 
and drug use. It is important to note that non-steroidal anti-inflammatory drugs, regularly 
taken by many athletes, can induce a mild state of neutropenia. In contrast, neutrophillia is a 
state of a high neutrophil count and usually increases within one hour of tissue injury. It is 
the hallmark of acute inflammation and any stressor, including bacterial infections, smoking, 
heavy exercise, nervousness, medication and pregnancy can increase neutrophil counts 
(217). 
 
The normal reference range for the absolute neutrophil count is 2-8 X 109/l. Results from the 
present study indicate increased neutrophil counts for all subjects, and the male and female 
groups at the finish line of the triathlon. Baseline values all fell within the normal range. 
There was a significant increase in the neutrophil count observed in all subjects, and the 
male group at the finish line in the caffeine group, compared to the placebo group. Although 
this was not statistically significant, the females, when receiving caffeine, also had higher 
neutrophil counts when compared to the placebo group at the finish line. There was also a 
significant difference in the neutrophil count values measured between males and females. 
When introducing the neutrophil count as a covariate to determine the influence of this on 
triathlon performance, no significant correlation was found.  
 
Apart from the absolute neutrophil values, the relative proportions of the different types of 
WBC in the circulation will change in response to infection or inflammation (5). It is important 
to consider the relative neutrophil count in the current study; all of the values for the baseline 
relative neutrophil count fell within the reference range of 40-75% of WBC count. All relative 
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neutrophil counts at the finish line in all subjects, and the male and female groups were 
slightly higher than 75% of the WBC count. There was a significant increase in the relative 
neutrophil count from baseline to the finish line in all subjects, and the male and female 
groups; however, this change was not due to caffeine supplementation. There was a 
significant difference in the relative neutrophil count measured at baseline and at the finish 
line between the male and female groups, with females exhibiting consistently higher values 
than males. The relative neutrophil count also had no significant influence on the overall time 
to complete the triathlon.  
 
Neutrophils act by releasing ROS and antimicrobial enzymes to form part of the body’s first 
line of defence against infectious agents. This response is usually decreased after intense 
endurance exercise (219). In the present study, caffeine increased neutrophil counts above 
that observed due to endurance exercise. This is not in keeping with other studies, such as 
the one by Walker et al. (2006) on 90 minute cycling at 70% VO2 max, followed by a time 
trial, which found that caffeine supplementation had no effect on neutrophil counts (132). 
The difference in these results may be due to the exercise protocol in the present study 
being a triathlon, and a race, which implies completing the set amount of work in the fastest 
time possible (i.e. not steady state exercise with a time trial at the end). The extra neutrophil 
counts found in the current study may suggest higher oxidative stress, although other, more 
accurate markers of oxidative stress needed to be studied to confirm this. 
 
The increase in neutrophils also suggests that the primary mechanism of action of caffeine is 
antagonism of the adenosine receptors (133). However, as increased cortisol levels were 
also observed, leukocytosis and neutrophillia could have resulted due to stimulation of the 
autonomic nervous system as increased cortisol increases recruitment of neutrophils from 
bone marrow to the circulation (133). A single study on soccer players reported neutrophillia 
after increased muscle stress resulting from caffeine supplementation and concluded that 
this may increase the risk of muscle damage in athletes (52). This avenue remains to be 
further elucidated since it was not the focus of this study. 
 
5.2.2.3 Lymphocytes 
Lymphocytes normally represent between 20-40% of the WBC count. Lymphocytopenia (low 
lymphocyte counts) can be associated with acquired conditions, such as infectious diseases 
(such as AIDS, viral hepatitis, tuberculosis and typhoid fever), autoimmune disorders, steroid 
therapy, blood diseases (such as Hodgkin’s disease and aplastic anemia) and radiation or 
chemotherapy or due to rare inherited causes (such as Wiskott-Aldrich syndrome, severe 
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combined immunodeficiency syndrome and ataxiatelangiectasia). In contrast, lymphocytosis 
(high lymphocyte counts) can be present due to acute viral or bacterial infections, smoking, 
autoimmune response or acute stress (217).  
 
In the current study, the absolute lymphocyte count values in all subjects, and the male and 
female groups, fell within the recommended reference range of 1.0 - 4.0 X 109/l. There was a 
significant increase in absolute lymphocyte count values between the baseline and the finish 
line in all subjects when receiving caffeine supplementation as well as in the male subjects 
receiving caffeine. However, there was no significant difference in the lymphocyte counts 
between the baseline and finish line in the female group receiving caffeine. None of the 
measurements in the placebo group were statistically significantly different from the baseline 
to the finish line. The increased absolute lymphocyte count measured at the finish line in all 
subjects and the male group, was due to caffeine supplementation.  
 
There was a trend towards higher lymphocyte count values at the finish line in the female 
group receiving caffeine, compared to the placebo group. There were no differences 
between lymphocyte counts measured for males and females. The lymphocyte count also 
did not influence the overall time to complete the triathlon. 
 
The relative proportion of lymphocytes as part of the WBC count should be between 20-
45%. The baseline relative lymphocyte count values fell within this recommended range, but 
finish line values for all subjects, and the male and female groups were below 20% of WBC 
count. The finish line values were also significantly lower than the baseline values, although 
this difference was not due to caffeine supplementation. There was a significant difference in 
the relative lymphocyte count between males and females, with males having consistently 
higher values than females, and the reduction in the relative count from baseline to finish line 
was more pronounced in males than in females.  
 
Our results, which showed an increase in the absolute lymphocyte count at the finish line 
(which was not an effect of altered hydration status), are in contrast to those reported by 
Walker et al. (2006), who found that after steady state and time trial cycling performance, the 
lymphocyte count was significantly lower in the caffeine group, compared to the placebo 
group (132). This may be due to the acute stress of competing in a triathlon race, compared 
to steady state exercise in a controlled laboratory environment. However, in keeping with the 
results from the present study, Bishop et al. 2005 also reported increased lymphocytes 
following a strenuous cycling protocol (220). The observed increase in lymphocyte counts 
can also be attributed to the effect of caffeine on the central nervous system, as seen with 
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increased neutrophil counts in the present study. The total increase in leukocytes may also 
increase muscle stress and the risk of musle damage in athletes (52). 
 
5.2.2.4 Other WBC counts 
Monocytes, eosinophils and basophils are discussed below. To the researcher’s knowledge, 
limited studies exist on these parameters with regard to endurance exercise and caffeine 
supplementation. This study provides new information on the effect of exercise and caffeine 
on these parameters of the WBC count.  
 
Monocytes make up 3 – 8% of the WBC count. Monocytes typically stay in the bloodstream 
for 1-3 days, and are then taken up by tissues and converted to macrophages with a specific 
function as part of the immune system and phagocytosis. Monocytopenia (low monocyte 
count) can be due to acute infections, stress, treatment with glucocorticoids, aplastic 
anaemia, hairy cell leukaemia, acute myeloid leukaemia, treatment with myelotoxic drugs 
and genetic syndromes (221). Monocytosis (high monocyte count) can indicate chronic 
infection or inflammation, especially when elevated with other components of the WBC count 
(217). 
 
All the monocyte values in the present study fell within the recommended reference range of 
0.0 - 1.0 X 109/l. There was a significant increase in the values measured at the finish line, 
compared to baseline values in all subjects, and the male and female groups. This increase 
was only due to caffeine supplementation in the entire group and this effect was not seen 
when evaluating genders apart. There were also no significant difference between monocyte 
values between males and females. The monocyte count did not have an influence on the 
overall time to complete the triathlon. 
 
The reference range for the relative contribution of monocytes to the WBC count is 2-10%. In 
the present study, all groups had relative counts within this range. However, in contrast to 
the absolute monocyte count, which increased from baseline to the finish line, the relative 
monocyte count decreased in all subjects, and the male and female groups. This decrease 
was not due to caffeine supplementation and did not influence the overall time to complete 
the triathlon. There were significant differences between the relative monocyte counts for 
males and females, with males having higher relative counts at baseline and lower relative 
counts at the finish line.  
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Eosinphils comprise 1-6% of the total WBC count. Eosinopenia (low eosinophil count) is 
difficult to determine as the values are normally very low. This is therefore not of clinical 
importance. Eosinophilia (high eosinophil count) can be present in allergic conditions, such 
as asthma or hay fever, as well as in parasitic infections (217).  
 
All eosinophil values fell within the recommended range of 0.0-0.5 X 109/l in the present 
study. There was a decrease in values measured at the finish line, compared to baseline 
values in all subjects, and the male and female groups. However, this decrease was not due 
to caffeine supplementation. There were also no significant differences between values 
obtained for males and females and the eosinophil count had no effect on the overall time to 
complete the triathlon.  
 
The percentage contribution of eosinophils to the total WBC count decreased from the 
baseline to the finish line during the present study. Baseline measurements were well within 
the recommended 1-6% of WBC count, but the finish line measurements were consistently 
below 1% of the WBC count for all subjects, and the male and female groups. This 
difference was not due to caffeine supplementation and is not clinically significant. Relative 
eosinophil counts did not differ significantly between males and females, and did not 
influence the overall time to complete the triathlon.  
 
Basophils are the least common component of the differential WBC count, constituting 0-1% 
of this. The functions of basophils are poorly understood, but these cells are known to play a 
role in phagocytosis and in producing histamine, a mediator responsible for allergy 
symptoms and inflammation. Basopenia (low basophil count) is also difficult to detect, due to 
the already low contribution of these cells to the total WBC count, and is not clinically 
significant. Basophillia (high basophil count) only occurs in rare circumstances (217).  
 
The absolute basophil count fell within the recommended reference range of 0.0-0.2 X 109/l 
in all subjects, and the male and female groups, when measured at baseline and at the finish 
line. There was a significant increase observed from baseline to finish line values in these 
groups. However, this increase in the absolute basophil count was not due to caffeine 
supplementation and did not differ between males and females. The absolute basophil count 
did not influence the overall time to complete the triathlon.  
 
In contrast to the absolute basophil count mentioned above, there was a decrease in the 
relative basophil count from baseline to finish line. This decrease was not due to caffeine 
supplementation and did not differ between males and females. The baseline relative 
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basophil count was above the recommended range (> 1%), but, finish line values returned to 
normal, and were within the recommended range of 0-1% of the total WBC count. The 
relative basophil count did not influence the overall time to complete the triathlon. 
 
Given the known large day-to-day variation in these parameters, the small differences 
reported here are likely not of clinical relevance.  
 
5.2.3 Plasma lactate 
Lactate is a by- or waste product of oxygen-independent glycolysis in the muscle. When 
glucose is broken down to form pyruvate to provide energy in an oxygen-independent 
environment, lactic acid is formed. This readily dissociates to form lactate and hydrogen 
ions. Lactate can then be used during oxygen dependent energy metabolism (as in the case 
with endurance exercise or triathlons) to produce glucose again in the liver via the Cori cycle 
(5). Therefore, lactate, which is derived from muscle, can be a very important gluconeogenic 
antecedent and a valuable metabolic intermediate, rather than just being a by-product of 
oxygen-independent glycolysis (222). In a review by Robergs et al. (2004) on the 
biochemistry of exercise-induced metabolic acidosis, it was concluded that, “an increased 
lactate production coincides with cellular acidosis and remains a good indirect marker for cell 
metabolic conditions that induce metabolic acidosis. If muscle did not produce lactate, 
acidosis and muscle fatigue would occur more quickly and exercise performance would be 
severely impaired” (223). 
 
All lactate levels, with the exception of baseline measurements in all subjects and the male 
caffeine group were, as expected during exercise, were well above the reference range for 
blood lactate levels (> 1.0-1.8 mmol/l). There were significant differences between the 
caffeine and placebo group in all subjects during transition (cycle → run) and 9 and 12 
minutes after the finish line, as well as in the male group during transition (cycle → run) and 
at 3 minutes after the finish line. There was an overall significant difference between lactate 
levels measured at various time points in the caffeine and placebo groups. The caffeine 
group had lower baseline values, which increased more during transition and 3 minutes after 
the finish line, and then showed a steady decline but were still higher than the values in the 
placebo group. In the placebo group there were higher baseline values, which increased 
more gradually during exercise, then declined faster after the finish line and subsequently 
increased again from 12 and 15 minutes after exercise. There were no differences in lactate 
measurements between males and females and none of the measurements taken 
influenced the overall time to complete the triathlon. 
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These results are in agreement with research conducted in 1985 by Gaesser et al. on 
incremental exercise. These authors found that the accumulation of blood lactate is not 
delayed by caffeine supplementation, and it may even increase the onset of blood lactate 
accumulation (224). In contrast, other studies examining the effect of energy drinks 
(containing caffeine) on blood lactate levels found an increase in blood lactate levels two 
minutes before and two minutes after Bruce treadmill tests, but this increase was not due to 
the energy drink (225). McNaughton 2008 reported an increase in blood lactate levels at the 
end of a one hour time trial performance in six male cyclists, irrespective of whether caffeine 
supplementation was administered or not (88). 
 
Therefore, caffeine increases the production of lactate, as seen in the results of the current 
study, where in the caffeine group there was lower baseline levels, which increased more 
during transition (cycle → run) and three minutes after the finish line, where after it showed a 
steady decline after finish line compared to the placebo group that had higher baseline 
levels, levels increased more gradually during exercise, then declined faster at the finish line 
and then displayed an upward curve from 12-15 minutes after exercise. The more drastic 
increase in lactate levels during transition and directly after exercise, can be used as a fuel 
source by converting lactate to glucose (gluconeogenesis) in the liver or to alanine and then 
to glucose in the muscle, thereby maintaining blood glucose levels, reducing fatigue and 
improving exercise performance. The steadier decline seen after exercise can also help to 
maintain blood glucose levels immediately after exercise. 
 
It appears in the present study that the main mechanisms of action of caffeine as an 
ergogenic aid is the effect on the central and autonomic nervous systems, as indicated by an 
increased cortisol response following exercise in the caffeine group, as well as increased 
leukocytosis, neutrophillia and lymphocytosis. The increased plasma lactate levels also 
suggest that the main mechanism of action is due to direct stimulation of the CNS or due to 
the adrenergic effect of caffeine supplementation. However, the latter was not measured in 
the present study.  
 
If we therefore revisit Figure 2.2 (Figure 5.1), we can conclude that the present study had the 
most profound effect on increased cortisol, leukocytes and plasma lactate (blocks shaded in 
blue) and that the effect of increased cortisol or the physical stress of exercise negated the 
effect of caffeine supplementation on testosterone and prolactin levels (blocks shaded in 
pink). 
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Figure 5.1 Mechanisms of action of caffeine supported by the present study’s results 
 
5.3 Factors influencing the ergogenic effect of caffeine 
supplementation 
5.3.1 Lifestyle 
5.3.1.1 Caffeine habituation 
 
Habitual caffeine intake 
In the present study, the mean habitual intake of the triathletes was ± 400 mg/day. This 
group of subjects can thus be classified as high habitual caffeine consumers (≤ 50 mg/day is 
considered low intake, whilst ≥ 300 mg/day is considered high habitual intake) (72) when 
interpreting the mean habitual caffeine intake. It was however noted that the SD was higher 
than the mean habitual intake, indicating that the subjects had a wide range of habitual 
caffeine intake. However, the mean intake is high in terms of the South African population, 
as it has been reported that the average caffeine consumption in South Africa is only 40 
mg/person/day (57).  
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The subjects were asked to abstain from caffeine-containing products for 14 days before 
each trial. Upon analysis of baseline caffeine levels, it is evident that the athletes adhered to 
this pre-race stipulation. 
The current habitual caffeine intake of this group of athletes does not compare to surveys 
done on other athletes. The present study population had a much higher habitual caffeine 
intake than British athletes (70). Chester et al. (2008) investigated caffeine consumption 
amongst British athletes following changes to the 2004 WADA List of Prohibited Substances 
and found that more cyclists used caffeine, compared to track and field athletes. The 
majority of the cyclists, nevertheless, consumed less than 200 mg caffeine per day (70).  
 
The main sources of caffeine in the study by Chester et al. (2008) were coffee, 
pharmaceutical preparations and energy gels/bars/powders. The most common reasons 
given for using caffeine included subjects enjoying the taste, wishing to potentially improve 
sporting performance and using caffeine for work/study purposes (for example to stay awake 
or improve concentration) (70). A study by Desbrow et al. (2006) on caffeine use and 
awareness by triathletes competing at the 2005 Ironman Triathlon World Championships 
revealed that the majority of triathletes planned to use caffeine-containing substances prior 
to or during the race. The most popular of these substances were cola drinks, caffeinated 
gels, coffee and NoDoz® tablets (226, 227).  
 
Although the mean daily caffeine intake found in the present study is higher than that 
reported by Chester et al. (2008), it is comparable to the self-reported mean daily intakes of 
caffeine in six Canadian recreational male athletes (running or cycling five times a week for 
more than three months). This was found to be as high as ± 700 mg/day (26). 
 
3.3.1.2 Influence of the pre-event meal on caffeine absorption 
The pre-event meal in the present study was consistent between the caffeine and placebo 
groups. This was expected as subjects were asked to repeat the same dietary intake before 
and on the day of both triathlons. The pre-event meal had no influence on the absorption of 
caffeine and therefore plasma caffeine levels were not affected by the pre-event meal.  
 
5.3.2 Menstrual patterns, oral contraceptive use and menopause 
Only eight percent (N = 1) of the females in the current study population experienced 
oligomenorrhea in the preceding 12 months. Five of the 12 females (42%) were post-
menopausal. Although the females had a low (< 45 kcal/kg FFM) estEA, it was still > 30 
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kcal/kg FFM and they seemed to reach their energy needs when looking at their energy 
intake. Menstrual dysfunction has been shown to occur at estEA levels of < 30 kcal/kg FFM 
(4). Subtle changes in menstrual function that can only be evaluated with urine or blood 
samples, such as luteal phase defect (LPD) and anovulation can also occur during transient 
times of energy deficit. LPD cycles in athletes are associated with a metabolic hormone 
profile indicative of a hypometabolic state. This is similar to that observed in amenorreheic 
female athletes (228).  
 
All of the pre-menopausal females in the current study used oral contraceptive medication. 
The prevalence of oligomennorhea and amenorrhea might have been higher had they not 
used oral contraceptives to regulate their cycle.  
 
When studying the effect of caffeine supplementation on exercise or sporting performance, it 
is important to note the phase of menstrual cycle (follicular, luteal or post-menopausal), as 
well as the possible use of oral contraceptive medication. Lynch et al. (1998) studied the 
effect of oral contraceptive use and the phase of the menstrual cycle on exercise 
performance (running) in 15 women. The authors found that exercise performance does not 
vary between the mid follicular phase and the late luteal phase of the menstrual cycle and it 
is not affected by oral contraceptive use (229). However, the effect is seen when caffeine 
supplementation enters the equation. Although some studies (230) have reported that the 
menstrual cycle or gender does not affect the pharmacokinetics of caffeine, others have 
reported the effects of the abovementioned parameters on the pharmacokinetics of caffeine. 
Lane et al. (1992) reported that the elimination of caffeine can be decreased in the luteal 
phase of the menstrual cycle, although the extent of this may be small (62). Delayed 
elimination, prolongs the half-life of caffeine, which could lead to increased plasma 
concentrations of caffeine and a greater risk of side-effects.  
 
In the present study, one of the research objectives was to determine if the phase of 
menstrual cycle (luteal or follicular) influenced plasma caffeine levels. The researcher 
determined the phase of the menstrual cycle by calculating the days since the last 
menstruation and using the self-reported length of the menstrual cycle. This is a limitation, 
because the phase of the menstrual cycle was self-reported and not measured. There were 
also no statistically significant differences in the overall time to complete the triathlon, 
regardless of whether the female athletes were in the luteal or follicular phase. This might 
have been a true effect or a type two error since the phases of the menstrual cycle might 
have been misreported. It was, however, interesting to note that although this result did not 
reach statistical significance, the females receiving caffeine supplementation during the 
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follicular phase had an overall faster time to complete the triathlon compared to the females 
receiving the placebo (4% decrease in time). Although it cannot be unequivocally proven in 
this study, the abovementioned finding suggests that during the follicular phase, caffeine 
supplementation has a more beneficial effect on sporting performance than during the luteal 
phase. This could possibly be due to fewer side-effects of caffeine supplementation (that 
could potentially impact exercise performance) being experienced or enhanced caffeine 
metabolism during the follicular phase. 
 
After observing a non-statistically significant 4% decrease in triathlon times for the females in 
the follicular phase compared to the luteal phase of the menstrual cycle, the researcher 
analysed the data according to individuals (Figure 5.2) 
 
 
Figure 5.2 Influence of the phase of menstrual cycle on the time to complete the 
triathlon in the caffeine and placebo groups 
F: Follicular phase, L: Luteal phase, black line indicates mean time to complete in caffeine and placebo groups 
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It is evident from the individual graph presented in Figure 5.1 that all, except for one female 
had a decreased time to complete the triathlon when receiving caffeine supplementation 
during the follicular phase of the menstrual cycle. If one therefore has to draw a conclusion 
or make a recommendation one can say caffeine may be more effective in the follicular 
phase, however, this remains to be substantiated. 
 
Caffeine metabolism may be altered / inhibited in post-menopausal women receiving 
hormone replacement therapy (192). In the current study, menopause did not influence 
plasma caffeine levels. It was, nevertheless, interesting to note that although there was no 
statistically significant difference, the post-menopausal group completed the triathlons on 
average 14-17% (20-30 minutes) slower than the females who had not yet reached 
menopause, irrespective of whether or not caffeine supplementation was given. This could 
have possibly also been related to the age of the post-menopausal females, who were 
typically older than the pre-menopausal females. However, this observation is less likely as 
one of the females who were post-menopausal and > 50 years, won the female race and 
came third overall. 
 
All seven pre-menopausal females used oral contraceptive medication, mainly for birth 
control. Subjects also indicated that they were using an oral contraceptive to regulate their 
cycle in addition to using it for birth control. As with hormone replacement therapy, oral 
contraceptive use has been known to interfere with caffeine metabolism and chronic use 
leads to increased plasma caffeine concentrations (63, 193). The use of oral contraceptive 
medication in the present study did not influence the plasma caffeine levels measured during 
transition (cycle → run) or at the finish line in the caffeine or placebo groups, nor did it have 
an effect on the overall time to complete the triathlon, irrespective of whether or not caffeine 
supplementation was given. 
 
Summarising the influence of menstrual cycle, menopause and oral contraceptive use on the 
ergogenic effect of caffeine supplementation, the self-reported phase of the menstrual cycle 
or oral contraceptive use had no effect on caffeine metabolism or the overall time to 
complete the triathlons. Although not statistically significant, but clinically relevant, we 
observed faster times when the women were in the follicular phase of the menstrual cycle 
whilst receiving caffeine supplementation, when compared with the luteal phase of the 
menstrual cycle. Post-menopausal women also completed the triathlons on average slower 
than pre-menopausal women, irrespective of caffeine supplementation. Oral contraceptive 
use had no effect on caffeine supplementation or time to complete the triathlons.  
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5.3.3 Genetic analysis 
5.3.3.1 CYP1A2*1F (rs762551) single nucleotide polymorphism (SNP) 
The CYP1A2*1F polymorphism has been associated with altered enzyme activity (160). 
Carriers of the CYP1A2*1F C-allele are “slow” caffeine metabolizers, whereas individuals 
who are homozygous for the A-allele (ancestral type) are “rapid” caffeine metabolizers (158, 
231-233).  
 
In the current study, the frequency of the C-allele (0.29, Table 4.12) associated with “slow” 
metabolism of caffeine was similar to the frequency reported for a Turkish population (0.27) 
(234), although slightly lower, than CYP1A2*1F frequencies, reported in Caucasian 
populations, such as in 114 British individuals (0.34) (160, 201), 495 German individuals 
(0.32) (235) and 236 Germans (0.32) (233), and much lower than the frequency reported in 
193 Swedes (0.57) (160, 236), Japanese individuals (0.63) (237) and African populations, 
such as Tanzanians (0.51) and Zimbabweans (0.43) (160, 238). Genotype frequencies of C-
allele carriers in this study (38%) were also lower compared to frequencies reported in 553 
young Caucasian individuals (59%) (232), 236 German individuals (54%) (233) and 35 male 
recreational competitive cyclists (54%) (165). 
 
In the current study, the CYP1A2*1F C-allele did not have a significant effect on plasma 
caffeine levels throughout the triathlons in the caffeine or the placebo groups, nor did it have 
any effect on the overall time to complete the triathlon. Even though this result was not 
statistically significant, those subjects with the A→C substitution had decreased plasma 
caffeine levels during transition (cycle → run) and at the finish line. This is in contrast with 
studies describing that individuals with an A→C substitution are “slower” metabolizers of 
caffeine (and therefore have increased plasma caffeine levels) compared to individuals who 
are homozygous for the CYP1A2*1F A-allele who are “rapid” metabolizers of caffeine (158).  
 
A recent study by Womack et al. (2012), evaluated CYP1A2*1F (rs762551) and its effect on 
6 mg/kg body weight caffeine supplementation and sporting performance in 35 well-trained 
male cyclists. These authors concluded that the time to complete a 40 km cycle was 
shortened in the A/A homozygotes, illustrating “rapid” caffeine metabolism and therefore 
increased exercise performance (165, 239). This is in keeping with current literature on this 
SNP, indicating that individuals who are homozygous for the CYP1A2*1F A-allele are “rapid” 
metabolizers of caffeine (158, 165, 240). Womack et al. (2012) speculated that the 
ergogenic effect found in “rapid” metabolizers of caffeine may be due to the fact that two of 
the metabolites of caffeine, paraxanthine and theophylline have higher binding affinities with 
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adenosine receptors. Therefore, if an individual metabolized caffeine more rapidly, 
paraxanthine and theophylline is produced more rapidly, leading to the enhanced ergogenic 
effect (165).  
 
5.3.3.2 CYP1A2*1D (rs35694136) single nucleotide polymorphism (SNP) 
CYP1A2*1D is one of the most extensively studied polymorphisms and has been associated 
with lower CYP1A2 enzyme activity. The frequency of the -2467T deletion is lower in 
Caucasians compared to Asians and Africans (160). The allelic frequency of *1D deletion 
allele is 0.05-0.24 in Caucasians (160, 201). The -2467delT appears much more frequently 
in Japanese populations (0.42-0.44) (160, 237, 241), in Egyptians (0.40) (160) and is very 
high in Turkish populations (0.92) (160, 242). In the present study group, which consisted 
solely of Caucasians, the -2467delT frequency (0.08) corresponded with that reported for 
other Cuacasian populations. There were no significant differences in the plasma caffeine 
levels measured during transition (cycle → run) or at the finish line, regardless of the 
presence of -2467delT. The presence of this deletion also did not have an influence on the 
overall time to complete the triathlon.  
 
5.3.3.3 CYP1A1-CYP1A2 (rs2472297-T and rs2470893-A) and the variant near 
the AHR gene (rs698865-T) 
Allele frequencies for all three SNPs, rs247229-T, rs2470893-A and rs698865-T, 
corresponded to that determined in Cuacasian populations  
(http://www.ncbi.nlm.nih.gov/projects/SNP/). 
 
CYP1A1 and CYP1A2 activity is co-regulated. Although the effects of CYP1A2 on caffeine 
metabolism have been studied extensively and is well established, the role of CYP1A1 in 
caffeine metabolism has not been verified (163). The aryl hydrocarbon receptor (AHR) 
induces members of the CYP1A1 and CYP1A2 family and is known to induce the activity of 
CYP1A1 and CYP1A2 by binding to DNA in the region between these two genes (163). 
 
CYP1A2 enzyme activity is increased in habitually high coffee consumers. It is known that 
lower activity of this enzyme can increase caffeine toxicity as this is the key enzyme 
responsible for caffeine metabolism. However, in the case of rs247229 and the SNP near 
the AHR gene, individuals can consume more caffeine without experiencing toxic or negative 
side effects, due to increased CYP1A1 and CYP1A2 enzyme activity; this increased enzyme 
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activity enhances the rate of caffeine metabolism, which leads to lower plasma 
concentrations of caffeine (163). 
 
In the current study, rs2472297-T, rs2470893-A alleles and the variant near the AHR gene 
(rs6968865-T) did not have any effect on plasma caffeine levels during transition (cycle → 
run) or at the finish line. None of these variants influenced the overall time to complete the 
triathlon.  
 
As discussed in the literature overview, a large interindividual variation in expression and 
activity of CYP1A2 exist. This has a direct influence on the clearance of drugs, such as 
caffeine, which is extensively metabolized by CYP1A2. Various genetic factors, such as 
epistasis, i.e. the effects of one gene being modified by several other genes, epigenetic 
factors, i.e. heritable changes in gene expression or cellular phenotype caused by 
mechanisms other than changes in the underlying DNA sequence, subcellular factors and 
intranuclear positioning of regulatory genes as well as environmental factors (such as 
smoking and use of medication) influence the expression and acitivity of CYP1A2 (162). This 
can partially explain this interindividual variability and the inconsistencies reported in genetic 
associations. It is unlikely that the metabolic phenotype can be predicted from a single SNP 
or haplotype. There are also distinct interethnic variations in CYP1A2 activity (162). 
 
Therefore, in this study, neither CYP1A2 gene polymorphism nor a variant near the AHR 
gene influenced caffeine supplementation’s effect on triathlon performance. This could have 
been due to the limited sample size or the fact that the effect is not easily discernible during 
a triathlon. In the present study, the “slower” metabolizers of caffeine did not experience a 
lesser effect of the caffeine supplementation.  
 
In conclusion, habitual caffeine intake did not affect caffeine ergogenicity in the present 
study as subjects abstained from caffeine intake for two weeks prior to both trials. It appears 
that caffeine supplementation may be more effective during the follicular phase of the 
menstrual cycle and that genetics does not influence caffeine supplementation’s 
ergogencity, although these results remain to be substantiated in a larger cohort.  
 
5.4 Factors influencing triathlon performance 
5.4.1 Medical history and supplement use 
The overall health of the study population was good, with few reported chronic diseases or 
chronic medication usage. Supplement use amongst the athletes was rife, with 85% of the 
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subject group taking some form of dietary supplementation. The most common reasons 
given for the use of supplements, namely to prevent illness, because of inadequate diet and 
to enhance exercise performance, coincided with the type of supplements used most 
frequently (multivitamins- and mineral formulations, and energy drinks and bars). The 
prevalence of supplement use is higher in the present study, compared to a survey by Dolan 
et al. (2011) on 401 triathletes. The authors found that 54% of triathlete’s surveyd use 
supplements, of which 21% use caffeine supplementation (243). 
 
The supplements most frequently consumed by the current study population are relatively 
low-risk supplements (i.e. low risk for potential adverse physiological effects, testing positive 
for banned substances or the potential for dependence, addiction or abuse). It is important to 
note that supplements and sports foods are widely used by physically active individuals, 
most often to improve exercise performance and overall health, or to improve or change 
parameters of body composition. It is important when evaluating and prescribing the use of 
supplements to judiciously consider the risk/benefit ratio of using a particular supplement.  
 
In South Africa, the dietary supplement market is currently poorly regulated by the Medicines 
Control Council. The widespread use of supplements, the fact that many products are readily 
available for sale directly to customers over the Internet and the possible contamination of 
dietary supplements, both directly and indirectly, further increase the potential for irrational 
drug use. The safety, purity, efficacy and proven benefit of supplements should be evaluated 
before use. Problems encountered with supplements and complementary medicines include, 
but is not limited to the following: i) all active pharmaceutical ingredients in the formulation 
may not have been identified and the dosages of these measured accurately and 
standardised; ii) these dosages may not be appropriate (for example high dosages of certain 
vitamins); iii) it can be difficult for consumers to assess whether doses are appropriate 
because of inadequate labelling; iv) lack of awareness amongst consumers about the need 
to check dosages and ingredients; v) the misconception that if something can be obtained 
without a prescription it is “safe”; vi) consumers may be taking more than one product and 
there may be duplication of ingredients which could result in toxicity; vii) a supplement could 
be inappropriate for a particular person due to co-morbidities or other medical conditions; 
and viii) there may be drug interactions between supplements and other medication taken.  
 
Currently, the World Anti-Doping Association (WADA) does not distinguish between 
deliberate cheating and inadvertent doping and the responsibility is solely the athlete’s (170, 
186).  
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Finally, although there are some supplements that may have a beneficial effect on athletic 
performance, for example carbohydrate supplements, it should be noted that no amount of 
supplementation can compensate for a poor diet (170). 
 
To summarize, the subjects had an overall good medical history, except for the prevalence 
of low BMD and osteopenia, which was found during the data collection. Supplement use 
was rife amongst the subjects. Supplement use included low risk supplementation such as 
carbohydrate-electrolyte solution, liquid meal replacements and multivitamin –and mineral 
supplements. The supplements used were quantified with the dietary intake, and even with 
supplement use, the dietary intake of this group was still inadequate for total energy and 
CHO intake as discussed below. 
 
5.4.2 Full blood count 
The heamatocrit and haemoglobin levels were also measured to detect any changes in 
plasma volume. The red blood cell counts, haemoglobin level and related indices reveals 
whether an individual is anaemic, whilst the white blood cell (WBC) count indicates whether 
an infection is present (5). 
 
Red blood cells, also known as erythrocytes, are mainly responsible for transporting oxygen 
and carbon dioxide between lungs and tissues. Haemoglobin is the oxygen-carrying pigment 
of RBC and the heamatocrit is the total blood volume packed with red blood cells. The 
heamatocrit is also known as the ratio of red blood cells to plasma and is expressed as a 
percentage of total blood volume. Platelets meanwhile are instrumental in coagulation or 
blood clotting (5).  
 
Interpretation of the red blood cell (RBC) count in isolation is not recommended or clinically 
significant. This needs to be interpreted in combination with the haemoglobin and 
heamatocrit values, and other components of the RBC count (217). RBC values obtained in 
the present study fell within the reference ranges (4.5-6.6 X 1012/l for males and 3.8-5.8 X 
1012/l for females). There was a significant reduction in RBC count from the baseline to the 
finish line, but this difference was not due to caffeine supplementation. There were no 
differences between RBC count values in males and females, and the RBC count did not 
influence the overall time to complete the triathlon.  
 
A decrease in haemoglobin is clinically used to define or diagnose anaemia, although further 
analyses of components of RBC are necessary to confirm this. Increased haemoglobin 
Stellenbosch University http://scholar.sun.ac.za
192 
 
levels are indicative of changes in plasma volume due to dehydration, alcohol use, smoking 
and the use of diuretics (217). In the present study, the haemoglobin values measured at 
baseline and at the finish line fell within the reference range (13.0-18.0 mg % for males and 
11.5-16.5 mg % for females). Therefore, the athletes in the current study were unlikely to 
have anaemia, especially as their iron intake as discussed with the dietary intake, was also 
above the DRI.  
 
There were no differences in values obtained at baseline and at the finish line, irrespective of 
caffeine supplementation and gender. The haemoglobin levels also had no influence on the 
overall time to complete the triathlon. 
 
In the present study, all heamatocrit values fell within the reference range (40-54% for males 
and 38-47% for females). There was a significant decrease in the heamatocrit values 
between the baseline and the finish line in all subjects, and the male and female caffeine 
groups. In the placebo group, there was only a significant decrease between baseline and 
finish line values in the male group. The decreases observed between the baseline and 
finish line values in the caffeine group were not due to caffeine supplementation and were 
present irrespective of gender. The heamatocrit values did not influence the overall time to 
complete the triathlon. 
 
A low platelet count, or thrombocytopenia, increases the risk of bleeding. This low count can 
be present due to viral infections, idiopathic causes, liver disease, medication, pregnancy 
and autoimmune diseases. Increased platelet counts or thrombocytosis appear in reactive 
conditions such as infection, inflammation, pregnancy and iron deficiency (217). The 
reference range for the platelet count is 150-400 X 109/l.  
 
The platelet count of all subjects, and the male and female groups fell within this range at 
baseline and at the finish line. There was, however, a significant increase in the platelet 
count from baseline to the finish line in all these groups. This increase was not due to 
caffeine supplementation and may instead have been due to exercise-induced infection or 
inflammation. This is also supported by increases in WBC count and more specifically the 
neutrophil and lymphocyte counts, although the latter was more significantly higher in the 
caffeine compared to placebo group. The abovementioned increase in the platelet count did 
not differ between genders. The platelet count did not influence the overall time to complete 
the triathlon.   
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5.4.3 Mood state 
Subjects completed a shortened version of the POMS questionnaire during the week before 
T1 and T2. This was completed to determine whether or not subjects had adequately 
recovered between the two exercise trials. When comparing the total scores, there were no 
differences between T1 and T2, which suggests that the subjects had adequate time 
between the two trials to recover fully. There were also no differences between the vigour 
and tension scores between T1 and T2. There was, however, a difference between the 
fatigue scores the week before T1 and T2, with females being more fatigued the week 
before T1 and males being more fatigued the week before T2. However, none of these 
scores measured during the week before T1 or T2 influenced the overall time to complete T1 
or T2. This confirms that subjects had recovered adequately between the two trials.  
 
To summarise, the mood state of the athletes was measured to determine if the athletes had 
sufficiently recovered between T1 and T2 and to measure the effect of caffeine 
supplementation on mood state. The 14 days between T1 and T2 allowed sufficient time for 
the athletes to recover fully between T1 and T2. 
 
5.4.4 Energy- and nutrient intake two days before as well as dietary 
strategies followed on race day 
5.4.4.1 Dietary intake two days before T1 and T2 
 
Energy and estimated energy availability (estEA) 
The daily energy requirements for athletes doing moderate intensity training 2-3 hours per 
day, 5-6 times per week, such as the training undertaken in this study population, is 50-80 
kcal/kg BW (170). The American Dietetic Association (ADA) and the American College of 
Sports Medicine (ACSM) recommends including enough energy to maintain optimal body 
weight and support exercise performance (183). The total energy intake of the athletes in 
this study group is therefore slightly low according to the abovementioned guidelines. The 
average energy intake of T1 and T2 was 37.7 kcal/kg BW for all subjects and 34.9 kcal/kg 
BW and 40.9 kcal/kg BW for males and females respectively. Therefore, the males had a 
much lower energy intake compared to the females. 
 
The total energy intake (kcal/kg BW) was lower in males than in females. There was no 
significant difference between the total energy intake two days before T1 and two days 
before T2, suggesting adherence to the experimental protocol, as subjects were asked to 
Stellenbosch University http://scholar.sun.ac.za
194 
 
consume the same foods that they would usually eat before a race and to repeat this before 
T1 and T2. The total energy intake two days before T1 and T2 also had no influence on the 
overall time to complete T1 or T2.  
 
The energy intake, when measured in kcal/kg BW as mentioned above was insufficient 
according to the guidelines. This is important to note, as athletes need more energy- and 
macronutrients in proportion to their body weight expressed in kilograms than sedentary 
individuals. Therefore, according to the ADA, “expressing energy- and macronutrient needs 
in terms of grams per kilogram body weight is a practical method to document these needs” 
(183).  
 
However, when comparing the energy intake in kilojoules (kJ) per day with the energy intake 
found in other studies, it seems similar. The athletes in the present study had an average 
energy intake of 10737.3 kJ, with males 10945.2 kJ and females 10500.0 kJ/day. The total 
energy intake is the same as reported in the literature on triathletes for females (Worme et 
al. (1990) 9058 kJ and Potgieter et al. (2011) 9004 kJ, but lower for males (Worme et al. 
(1990) 11591 kJ and Potgieter et al. (2011) 14535 kJ (71, 244). 
 
As discussed in the literature review, the International Olympic Committee (IOC) 
recommended in its 2003 and 2010 consensus statement on sport nutrition that estimated 
energy availability (estEA) is a better indication of an athlete’s energy status than energy 
balance (4). Calculating estEA can identify those athletes at risk of being energy deficient. 
Several physiological responses are adversely affected by a low estEA (< 30 kcal/kg FFM).  
Physiological responses known to be affected by a low estEA include a physically active 
female’s menstrual cycle, which could result in reproductive dysfunction (4); the immune 
system functioning (4, 245, 246) and bone health (247). The estEA should therefore be at 
least 30-45 kcal/kg FFM in order to sustain exercise and promote good health (4).  
 
The group of athletes in the current study population had a mean estEA of less than 30 
kcal/kg FFM, with males between 20-25 kcal/kg FFM and females between 33-37 kcal/kg 
FFM. The range of estEA was wide, with only 30.7% (8/26) athletes having an estEA > 30 
kcal/kg FFM. Sixty-nine percent (18/26) of athletes had a low estEA, of which 44.4% (8/18) 
had an estEA < 20 kcal/kg FFM and 16.6% (3/18) an estEA < 10 kcal/kg FFM. Furthermore, 
78.6% (11/14) of the males were identified with a low estEA compared to 58.3% (7/12) of the 
females.  
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This was interesting to note, as the athletes were supposed to have a high energy intake 
(possibly due to CHO-loading) and low exercise energy expenditure as they were tapering 
down their exercise before the races.   
 
However, the low estEA could have been due to various other factors. First, although the 
estEA in the present study was low when calculated for “low” or tapering training days and the 
subjects were instructed to refrain from exhaustive exercise for the two days leading up to 
the races, the ideal time period to calculate the estEA is seven days to account for high- and 
low volume training days. Second, the activity of daily living was calculated in the formula to 
determine estEA. The METs value used to represent general daily living is based on the 
assumption that these athletes typically would do, as they did not keep an exercise log of 
daily activities, but only of planned exercise. Third, the record keeping of their planned 
exercise and food intake was done with a food record. Although the food record have 
numerous advantages, such as not relying on an individual’s memory and that it can provide 
a detailed account of a subject’s intake and exercise habits, it does have a high subject 
burden and subjects may have changed their usual eating and training routines because 
they knew they were being monitored.   
 
With this said, the estEA in the present study was low for the total group. Differences found 
between estEA of males and females can be attributed to the females reporting a higher 
energy intake compared to males.  A low estEA is reversed by increasing energy intake to 
match daily energy expenditure and reduced training is not always needed (206). The 
reason for this is because the consequences of a low estEA are not necessarily due to stress 
or exercise, but rather the energy cost of exercise. Therefore, increasing energy intake or 
decreasing training, can alone, or in combination lead to more favourable estEA and 
ultimately decrease the negative consequences associated with a low estEA (206).  
Carbohydrate 
CHO requirements for physically active individuals (moderate-high intensity training, 2-3 
hours per day, 5-6 days per week endurance programme and moderate-high intensity, 1-3 
hours/day) range between 5-8 g/kg BW (170) and 6-10 g/kg BW (169, 183). However, as 
dietary intake in the present study was measured in the two days before T1 and T2, it was 
expected that the athletes would be CHO loading, as the events lasted longer than 90 
minutes. CHO loading is a strategy designed to optimize muscle glycogen stores prior to 
endurance events lasting longer than 90 minutes (168). This strategy has been proven to 
enhance performance during endurance exercise, work output and immunity; and to 
maintain muscle tissue stores (174). The CHO loading regime is complemented by including 
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a pre-event meal rich in CHO before the race, as well as optimal CHO intake during the 
event (174). CHO loading requirements range from 8-10 g/kg BW for 1-3 days prior to the 
event (174) to 7-12 g/kg BW for 24 hours prior to the event (169).  
 
The athletes in the present study did not achieve the abovementioned recommended daily 
CHO requirements and also did not meet the recommendations for CHO loading, as they 
had a mean intake of 4-5 g/kg BW for all subjects, < 4 g/kg BW for the males and 4.5-5.5 
g/kg BW for the females. This is of concern, as literature has indicated the significant value 
of increasing CHO intake in the days leading up to an endurance event and its effect on 
increased endurance performance during events lasting > 90 minutes by 2-3% over a set 
distance, due to the super-compensation of muscle glycogen stores (168, 169, 248).   
 
Although not measured in the study, a subjective observation in the present study population 
was that the male athlets were more aware of their body composition and in general more 
focussed on dietary intake. This could in part explain why the males had a lower dietary 
intake compared to the female group. The lower CHO intake in the male group is consistent 
with results from Frentsos et al. (1997) amongst elite triathletes (4.0 g/kg BW) (240), but 
differed from results reported by Potgieter et al. (2011), 5.3 g/kg BW (61), Nogueira et al. 
(2004), 4.5-11.3 g/kg BW (241) and Worme et al. (1990), 5.1 g/kg BW (235). The CHO 
intake of the females were in keeping with CHO intakes found by Nogueira et al. (2004) in 
endurance athletes, 4.4-7.2 g/kg BW (241) and Worme et al. (1990) in 21 female triathletes, 
4.9 g/kg BW (235), but higher than the CHO intake of triathletes reported by Potgieter et al. 
(2011), 3.5 g/kg BW (61). 
 
If CHO-loading requirements are not met, athletes should nevertheless aim to reach the 
requirements for daily CHO intake. The CHO intake of the whole group, and of the males 
and females, did not differ between T1 and T2, but it was evident that the CHO intake 
positively influenced the overall time to complete the triathlon (increased intake improved 
time to complete), reaching statistical significance in the male group for T2. It is interesting to 
note that the CHO intake influenced the performance of the male subjects, who generally 
had a lower CHO intake. Therefore, a practical recommendation to these athletes would be 
to increase their CHO intake in the two days leading up to a race, as this can improve their 
triathlon performance. 
  
The DRI of fibre is 20-30 g/day (176). The group had a fibre intake of 22-27 g/day, which 
falls within the recommended reference range, with males having slightly higher fibre intake 
than females. This is in keeping with the previous results from Potgieter et al. (2011), where 
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the male group had a fibre intake of 26.7 g/day and the female group 22.2 g/day (71). Fibre 
intake did not differ before T1 and T2, but influenced the overall time to complete both T1 
and T2. A higher fibre intake was associated with a shorter time to complete the triathlons, 
especially T2. It does however seem that the effect was rather due to the intake of CHO, 
than the intake of fibre, as those that chose to eat CHO, chose food items high in fibre such 
as oats and brown bread. There is also evidence from the literature that a high CHO diet can 
reduce ad libitum energy intake, due to its appetite suppressing nature. This appetite 
reducing effect might be related to its fibre content (4). The relative high fibre intake of our 
athletes might have had an appetite suppressive effect contributing towards low energy and 
CHO intakes. This is, however, purely speculative as we did not measure appetite or hunger 
ratings. The high fibre intake is also in contrast with recommendations that CHO-loading 
should contain mostly high glycaemic index CHO, low fibre/residue CHO-rich foods (168, 
169, 174). This association between a higher fibre intake and a decreased time to complete 
the triathlons could also have been a coincidence because of the many variables studied 
and the relatively small sample size. 
Protein 
The protein intake in the present study ranged from 1.5 – 2.0 g/kg BW, and was higher in the 
female group (1.7 – 2.0 g/kg BW) compared to the male group (1.4 g/kg BW for both T1 and 
T2). It is recommended that athletes performing moderately intense training have a protein 
intake ranging from 1.0-1.5 g/kg BW (170, 249) or 1.2 – 1.7 g/kg BW (183). The protein 
intake in the total group was therefore sufficient, if not slightly high, especially for the female 
group. The protein intake did not differ between T1 and T2.  When comparing the protein 
intake of the current study group to the habitual protein intake of triathletes reported in the 
literature, it falls within the same ranges as reported by Potgieter et al. (2011), (1.95 g/kg BW 
for males and 1.2 g/kg BW for females) (61), Nogueira et al. (2004), (1.2-2.0 g/kg BW for 
males and females) (241) and Worme et al. (1990), (1.4 g/kg BW for males and females) 
(235). 
Fat 
Dietary fat requirements are similar in physically active individuals compared to their non-
physically active counterparts. It is important for athletes to consume adequate amounts of 
fat in order to achieve optimal health, replenish intramuscular triacylglycerol stores after 
exercise and to ensure adequate intake of essential fatty acids and the fat soluble vitamins 
A, D, E and K (170, 183). According to the ISSN, fat requirements range from 30-50% of 
total energy and can also be calculated in g/kg BW (0.5-1.5 g/kg BW). It is recommended 
that when an athlete is attempting to reduce his/her body weight, fat intake should be 
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decreased to 0.5-1.0 g/kg BW (170). The ADA and ACSM recommend a daily fat intake of 
20-35% of total energy intake, and that this fat intake should consist of 10% 
monounsaturated fatty acids, 10% polyunsaturated fatty acids and 10% saturated fatty acids 
(183).  
 
The group of athletes in the present study had a daily fat intake of 1.2-1.4 g/kg BW (30-35% 
of total energy), with males at the lower end and females towards the higher end of this 
range. This is in accordance with the abovementioned daily fat intake recommendations of 
the ISSN, ADA and ACSM. The fat intake did not differ between T1 and T2, nor did it have 
an influence on the overall time to complete T1 or T2. The fat intake of the current study 
group compares to the results from Potgieter et al. (2011), which found a total fat intake of 
29.8% for females and 34.6% for males (71). 
Alcohol 
The alcohol intake differed significantly before T1 and T2 in the male group. However, the 
alcohol intake in the male group before T1 and T2 still fell below the prudent dietary 
guidelines of 10-20 g/day. Alcohol intake also did not influence the overall time to complete 
T1 or T2. The average alcohol intake of T1 and T2 in the present study (8.5 g/day for all 
subjects, and 12.3 g/day and 1.4 g/day for males and females respectively, is in line with the 
results from Potgieter et al. (2011), who found habitual alcohol intakes of 14.9 g/day and 2.9 
g/day for males and females respectively (71).  
Micronutrients  
Two micronutrients, namely calcium and iron are of particular relevance in this study 
population. The micronutrient content of supplements were not quantified, therefore, it 
should be noted that, in some cases, calcium and iron inake may even be higher due to the 
use of supplements.  
Calcium and the calcium: protein ratio is important for bone health, while sufficient dietary 
iron intake is important to reduce the risk for iron deficiency anaemia which is associated 
with decreased aerobic capacity and could thus influence sporting performance. 
 
Calcium is essential for numerous processes in the body, such as the maintenance, growth 
and repair of bone tissue; the maintenance of blood calcium levels; muscle contraction; 
nerve conduction and blood clotting (183). A decrease in calcium intake can lead to an 
increased risk for developing low BMD, osteopenia or osteoporosis (183). As these 
parameters were studied in the current study population, it was necessary to evaluate the 
subjects’ calcium intake as well. When grouping males and females together, the subjects 
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consumed adequate amounts of calcium (1000-1500 mg/day), when compared to DRIs of 
1000-1200 mg/day (176). When males and females were evaluated independently, the 
males had a lower calcium intake, as mean calcium levels in this group were below 1000 
mg/day. These levels were however, still above 67% of the DRI and therefore adequate. The 
females, had a mean calcium intake of 1200-2200 mg/day, which is also adequate when 
compared to the DRI of 1000-1200 mg/day (176). These results are slightly different from 
those found in 2011 by Potgieter (1250.4 mg/day and 968.1 mg/day for males and females 
respectively) (71). Guezennec et al. (1998) found that in 10 737 school children, college 
students, military personnel and athletes registered in sports federations (age range 7-50 
years), the mean calcium intake was 1242±842 mg/day but that 50% of the population 
consumed < 1000 mg calcium per day (250). 
 
When evaluating bone health, it is also fitting to monitor or evaluate the calcium:protein ratio, 
which should be 20 mg of calcium for each gram of protein consumed (i.e. 20:1) (204). In the 
current study, the subjects had a higher than recommended protein intake but an adequate 
calcium intake. This led to a low calcium:protein ratio of 10:1 in all subjects, 9:1 for males 
and 10-12:1 for females.  
 
This low calcium:protein ratio is concerning as an increased animal protein intake is 
associated with increased urinary calcium excretion, thus if adequate dietary calcium is not 
ingested suffient amounts of dietary calcium will not be available for bodily functions such as 
bone mineralization (251). On the other hand, intake of sufficient amounts of dietary protein 
is also important to provide substrate for bone matrix as well as to stimulate insulin-like 
growth factor-1 (IGF-1) needed for osteoblast-mediated bone turnover (252) and therefore, 
both nutrients should be ingested in the correct amounts. Athletes should be educated on 
increasing dietary calcium intake further as their protein intake increases, as many already 
have low bone mass.  
 
Sufficient iron intake is also important, especially for endurance athletes, as iron is needed to 
form haemoglobin and myoglobin, as well as enzymes important for energy production (183, 
253) . The oxygen-carrying capacity of iron is particularly important for endurance athletes, 
and for normal functioning of the nervous and immune systems. Iron deficiency is common 
in athletes, especially in females with a low energy intake. Such a deficiency can severely 
reduce muscle function and exercise capacity (183, 253). Haymes et al. (1989) found that in 
11 female distance runners, 12 sprinters and 11 moderately active females that low levels of 
ferritin is more common amongs distance runners than sprinters (254). 
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In the present study, the subjects had a total iron intake of 17 mg/day; the male group had a 
mean intake of 20 mg/day and the female group a mean intake of 14 mg/day. These daily 
intakes are sufficient when compared to the DRI’s for iron (6-8 mg/day for females and 8-18 
mg/day for males) and is in accordance with previous results from Potgieter et al. (2011) on 
triathletes (21.5 mg/day and 14.9 mg/day for males and females respectively) (71). 
 
It was expected that the daily iron intake for both male and female subjects would be 
adequate, as the subjects’ protein intake was sufficient, if not abundant, in the two days 
leading up to T1 and T2. Protein-rich foods are good sources of especially heam-iron, which 
has a high bioavailability (255) and the athletes in the present study had an adequate protein 
intake.  
 
The subject’s diets were characterised by protein being one of the most widely-ingested food 
groups, with chicken, eggs, red meat, peanut butter, low-fat milk and yogurt, and tuna, all 
good sources of protein were amongst the top 15 most consumed food items. 
 
It has been reported that an iron deficiency is common among female runners. Reasons why 
iron deficiency is more prevalent among female runners include that they often consume an 
inadequate dietary intake of protein and vitamin C, a high dietary intake of fibre, which 
interferes with iron absorption and the increased losses through menses and losses through 
sweat (256), which is not the case in the current study population. The females consumed 
adequate if not slightly elevated amounts of protein, normal intakes of dietary fibre, had 
normal haemoglobin levels and the females also reported mostly normal menstrual function, 
thereby reducing their risk for iron deficiency anaemia.  
Characteristics of dietary intake two days before T1 and T2 
It is also important to consider the characteristics of the dietary intake in the two days before 
T1 and T2 as not only the total energy- and nutrient content is important, but also consuming 
the right amount of foods from a variety of food groups. The subjects, on average, ate 6-7 
meals per day, as per prudent dietary and food-based dietary guidelines. Although the CHO 
intake was lower than the recommendations for athletes, the most widely-consumed food 
groups were starch and protein, with the top 15 food choices including oats, brown bread, 
rusks, fruit, pasta, pizza, red meat, chicken, tuna, eggs, and low-fat milk or yogurt. Reasons 
why the athletes had a low CHO intake, may have been due to small portion sizes, to keep 
body weight low before the race, to avoid gastrointestinal discomfort before the race or 
because of insufficient knowledge regarding the benefits of increasing CHO intake in the 
days leading up to a race.  
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It was also interesting to note that the drink consumed most often by the subjects was 
rooibos tea. This may have occurred due to caffeine/coffee abstinence being a requirement 
of the study. It was evident from the food groups chosen, that the subjects enjoy a diet low in 
fat and high in protein, with the exception of pizza, which was eaten quite often. Lastly, the 
CHO foods chosen were mostly high in fibre, which is in accordance with prudent guidelines 
(257).  
 
5.4.4.2 Pre-event dietary intake before T1 and T2 
It is recommended that the CHO intake for a pre-event meal be between 1-2 g/kg BW, 3-4 
hours before the event (174) or 1-4 g/kg BW, 1-4 hours before the event (169). Low to 
moderate glycaemic index (GI) foods may be beneficial as part of a pre-event meal, if 
athletes do not consume CHO during the exercise. However, the effect of the pre-event GI is 
diminished as soon as CHO are ingested during subsequent exercise. Individual tolerance to 
the type and amount of CHO and preference of the type of CHO is important in order to 
ensure gastrointestinal comfort and optimal exercise performance (168).  
 
According to the latest ISSN recommendations, protein should be added to the pre-event 
meal. The recommendation is to include 0.15-0.25 g/kg BW protein with the recommended 
1-2 g/kg BW CHO, 3-4 hours before an event (174). 
 
Most of the subjects (85%) ate a pre-event meal the morning of the triathlons. The most 
commonly-consumed foods were bananas, oats (50-100g) and brown bread (1-2 slices) with 
peanut butter. This pre-event meal was sufficient with regards to protein content (0.2 g/kg 
BW and 0.1 g/kg BW for males and females respectively), but the CHO content was 
inadequate (< 1 g/kg BW for all subjects, and the male and female groups). The dietary CHO 
and protein intake did not differ in the pre-event meal before T1 and T2. However, as 
expected, the CHO content of the pre-event meal influenced the overall time to complete T2 
in all subjects. It is thus evident that a higher CHO content in the pre-event meal leads to a 
decreased overall time to complete T2. The reason why there may be differences in 
correlations between CHO intake and performance in T1 and T2, despite the fact that the 
mean CHO intake before T1 and T2 is similar is due to the fact that mean intakes are 
reported and inter-subject variability between T1 and T2 may exist.  
 
The average CHO intake of T1 and T2 of the pre-event meal was much lower compared to 
studies on high-level triathletes. Cox et al. (2010) analysed the pre-event and during event 
dietary intake of 44 male and 18 female triathletes. The authors found that the male athletes 
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consume on average 2.9 g/kg BW and 3.3 g/kg BW CHO in the pre-event meal for males 
and females respectively (258). This is much higher compared to our current study group 
(0.8 g/kg BW and 0.5 g/kg BW for males and females respectively). Cox et al. (2010) also 
reported pre-event protein intake to be 0.5 g/kg BW for males and females (258), which is 
much higher than the current study group. Fat intake for the pre-event meal as determined 
by Cox et al. (2010) was 0.3 g/kg BW and 0.2 g/kg BW for males and females (258), 
whereas our current study group had slightly lower fat intake before the event (0.2 g/kg BW 
for males and 0.1 g/kg BW for females). Comparing our results with the study by Cox et al. 
(2010), it is evident that the elite level triathletes studied had a more substantial pre-event 
meal compared to our study group. A possible explanation for this may be that our athletes 
were asked to bring their pre-event meal to the race, and consume it after the baseline blood 
samples were taken.   
 
5.4.4.3 Dietary intake during T1 and T2 
Muscle fatigue and low blood glucose levels are common complaints during endurance 
exercise. These complications can inhibit exercise performance. Therefore, optimal CHO 
intake during endurance events is pivotal in sustaining desired sporting performance (168). 
McGawley et al. (2012) investigated the effect of CHO supplementation compared to 
placebo supplementation during a simulated Olympic-distance triathlon in six male and four 
female amateur triathletes. The authors found that CHO supplementation improved triathlon 
performance and that supplementing with CHO during the cycle leg of an Olympic-distance 
triathlon, significantly improves subsequent 10 km run performance (259). Therefore, the 
recommended CHO intake during events lasting longer than 60 minutes is 0.7 g/kg BW or 
30-60 g/hour (174) and 30-60 g/hour for events lasting 1-2.5 hours (169). The ADA and 
ACSM recommend that CHO be ingested at a rate of 30-60 g/hour (183).  
 
Only 62% of the subjects in the current study ingested a food or drink during the triathlons. 
This is low, considering the importance of ingesting CHO during endurance events. Reasons 
why the triathletes did not take in any food or drink during the triathlons could have included 
difficulty to carry the drinks, especially during the swim and run sections (however, during 
transition and the cycle it would have been easier), availability of drinks (the researcher only 
provided water during the race, the athletes consumed their own food/drink during the 
triathlons) or insufficient knowledge regarding the importance of consuming CHO during an 
event. Most of these subjects ingested some form of CHO-electrolyte solution, such as 
Energade® (8.0 g CHO/100 ml), PVM Octane® (83.1 g CHO / 100 g) or 32 GI® (94.2 g CHO / 
100 g). Subjects also chose PVM® energy bars (1-2 bars per race) (60.9 g CHO / 100 g) and 
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GU® energy gels (3-4 gels per race) (62.5 g CHO / 100 g) as food consumed during the 
triathlons. When comparing the dietary intake of the study group to the recommendations 
mentioned before, it is evident that the athletes who were taking CHO during the event were 
consuming sufficient amounts (> 0.7 g/kg BW). The CHO intake for the male group differed 
between T1 and T2; however, it did not have an effect on the overall time to complete the 
events in all subjects, males or females.  
 
The carbohydrate intake ingested during the event in our current study group, compares 
favourably to the results reported by Cox et al. (2010) in terms of the CHO content ingested 
during the race. Although, in our study we had less subjects ingesting CHO during the event, 
the amount reported were in line with recommendations and higher than those reported by 
Cox et al. (2010). In the present study the CHO intake during the event was 87 g and 82 g 
for males and females respectively, compared to 48 g and 49 g for males and females 
respectively as reported by Cox et al. (2010) (258).  
 
As discussed in the literature review, the addition of protein to carbohydrate (CHO: Protein 
ratio of 3-4:1) during exercise has proved beneficial in terms of improving endurance 
performance, enhancing muscle glycogen stores, decreasing damage to muscle fibres and 
enabling better adaptations to training (174, 177, 179, 180). The current study population 
had a very high CHO:protein ratio, meaning they were not adding protein to the 
carbohydrate-electrolyte solution consumed during exercise or ingesting any type of protein 
during exercise. This is, however, still an experimental practice because there are studies 
showing no improvement in performance with the addition of protein (181, 182). The 
researcher would therefore not at this stage recommend athletes to add protein to their 
carbohydrate-electrolyte solutions during exercise. Although, by doing so won’t cause any 
harm or impede exercise performance. 
 
The results obtained from the dietary intake data of the athletes and the practical application 
emanating from these results are discussed in the following paragraph. 
 
The subjects had a diet low in energy, estEA and CHO and should be educated on the 
importance of increasing their energy and CHO intake in the days leading up to a race as 
this could significantly improve their triathlon performance. The estEA should have been 
higher in these two days, as the subjects were tapering for the race and therefore, heavy 
training days would further decrease estEA in the present study population. The CHO intake 
neither reached recommendations for habitual CHO intake nor for CHO loading which is 
recommended in the days leading up to a race. This has a direct effect on triathlon 
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performance as CHO loading strategies have been proven in literature to be beneficial in 
terms of sport/exercise performance. All other nutrients, including protein fat, iron and 
calcium intake was adequate. The calcium:protein ratio was low for all, suggesting that they 
are not taking in enough calcium for the amount of protein they are taking in and this could 
possibly negatively affect bone health.  
 
The pre-event meal of the subjects was low in CHO. As expected and in accordance with 
literature, the low CHO intake negatively influenced the overall time to complete the 
triathlons. Only 2/3 of the athletes consumed a carbohydrate-electrolyte solution during the 
triathlon. Athletes should be educated to include a carbohydrate-electrolyte solution during 
sporting events lasting longer than 90 minutes as it has been proven to be beneficial for 
sport performance. Of these 62% drinking carbohydrate-electrolyte solutions, the CHO 
content was adequate. 
 
Dolan et al. (2011) reported that only 19.7% of 401 triathlete’s surveyd regarding their 
training, nutrition, and mental preparation consulted with nutrition professionals and that > 
55% of these triathletes consulted with triathlon coaches (243). These statistics, coupled 
with the dietary inadequacy found in the current study emphasizes the need for athletes, and 
the triathletes in the present study to consult with nutrition professionals in order to obtain 
sufficient and evidence-based knowledge regarding nutrition and triathlon performance.  
 
5.4.5 Body composition and bone mineral density 
5.4.5.1 Bone densitometry 
 
The role of exercise in bone health 
The relationship between physical activity and bone densitometry is complex in nature. 
Although the benefits of regular physical activity on bone mineral density (BMD) have been 
shown (260), such activity does not always seem to have a beneficial effect on bone 
metabolism (261). Bone mineral density can be reduced during high level training and even 
in some rigorous recreational activity (261). Nichols et al. (2007) also described that impact 
sports may improve BMD, but non-impact sports such as swimming and cycling have no 
benefit in terms of BMD (262). Important factors when considering the positive or negative 
effects of sport or physical activity on BMD includes the impact force that causes 
compression or deflection of bones, hormonal regulation, the type and intensity of exercise, 
gender and age (261).  
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Guillaume et al. (2011) confirmed that cycling has no beneficial effect on BMD and found 
that many cyclists had decreased BMD when compared to non-active controls. These 
authors attributed the decreased BMD to the biomechanics of cycling, which does not inflict 
loading on the bones and therefore does not increase BMD (263). Other studies found lower 
BMD in runners and swimmers compared to judoists, but no difference between runners and 
swimmers (264). Hinrichs et al. (2010) reported lower BMD, especially of the lumbar spine, 
in cyclists, triathletes and runners, but intermediate BMD of the femur in runners and 
triathletes. The authors attributed this to the repetitive impact of running on the femoral neck. 
The authors also stated that endurance athletes, in particular runners, can have increased 
bone loss due to hormonal imbalances and nutritional inadequacy (261).  
 
In the present study, 18% (2/11) of males < 50 years had low BMD and 33% (1/3) of males > 
50 years presented with osteopenia of the anterior-posterior spine and a high prevalence of 
low BMD (72% (5/7)) and osteopenia (40% (2/5)) was found in the pre –and post-
menopausal females respectively. The whole body classification of the females also showed 
that 14% (1/7) (pre-menopausal) and 20% (1/5) (post-menopausal) were osteoporotic, 
according to the WHO and ACSM criteria for the two groups respectively. This finding is 
significant in terms of the risk factors for developing osteoporosis, especially in light of the 
low estEA and the nature of training and competing in triathlons. Nichols et al. (2007) 
reported that the positive effect of physical activity on BMD can be reduced by nutritional 
status, and especially by low estEA (262). 
 
The role of estEA in bone health  
Low estEA as described in point 5.2.2.1, can negatively impact on bone health and 
development. When estEA is < 30 kcal/kg FFM, it can indirectly influence bone health by 
influencing bone turnover and leading to amenorrhea in females. Amenorrhea in turn, 
reduces circulating levels of estrogen, a hormone which is important for bone formation. It is 
therefore recommended to increase energy intake to compensate for the increased energy 
expenditure during training in order to improve estEA (206).  
 
Increased physical activity can decrease BMD and increase bone loss due to athletes 
presenting with a negative energy balance (265). A reduced BMI can lead to reduced bone 
formation and disturbances in endocrine function. Nutrition is important, as it provides the 
substrate for synthesis of bone tissue as well as increased levels of hormones that are 
important for bone health (265).  These endocrine disturbances include the attenuation of 
insulin release and increased levels of cortisol, catecholamines, glucagon and growth 
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hormone (265). The latter hormones are responsible for enhancing fatty acid oxidation 
during times of strenuous or prolonged physical activity when carbohydrate is preserved for 
tissues such as the brain (265). During prolonged exercise, muscle and liver glycogen stores 
become depleted and proteolysis occur in order to provide substrate for gluconeogenesis 
(265). This is present when an athlete exercises in an energy deficient state. When this 
action is repeated regularly and sustained during heavy training, endocrine changes occur. 
An increased cortisol level decreases osteoblast function and increases osteoclast function, 
whereas a reduced insulin-like growth factor-1 (IGF-1) reduces osteoblast function as well as 
synthesis of bone collagen (265). These changes can also lead to a negative nitrogen 
balance, which disrupts skeletal integrity by reducing muscle mass and strength (265).  
 
Miller et al. (2012) reported findings regarding energy deficiency, menstrual disturbances 
and low BMD on 191 physically active Australian females (18-40 years). The authors 
concluded that very few (< 10%) of these women have the knowledge regarding the 
negative effects of low estEA or energy deficiency and subsequent menstrual dysfunction on 
bone health (266). Therefore, education programs are essential to ensure that athletes take 
the necessary steps to prevent this negative effect on bone health. Ihle et al. (2004) 
evaluated the dose-response relationship between estEA and bone turnover in 29 healthy, 
young exercising women and found that bone resorption is increased when the estEA is < 20 
kCal/kg FFM (247). Barrack et al. (2010) found in 39 female adolescent cross country 
runners that an increased bone turnover was associated with energy deficiency (267). 
 
The estEA in the current study was calculated for two days prior to the race, while the 
subjects were tapering. Therefore, it is safe to say that the estEA would be even lower in this 
group on hard training days. Although there was no statistically significant correlation found 
between estEA and BMD in the current study population, the low estEA, coupled with the high 
prevalence of low BMD and osteopenia is worrying. It should be recommended to the 
athletes in the present study to sustain energy balance by specifically increasing 
carbohydrate intake to replace glycogen stores and to maintain nitrogen balance, and where 
necessary to increase body weight. 
 
The role of menstrual function in bone health  
The high prevalence of low BMD, osteopenia and even osteoporosis in the female group of 
the present study, warrants the discussion of menstrual function and menopause in relation 
to bone health. Estrogen is an important hormone in terms of bone health. Decreased levels 
of estrogen can increase bone turnover and bone resorption (259).  
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In the present study, a high prevalence of low BMD (72% (5/7)) and osteopenia (40% (2/5)) 
was found in the pre –and post-menopausal females respectively. The whole body 
classification of the females also showed that 14% (1/7) (pre-menopausal) and 20% (1/5) 
(post-menopausal) was classified as osteoporotic.  
 
In pre-menopausal women, energy deficiency is associated with hypoestrogenism (268). An 
estrogen deficiency combined with energy deficiency increases bone loss and resorption 
and decreases bone formation (268). Therefore, the energy deficiency is the primary 
stimulus (259).  
 
Being female in itself is a risk factor for the development of osteoporosis due to the fact that 
females are in general smaller and thinner compared to males and because menopause has 
been shown to be an independent risk factor for developing osteopenia / osteoporosis due to 
the significant decrease in estrogen production that occurs during the first 4-8 years after 
menopause. Estrogen, which is produced by the ovaries, has a protective effect on bone. 
Menopause is typically reached between the ages of 45-55 (269-271) and therefore, the 
prevalence of osteoporosis is higher in women over the age of 50 as the hormonal influence 
of estrogen on bone health decreases after menopause (272). The consequence of which 
are changes in bone structure, quality and density, leading to fractures and an increased risk 
in morbidity and mortality (272). A systematic review conducted by Wallace and Cumming 
(2000) reported that in post-menopausal women, the BMD of the lubar spine was positively 
influenced by impact and non-impact exercise (263). 
 
Other factors influencing bone health 
As described in the previous point, the incidence of primary osteoporosis may be higher in 
females than in males, due to normal bone loss with age, coupled by bone loss in females 
after menopause. Several risk factors (271) for the development of osteoporosis is prevalent 
in the current study population, including, but not limited to gender (female), race 
(Caucasian), age (some females are > 40 years), menopause (five females are post-
menopausal, which leads to decreased oestrogen levels and bone loss), excessive exercise 
(especially non-weight bearing exercise such as swimming, cycling and running), a diet high 
in protein (>75 g /day) with a low calcium:protein ratio, low energy intake, low estEA and a 
habitual high caffeine intake (caffeine intake of > 1 000 mg/day can lead to increased urinary 
calcium excretion and a negative calcium balance). Other risk factors not present in the 
current study population include a high fibre intake (subjects had a normal fibre intake) and 
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illness or use of medication (subjects did not report any illness or use of medication that 
might influence bone health). Risk factors not measured/reported in the current research 
study, include a family history of osteoporosis, hormone replacement therapy, excessive 
alcohol use, smoking, high dietary intake of sodium, vitamin A, aluminium and phosphorus, 
low exposure of, or dietary intake of vitamin D, magnesium and fluoride.  
 
In the present study, the researcher also found a significant positive correlation between 
height and BMD, with an increased height being associated with an increased BMD. This 
could possibly be due to the excess weight beared by the skelet, as small body size is a risk 
factor for developing osteoporosis. This link warrants further investigation in terms of the 
relationship between height, frame size and BMD. 
5.4.5.2 Body composition and anthropometry 
Measuring body composition is a valuable tool in assessing and enhancing sporting 
performance. Changes in body composition can be used to identify the type of training and 
how much training is needed to optimize body composition for a specific sport or exercise 
program. Seasonal variations exist with regard to body composition measurements and 
values should be interpreted according to training programs (187). The present study was 
conducted directly after the competitive season and therefore it was assumed that the 
athletes would have a better body composition range than might be expected out of season.   
Anthropometry, in particular the determination of the body mass index (BMI) using height 
and weight measurements, has limited application in sport performance. Although the BMI 
has been shown to correlate well with estimates of fat mass when the BMI is within the 
normal ranges (18.4-24.9 kg/m2) and in non-athletic populations, it can significantly under- or 
over-estimate fatness at the extremities of the BMI ranges. It is known, for example that 
using the BMI, a very muscular person can be classified as being overweight or a very lean 
person as underweight (although not malnourished) (187). This is seen in the current study 
as well. Although the total subject group, males and females had a normal BMI, the males 
had a higher BMI compared to females, even though they had lower percentage body fat. 
Therefore, it is important to determine all components of body composition in athletes, not 
only to determine the influence of training programs, but also to determine the influence of 
fatness on exercise performance.  
 
This is of particular importance in female athletes, as a body fat percentage below the 
recommended range can influence not only sporting performance, but also sexual 
maturation and fertility (187, 273). It has also been reported that eumenorrheic and 
amenorrheic athletes have similar body fat percentages, suggesting that the main risk factor 
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for menstrual dysfunction is energy deficit, and not necessarily the percentage of body fat or 
body composition (274). An increase in energy intake, without reducing exercise volume, 
restores reproductive function, suggesting that energy intake, rather than training volume, is 
important when evaluating sexual maturation and fertility (274). Low energy intakes are not 
only prevalent in female athlete populations, but in male athletes as well. In the latter, lower 
fatness, BMD and rapid weight loss can lead to decreased testosterone levels, influencing 
overall health and athletic performance (275).  
 
The percentage body fat in the current study population was interpreted as appropriate for 
triathletes, according to reference values from the ADA and ACSM (i.e. 6-15% for male and 
female triathletes). The males in the current subject group had a mean percentage body fat 
of 10-11%, which is within the abovementioned recommended range for triathletes. The 
females in the current study group, however, had a higher than recommended percentage 
body fat (19%) when compared to the ADA recommendations of 6-15% (207, 276). 
 
Although the ideal percentage body fat for athletes and triathletes specifically differs in the 
literature, there appears to be a general trend toward optimizing body composition to 
optimize triathlon performance. The ideal percentage body fat has been described as 
between 6-10% for male and 11-18% for female triathletes (277). According to Worme et al. 
(1990), who did a study on 21 female and 50 male recreational triathletes, the percentage 
body fat was 15% and 24% for men and women respectively (244). The latter agrees with 
findings in the previous study by the researcher on triathletes residing in the Western Cape, 
where the percentage body fat was found to be 13% for men and 21% for women (71). A 
study done on eight female and ten male athletes competing in the Ironman triathlon in New 
Zealand found the percentage body fat to be 15% and 22% for men and women respectively 
(278).  
 
To summarize; male triathletes have a percentage body fat within the recommended range, 
while female triathletes have levels similar to those of sedentary women. A positive 
correlation was found between height and BMD. Although there were no statistical significant 
correlations between BMI, body weight and BMD in the present study, the BMI of the 
athletes fell within the normal range, which might have a positive effect in terms of protection 
against the development of osteoporosis as a decreased BMI or body weight are also seen 
as risk factors for developing osteoporosis. This is of relevance in our study population as 
there was a high prevalence of low BMD and osteopenia in the male and female groups. 
Together with other risk factors, such as low estEA, low energy intake, low calcium:protein 
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ratio, menopause, pre-disposition due to ethnicity and excessive non-weight bearing 
exercise, these athletes are at and increased risk for developing osteoporosis.  
 
5.4.6 Training two days before race day 
5.4.6.1 Usual training habits/regime 
The current study population can be described as provincial-level triathletes. All subjects 
were either part of the 2010 or 2011 Western Province Triathlon team. The usual duration of 
training per week (± 13 hours) is in accordance with reported literature on senior national 
Olympic-distance triathletes from Great Britain, who trained for approximately 15 hours per 
week (279). The triathletes in the current study trained on average 1-2 times per day, 
averaging 1-2 hours per training session.  
 
The average number of Olympic-distance triathlons completed by the whole subject group, 
in the preceding year was 4-5, which included amongst others, Western Province trials, 
Western Province Championships and the South African Championships. Some of the 
subjects also competed at the World Triathlon Championships. The Olympic-distance 
personal best finishing time ranged from 2 hours 20 minutes for males to 2 hours 30 minutes 
for females, which is in keeping with finishing times of amateur-level male and female 
triathletes (2 hours 20 minutes) reported by Jeukendrup et al. (2005) (121).   
 
5.4.6.2 Training characteristics before triathlon 1 and triathlon 2 
Training characteristics were also determined for the two days leading up to T1 and T2. This 
was important to assess adherence to the research protocol and to ensure that the training 
characteristics were the same before each event. It is recommended that athletes taper (i.e. 
decrease the amount and frequency of training, not the intensity of training) in the two days 
leading up to a race. The subjects adhered to the study protocol and the only training 
characteristic that differed between the two days preceding T1 and T2 was the running 
exertion in males, which was rated slightly, but statistically significantly higher before T2. 
However, this did not influence the overall time to complete either T1 or T2 
 
In summarising the training characteristics of the subjects; the athletes spent ±13 hours per 
week training, including swimming, cycling, running and other exercise such as rowing or 
going to the gym. This classifies them as being amateur, age group or provincial-level 
triathletes. The training before T1 and T2 did not differ significantly and did not influence 
their overall time to complete T1 or T2.  
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5.4.7 Caffeine withdrawal 
The subjects were asked to abstain from caffeine and caffeine-containing products for two 
weeks (14 days) before T1 and T2. Due to the abstinence of caffeine in the diet, caffeine 
withdrawal was expected in subjects who habitually use > 300 mg caffeine per day (our 
study population had a habitual caffeine intake of ±400 mg /day). Subjects were asked to 
complete a questionnaire (Appendix 3.13) before T1 to describe any possible caffeine 
withdrawal symptoms experienced in the two weeks prior to T1. Expected symptoms of 
caffeine withdrawal included headaches, fatigue, lethargy and flu-like symptoms, weariness, 
apathy, weakness, drowsiness, decreased motor behaviour, increased heart rate, increased 
muscle tension, tremor, nausea and vomiting (26, 41, 57, 68, 100, 280-284).  
 
These symptoms typically commence within 12-24 hours after abstaining from caffeine (57, 
68, 285) and peak within 24-48 hours after cessation of caffeine intake. Plasma caffeine 
levels decrease to baseline (< 1 mg/l) within 4-7 days after caffeine abstinence (57, 69). As 
expected, all these withdrawal symptoms can have the potential to significantly inhibit 
exercise performance, particularly in the 2-4 days after the commencement of caffeine 
withdrawal. As soon as caffeine intake is resumed, however, the symptoms subside. It is 
suggested that athletes avoid caffeine and caffeine-containing products for at least one 
week before competitions, to allow any caffeine withdrawal symptoms to have passed (69). 
Withdrawal symptoms have been reported in subjects consuming as little as 129 mg per day 
(57, 283, 284). 
 
In the current study group, almost half of the subjects (46%) experienced headaches in the 
two weeks before T1. Frequent and severe headaches are caused by vasodilation of 
cerebral blood vessels due to caffeine abstinence (69). Other symptoms, such as fatigue, 
lethargy and flu-like symptoms were present in approximately a third of subjects. Only 
headaches experienced during the two weeks prior to T1 influenced the overall time to 
complete T1; all subjects, and the male and female groups that did not experience 
headaches during this time demonstrated a significantly shorter overall time to complete this 
triathlon.   
 
5.4.8 Side-effects of caffeine supplementation 
The subjects were asked to complete a questionnaire on the side-effects of caffeine that 
may have been experienced. The caffeine group experienced statistically significantly more 
shakiness, heart palpitations and gastrointestinal disturbances compared to the placebo 
group. However, when these side effects were entered as covariates to determine the effect 
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of these on the overall time to complete the triathlons, only heart palpitations influenced the 
overall time to complete the triathlon. However, this association was not due to caffeine 
supplementation, as the overall time to complete the triathlon was longer in the placebo 
group who experienced heart palpitations, compared to the caffeine group. 
 
Therefore, caffeine supplementation in the present study increased plasma caffeine levels to 
peak plasma caffeine levels as expected. We can conclude from this that using 70% 
microencapsulated caffeine is effective in elevating plasma caffeine levels sufficiently to 
have an ergogenic effect. Caffeine withdrawal was experienced by the subjects during the 
first 14 days of caffeine abstinence; the most prevalent withdrawal symptoms experienced 
included headaches, fatigue, lethargy and flu-like symptoms. The authors suggests that 
athletes who plan on using caffeine as an ergogenic aid, abstain from caffeine containing 
products at least 14 days prior to their race, to allow sufficient time for withdrawal symptoms 
to pass. Some of the athletes experienced symptoms such as heart palpitations, shakiness 
and GIT disturbances. Although these are symptoms recognized in the literature as side 
effects of caffeine supplementation, they occurred irrespective of caffeine supplementation in 
the present study and were not association with the overall time to complete the triathlons.  
 
5.4.9 Hydration status and changes in plasma volume 
Albumin constitutes almost 60% of plasma proteins. It is produced by the liver and exerts 
osmotic pressure to maintain water balance between blood and tissues (5). Serum albumin 
levels in the present study were determined to detect any changes in plasma volume that 
might occur due to exercise and to adjust other biochemical parameters accordingly. Serum 
albumin levels measured at baseline, during transition (cycle → run) and at the finish line fell 
within the recommended reference range (35-50 g/l), with the exception of the male group’s 
serum albumin measured during transition (cycle to run), which was elevated beyond the 
normal reference value. The serum albumin levels for all subjects, and the male and female 
groups were elevated during transition (cycle → run), but returned to baseline values when 
measured again at the finish line.  
 
The only parameter measured during transition (cycle → run), was plasma caffeine levels. 
Plasma caffeine does not need to be corrected for albumin values. All the other parameters 
that could potentially be influenced by changes in plasma volume, such as the full blood 
count), were only measured at baseline and at the finish line. There were no significant 
differences in baseline and finish line serum albumin levels in all subjects, and the male and 
female groups, irrespective of whether caffeine supplementation was given or not. 
Stellenbosch University http://scholar.sun.ac.za
213 
 
To conclude, serum albumin levels did not differ significantly from baseline to finish line in 
the present study. Therefore it was not needed to adjust any blood values as caffeine 
supplementation had no effect on hydration status and the athletes maintained plasma 
volume before and after the triathlons. 
 
General health, energy- and nutrient intake two days before as well as dietary strategies 
followed on race day, body composition and bone mineral density, training two days before 
race day, side-effects of caffeine withdrawal, side effects of caffeine supplementation and 
hydration status and plasma volume may influence Olympic-distance triathlon performance.   
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CHAPTER 6: CONCLUSION 
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6.1 Summary of findings  
The main aims of this study were to i) investigate the performance-enhancing or ergogenic 
effect of caffeine supplementation during a real-life triathlon competition; ii) evaluate several 
parameters that could in part explain why caffeine supplementation is ergogenic, iii) 
investigate possible factors influencing the ergogenicity of caffeine supplementation and iv) 
investigate possible confounding factors influencing Olympic-distance triathlon performance.  
 
To our knowledge, this is the first study evaluating these factors in relation to caffeine 
supplementation and triathlon competition.  
 
Caffeine supplementation improved Olympic-distance triathlon performance. This effect was 
seen in both males and females. The greatest effect was seen on the overall time to 
complete the triathlon, as well as the swim section of the triathlon. There were no statistically 
significant differences in RPE values or mood state between the caffeine and placebo trials, 
although a trend was observed with regard to lower RPE values in the caffeine compared to 
placebo trial. 
 
Caffeine supplementation made no difference to the markers of endocrine-stress response, 
except for cortisol, which increased beyond that of the effect observed from endurance 
exercise in the caffeine, compared to placebo group. Other markers (testosterone, prolactin 
and dehydroepiandrosterone sulphate) displayed gender differences as expected, but no 
differences were observed in the caffeine and placebo groups. Exercise-induced 
inflammation or infection was more pronounced when receiving caffeine supplementation, as 
seen with the elevated levels of white blood cell and lymphocyte counts in the caffeine 
compared to the placebo groups. Exercise is an independent stressor and influenced the 
other components of the full blood count by increasing neutrophils, monocytes, basophils 
and platelet counts and by decreasing eosinophils, red blood cells and heamatocrit, with no 
change in haemoglobin levels. Caffeine also facilitated greater lactate production. The 
mechanism by which caffeine elicits its ergogenic effect is not clear from the current study’s 
results, although it appears that the greatest effect of caffeine supplementation is due to its 
direct effect on the central (antagonism of adenosine receptors) and indirect effect on the 
autonomic nervous system (increased cortisol levels).  
 
The self-reported phase of the menstrual cycle, menopause status or oral contraceptive use 
had no statistically significant effect on caffeine metabolism or the overall time to complete 
the triathlons. Clinically relevant findings were that faster performance times were achieved 
when the women were in the follicular phase of the menstrual cycle whilst receiving caffeine 
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supplementation. Post-menopausal women completed the triathlons on average slower than 
pre-menopausal women, irrespective of caffeine supplementation. Upon genetic analysis, it 
was evident that in this small subject group, CYP1A2 gene polymorphism did not influence 
caffeine supplementation’s effect on triathlon performance significantly.  
 
The subjects had a high habitual caffeine intake (±400 mg/day). The athletes had a good 
medical history. The dietary intake (including supplement use) two days before T1 and T2 
did not differ. The subjects had a diet low in energy, estEA and CHO, with sufficient protein 
and fat intake. The subjects had sufficient iron and calcium intake, but a low calcium:protein 
ratio. This, together with other risk factors, such as a high prevalence of low bone mineral 
density and osteopenia, menopause, pre-disposition due to ethnicity and excessive non-
weight bearing exercise, places this group at risk for developing osteoporosis. The pre-event 
meal of the subjects contained sufficient protein, although it was low in carbohydrates. Only 
2/3 of the athletes consumed a carbohydrate-electrolyte solution during the triathlon. Of 
these, the CHO content during the event was adequate. The athletes have a percentage 
body fat within the recommended range for healthy individuals, and spent on average ±13 
hours per week training.     
 
Caffeine withdrawal symptoms, such as headaches, fatigue, lethargy and flu-like symptoms 
were experienced by the subjects, but 14 days of caffeine abstinence allowed sufficient time 
for these symptoms to pass and not affect triathlon performance. Side-effects of caffeine, 
such as heart palpitations, shakiness and gastrointestinal tract disturbances were observed, 
but did not influence triathlon performance.   
 
Serum albumin levels did not differ significantly from baseline to finish line in the present 
study. Therefore it was not needed to adjust any blood values as caffeine supplementation 
had no effect on hydration status and the athletes maintained plasma volume from before to 
after the triathlons.  
 
6.2 Conclusions 
This research study demonstrated that double-blind, randomized crossover controlled 
clinical field trials and not only laboratory experiments are necessary to establish the real 
effect of caffeine supplementation on triathlon performance. The researcher also provided an 
assessment of several parameters that could in part explain the ergogenicity of caffeine 
supplementation, factors influencing the ergogenicity of caffeine supplementation as well as 
factors influencing Olympic-distance triathlon performance. Furthermore, to our knowledge, 
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this study was the first field-study to determine the effects of caffeine supplementation during 
an Olympic-distance triathlon on performance in both male and female provincial-level 
Olympic-distance triathletes.  
 
It can thus be concluded that a field trial and not only laboratory experiments are necessary 
to establish the real effect of caffeine supplementation on Olympic-distance triathlon 
performance. The researcher therefore accepts the hypotheses, that i) double-blind, 
randomized, crossover, controlled, clinical field trials and not only laboratory experiments are 
necessary to establish the real effect of caffeine supplementation on the performance time, 
rating of perceived exertion and mood state before, during and after an Olympic-distance 
triathlon; ii) the endocrine-stress response, oxidative stress and plasma lactate levels could 
potentially explain the ergogenic effect of caffeine supplementation; iii) lifestyle, gender and 
genetics may influence the ergogenicity of caffeine supplementation although this remains to 
be substantiated in a larger cohort; and iv) general health, energy- and nutrient intake, body 
composition, training status, caffeine withdrawal symptoms and side effects of caffeine 
supplementation influence Olympic-distance triathlon performance.  
 
6.3 Summary of contributions 
This is the first study, to the researcher’s knowledge, assessing and evaluating the effect of 
caffeine supplementation on Olympic-distance triathlon performance. This double-blind, 
randomized, cross-over, controlled clinical field study evaluated the effect of caffeine 
supplementation on triathlon performance, rating of perceived exertion and mood state. The 
study was extremely well-controlled in terms of factors that could potentially influence the 
ergogenicity of caffeine supplementation, such as lifestyle, gender-related factors (menstrual 
cycle, menopause and oral contraceptive use) and genetics (CYP1A2 gene polymorphism) 
as well as factors that could potentially influence exercise performance, such as general 
health, energy- and nutrient  intake, body composition and bone mineral density, training in 
the days leading up to a race, side-effects of caffeine withdrawal and supplementation and 
hydration status. The results further indicated the primary mechanism of action with regard 
to the ergogenic effect of caffeine supplementation is as a result of direct stimulation of the 
CNS and indirect stimulation of the autonomic nervous system. 
 
This study can be seen as a benchmark for other field studies. A particular strength of the 
study is the fact that is a field study and not a controlled laboratory experiment. Variations in 
the effect of caffeine as an ergogenic aid exist when an athlete is placed in the acute stress 
situation of an actual race.  
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A particular strength of the study is the multi-disciplinary nature, combining research in 
nutrition, physiology, exercise science and genetics.   
 
Differentiating between subjects on a gender basis is important and included in this study. 
 
6.4 Limitations of the current study  
The sample size in this study was relatively limited in the context of nutritional sciences and 
genetic analysis. However, when considering other studies in the field of physiology and 
exercise science, the sample size compares favourably. The South African triathlete 
population is fairly small, so that the study sample is representative of the available pool.  
 
Genetic analysis was included for completeness due to suggestions of polymorphisms 
affecting caffeine metabolism and ultimately exercise performance, in the caffeine-related 
literature specifically. Our result indicates that there was not a major variation in terms of 
genetic make-up related to caffeine metabolism in our population. However, this obviously 
does not exclude the possibility of a statistically significant genetic influence on caffeine 
metabolism in a more diverse and larger group. This issue should be further investigated in a 
population of adequate total size (e.g. endurance runners) to allow for proper genetic 
analytical procedures with sufficient statistical power. Furthermore, haplotype analyses 
would also have been more effective than single SNP analyses, as an extended haplotype 
defined by the known SNPs could detect an unknown variant influencing caffeine 
metabolism (286). 
 
6.5 Recommendation for triathletes with regard to caffeine 
supplementation 
The researcher would recommend the use of caffeine supplementation as an Olympic-
distance triathlon performance enhancing supplement. The significant decrease in the time 
to complete the triathlon when given caffeine supplementation can make the difference 
between winning a race, achieving a podium position or making the cut-off for selection for 
provincial or national teams. A recommendation can be made to these athletes to ingest 6 
mg/kg body weight caffeine, 45-60 minutes before the start of an Olympic-distance triathlon. 
The researcher would further recommend that athletes abstain from caffeine containing food 
and drink for two weeks prior to the planned race, in order to achieve the optimal benefit of 
caffeine supplementation as well as to ensure sufficient time for caffeine withdrawal 
symptoms to pass, especially as these athletes are high habitual caffeine consumers.  
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6.6 Recommendations and future research  
The present study was novel in that it had a multidisciplinary approach. The study evaluated 
the effect of caffeine supplementation on Olympic-distance triathlon performance, while 
controlling for most factors associated with exercise performance. However, due to the 
multiple variables studied in three distinct fields (nutrition, physiology and genetics), the 
same depth cannot be expected when compared with studies conducted in only one of these 
fields.   
 
Furthermore, in our opinion, the current study provides the best possible field assessment of 
caffeine’s benefits in the context of triathlon specifically. Future studies could include larger 
sample sizes by picking a different sporting discipline, and focus especially on detecting 
differences between males and females and to further investigate possible effects of 
CYP1A2 gene polymorphism. Other genes (such as CYP3A4 and CYP2C8/9) and 
epigenetic factors can also be included to provide a more comprehensive analysis of the role 
that various genes and polymorphisms may play (Figure 2.2). 
Studies could also be conducted utilising triathlons of shorter or longer duration, to 
determine the effect of caffeine supplementation performance in non-Olympic-distance 
triathlons.   
 
Additional extensions to this study can include a more in depth assessment with regards to 
the dosage of caffeine supplementation in habitual and non-habitual caffeine consumers and 
the influence of gender and the menstrual cycle on the ergogenicity of caffeine 
supplementation in a larger cohort. 
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